<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD004868.pub4" GROUP_ID="NEONATAL" ID="610003092917333421" MERGED_FROM="" MODIFIED="2014-04-16 17:09:05 +0100" MODIFIED_BY="Yolanda Brosseau" NOTES="&lt;p&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.6&lt;br&gt;Exported from Review Manager 4.2.3&lt;br&gt;Exported from Review Manager 4.2.2&lt;br&gt;Exported from Review Manager 4.2&lt;/p&gt;&lt;p&gt;CL 3/04 (protocol)&lt;br&gt;CL 3/06 (review)&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2014-04-16 12:08:19 -0400" NOTES_MODIFIED_BY="Yolanda Brosseau" REVIEW_NO="" REVMAN_SUB_VERSION="5.2.3 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="6.0">
<COVER_SHEET MODIFIED="2014-04-16 17:09:05 +0100" MODIFIED_BY="Yolanda Brosseau">
<TITLE>Late erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants</TITLE>
<CONTACT MODIFIED="2014-04-16 17:09:05 +0100" MODIFIED_BY="Yolanda Brosseau"><PERSON ID="8350" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Arne</FIRST_NAME><LAST_NAME>Ohlsson</LAST_NAME><POSITION>Professor Emeritus</POSITION><EMAIL_1>aohlsson@mtsinai.on.ca</EMAIL_1><ADDRESS><DEPARTMENT>Departments of Paediatrics, Obstetrics and Gynaecology and Institute of Health Policy, Management and Evaluation</DEPARTMENT><ORGANISATION>University of Toronto</ORGANISATION><ADDRESS_1>600 University Avenue</ADDRESS_1><CITY>Toronto</CITY><ZIP>M5G 1X5</ZIP><REGION>Ontario</REGION><COUNTRY CODE="CA">Canada</COUNTRY></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2014-04-16 17:09:05 +0100" MODIFIED_BY="Yolanda Brosseau"><PERSON ID="12362BCC82E26AA201A256C78A74FEEB" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Sanjay</FIRST_NAME><MIDDLE_INITIALS>M</MIDDLE_INITIALS><LAST_NAME>Aher</LAST_NAME><POSITION>Director</POSITION><EMAIL_1>ahersm@googlemail.com</EMAIL_1><ADDRESS><DEPARTMENT>Neonatology</DEPARTMENT><ORGANISATION>Dr. Aher's Neocare Hospital</ORGANISATION><ADDRESS_1>Near Tusakhre Lawns</ADDRESS_1><ADDRESS_2>Mumbai Naka</ADDRESS_2><CITY>Nashik</CITY><ZIP>422002</ZIP><REGION>Maharashtra</REGION><COUNTRY CODE="IN">India</COUNTRY><PHONE_1>0253-2318509</PHONE_1></ADDRESS></PERSON><PERSON ID="8350" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Arne</FIRST_NAME><LAST_NAME>Ohlsson</LAST_NAME><POSITION>Professor Emeritus</POSITION><EMAIL_1>aohlsson@mtsinai.on.ca</EMAIL_1><ADDRESS><DEPARTMENT>Departments of Paediatrics, Obstetrics and Gynaecology and Institute of Health Policy, Management and Evaluation</DEPARTMENT><ORGANISATION>University of Toronto</ORGANISATION><ADDRESS_1>600 University Avenue</ADDRESS_1><CITY>Toronto</CITY><ZIP>M5G 1X5</ZIP><REGION>Ontario</REGION><COUNTRY CODE="CA">Canada</COUNTRY></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2013-12-03 11:39:08 -0500" MODIFIED_BY="Arne Ohlsson">
<UP_TO_DATE>
<DATE DAY="1" MONTH="7" YEAR="2013"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="1" MONTH="7" YEAR="2013"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="1" MONTH="7" YEAR="2015"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2004"/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="2006"/>
<LAST_CITATION_ISSUE ISSUE="4" YEAR="2014"/>
</DATES>
<WHATS_NEW MODIFIED="2014-03-04 19:05:49 -0500" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2014-03-04 19:05:49 -0500" MODIFIED_BY="[Empty name]">
<DATE DAY="5" MONTH="7" YEAR="2013"/>
<DESCRIPTION>
<P>This update was initiated following feedback from Dr. Robin Ohls. Our inclusion of the study by Dr. Romagnoli and co-workers (<LINK REF="STD-Romagnoli-2000" TYPE="STUDY">Romagnoli 2000</LINK>) in the early EPO review was questioned by Dr. Robin Ohls, who suggested the study should be included in the late EPO review. We contacted Dr. Romagnoli and he informed us that the mean (± SD) age of the infants when EPO treatment was started was 10 ± 1 days. We therefore moved the study to this Late EPO review.</P>
<P>As expected, when this study (n = 230) was added the results of the meta-analyses changed. The outcome of BPD (defined as need for supplemental oxygen at 28 days of life) is now of borderline statistical significance with an increased risk in the EPO group. Becasue of the very high heterogeneity (I² = 97%) the results should be interpreted with caution.</P>
<P>Our decision to divide the EPO studies into early and late based on initiating EPO treatment at the cut-off of &#8804; 7 days of age for early and &gt; 7 days for late treatment with EPO, although somewhat arbitrary, was chosen based on previously published meta-analyses (<LINK REF="REF-Garcia-2002" TYPE="REFERENCE">Garcia 2002</LINK>; <LINK REF="REF-Kotto_x002d_Kome-2004" TYPE="REFERENCE">Kotto-Kome 2004</LINK>) to allow us to compare the results between our reviews and previously published reviews.</P>
<P>In this update there is a trend towards a non-significant increased risk of retinopathy (ROP) of prematurity.</P>
<P>The concern for an increased risk of ROP is real and because of the arbitrary cut-off age for early vs late EPO treatment we decided post hoc to perform a secondary analysis including all studies that reported on ROP stage &#8805; 3 regardless of the age at initiation of EPO treatment. This analysis is included in the updated Early EPO review and shows an increased risk of ROP &#8805; 3 when all studies of EPO regardless of age at initiation of the treatment were included in the analysis.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2013-11-04 07:59:54 -0500" MODIFIED_BY="[Empty name]">
<DATE DAY="5" MONTH="7" YEAR="2013"/>
<DESCRIPTION>
<P>We searched the literature on July 1st, 2013, and identified no new trials for inclusion. However, one trial was moved from the review of <I>Early erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants</I> (<LINK REF="REF-Ohlsson-2012" TYPE="REFERENCE">Ohlsson 2012</LINK>) to this review of later EPO treatment (see above).</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2013-11-04 09:53:43 -0500" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2013-08-15 10:56:38 -0400" MODIFIED_BY="[Empty name]">
<DATE DAY="10" MONTH="5" YEAR="2012"/>
<DESCRIPTION>
<P>The updated searches identified one additional trial for inclusion (20 additional enrolled infants)and identified some for exclusion.</P>
<P>With the inclusion of this trial there was no longer a significant reduction in the total volume (mL/kg) of blood transfused per infant</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2013-11-04 09:53:43 -0500" MODIFIED_BY="[Empty name]">
<DATE DAY="10" MONTH="5" YEAR="2012"/>
<DESCRIPTION>
<P>This updates the existing review "Late erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants" published in the Cochrane Database of Systematic Reviews (<LINK REF="REF-Aher-2012b" TYPE="REFERENCE">Aher 2012b</LINK>) and updated in February 2010.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2012-05-28 14:24:10 -0400" MODIFIED_BY="[Empty name]">
<DATE DAY="26" MONTH="2" YEAR="2010"/>
<DESCRIPTION>
<P>This review updates the existing review "Late erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants" published in the Cochrane Database of Systematic Reviews (<LINK REF="REF-Aher-2006b" TYPE="REFERENCE">Aher 2006b</LINK>).</P>
<P>Updated search found no new trials.</P>
<P>No changes to conclusions.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-02-26 13:18:42 -0500" MODIFIED_BY="[Empty name]">
<DATE DAY="25" MONTH="9" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2012-05-28 15:42:00 -0400" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Mount Sinai Hospital, Toronto</NAME>
<COUNTRY CODE="CA">Canada</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2012-05-28 15:42:00 -0400" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2012-05-28 15:42:00 -0400" MODIFIED_BY="[Empty name]">
<NAME>Eunice Kennedy Shriver National Institute of Child Health and Human Development National Institutes of Health, Department of Health and Human Services</NAME>
<COUNTRY CODE="US">USA</COUNTRY>
<DESCRIPTION>
<P>Editorial support of the Cochrane Neonatal Review Group has been funded with Federal funds from the Eunice Kennedy Shriver National Institute of Child Health and Human Development National Institutes of Health, Department of Health and Human Services, USA, under Contract No. HHSN275201100016C</P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2014-04-16 12:08:19 -0400" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2013-11-25 15:52:51 -0500" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2008-09-25 09:14:37 -0400" MODIFIED_BY="[Empty name]">Late erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants</TITLE>
<SUMMARY_BODY MODIFIED="2013-11-25 15:52:51 -0500" MODIFIED_BY="[Empty name]">
<P>
<B>Review question</B>
</P>
<P>We reviewed the evidence about the effectiveness and safety of late initiation of erythropoietin treatment between eight and 28 days after birth, in reducing the use of red blood cell (RBC) transfusions in preterm and/or low birth weight infants.</P>
<P>
<B>Background</B>
</P>
<P>The percentage of circulating red blood cells (hematocrit) falls after birth in all infants. This is particularly true in preterm infants due to their poor response to anaemia and to the amount of blood that is drawn for necessary testing. Low plasma levels of erythropoietin (a substance in the blood that stimulates red blood cell production) in preterm infants provide a rationale for the use of erythropoietin to prevent/treat anaemia.</P>
<P>
<B>Search date</B>
</P>
<P>The evidence is current to July, 2013.</P>
<P>
<B>Study characteristics</B>
</P>
<P>To date 1591 infants (between eight and 28 days of age) born preterm have been enrolled in 30 studies of late administration of EPO to reduce the use of red blood cell transfusions and to prevent donor exposure. </P>
<P>
<B>Study funding sources</B>
</P>
<P>We as reviewers have not received any funding for this review and we have no conflict of interest to declare.</P>
<P>
<B>Key findings</B>
</P>
<P>The risk of receiving red blood transfusion is reduced following initiation of EPO treatment. However, the overall benefit of EPO is reduced as many of these infants had been exposed to donor blood prior to entry into the trials. Treatment with late EPO did not have any important effects on death or common complications of preterm birth, except for trends in an increased risk for retinopathy of prematurity. Retinopathy of prematurity is a disease of the eye affecting babies born preterm. It is thought to be caused by disorganized growth of retinal blood vessels, which may result in scarring and retinal detachment. Retinopathy of prematurity can be mild and may resolve spontaneously, but it may lead to blindness in serious cases. </P>
<P>
<B>Quality of the evidence</B>
</P>
<P>The study quality varied and important information regarding the random sequence generation and whether the allocation was concealed or not was often missing. Sample sizes were small and long-term outcomes (18 to 24 months corrected age) were not reported.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2013-11-25 15:49:26 -0500" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2012-05-10 16:19:19 -0400" MODIFIED_BY="[Empty name]">
<P>Low plasma levels of erythropoietin (EPO) in preterm infants provide a rationale for the use of EPO to prevent or treat anaemia.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2013-11-08 05:39:24 -0500" MODIFIED_BY="[Empty name]">
<P>To assess the effectiveness and safety of late initiation of erythropoietin (EPO) between eight and 28 days after birth, in reducing the use of red blood cell (RBC) transfusions in preterm and/or low birth weight infants.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2013-11-25 15:24:11 -0500" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, and CINAHL in July 2013. Additional searches included the Pediatric Academic Societies Annual Meetings from 2000 to 2013 (Abstracts2View&#8482;) and clinical trials registries (www.clinicaltrials.gov; www.controlled-trials.com; and who.int/ictrp/en). For this update we moved one study from the early EPO review to this late EPO review.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2012-08-12 09:35:36 -0400" MODIFIED_BY="[Empty name]">
<P>Randomised or quasi-randomised controlled trials of late initiation of EPO treatment (started at &#8805; eight days of age) versus placebo or no intervention in preterm (&lt; 37 weeks) and/or low birth weight (&lt; 2500 g) neonates.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2013-11-04 08:12:48 -0500" MODIFIED_BY="[Empty name]">
<P>We performed data collection and analyses in accordance with the methods of the Cochrane Neonatal Review Group.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2013-11-25 15:49:26 -0500" MODIFIED_BY="[Empty name]">
<P>We include 30 studies (31 comparisons) randomising 1591 preterm infants. Literature searches in 2013 did not identify any new study for inclusion. For this update we moved one study enrolling 230 infants from the early EPO review to this late EPO review.</P>
<P>Most included trials were of small sample size. The meta-analysis showed a significant effect of the use of one or more RBC transfusions (20 studies (n = 1142); typical risk ratio (RR) 0.71, 95% confidence interval (CI) 0.64 to 0.79; typical risk difference (RD) -0.17, 95% CI -0.22 to -0.12; typical number needed to treat for an additional beneficial outcome (NNTB) 6, 95% CI 5 to 8). There was moderate heterogeneity for this outcome (RR I²<SUP> </SUP>= 68%; RD I²<SUP> </SUP>= 60%). We obtained similar results in secondary analyses based on different combinations of high/low doses of EPO and iron supplementation. There was no significant reduction in the total volume (mL/kg) of blood transfused per infant [typical mean difference (MD) -1.6 mL/kg, 95% CI -5.8 to 2.6); 5 studies, 197 infants]. There was high heterogeneity for this outcome (I² = 92%). There was a significant reduction in the number of transfusions per infant (11 studies enrolling 817 infants; typical MD -0.22, 95% CI -0.38 to -0.06). There was high heterogeneity for this outcome (I² = 94%).</P>
<P>Three studies including 404 infants reported on retinopathy of prematurity (ROP) (all stages or stage not reported), with a typical RR 1.27 (95% CI 0.99 to 1.64) and a typical RD of 0.09 (95% CI -0.00 to 0.18). There was high heterogeneity for this outcome for both RR (I² = 83%) and RD (I² = 82%). Three trials enrolling 442 infants reported on ROP (stage &#8805; 3). The typical RR was 1.73 (95% CI 0.92 to 3.24) and the typical RD was 0.05 (95% CI -0.01 to 0.10). There was minimal heterogeneity for this outcome for RR (I² = 18%) but high heterogeneity for RD (I² = 79%). There were no significant differences in other clinical outcomes. There was no reduction in necrotizing enterocolitis in spite of a reduction in the use of RBC transfusions. Long-term neurodevelopmental outcomes were not reported.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2013-11-19 14:42:57 -0500" MODIFIED_BY="[Empty name]">
<P>Late administration of EPO reduces the use of one or more RBC transfusions, the number of RBC transfusions per infant (&lt; 1 transfusion per infant) but not the total volume (ml/kg) of RBCs transfused per infant. Any donor exposure is likely not avoided as most studies included infants who had received RBC transfusions prior to trial entry. Late EPO does not significantly reduce or increase any clinically important adverse outcomes except for a trend in increased risk for ROP. Further research of the use of late EPO treatment to prevent donor exposure is not indicated. Research efforts should focus on limiting donor exposure during the first few days of life in sick neonates, when RBC requirements are most likely to be required and cannot be prevented by late EPO treatment. The use of satellite packs (dividing one unit of donor blood into many smaller aliquots) may reduce donor exposure. </P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2014-04-16 12:08:19 -0400" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2014-04-16 12:07:28 -0400" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2013-11-23 11:27:43 -0500" MODIFIED_BY="[Empty name]">
<P>After birth, the haemoglobin concentration of newborn infants falls to minimal levels of 11 g/dL in term infants by eight to 12 weeks of age, and 7.0 to 10.0 g/dL in preterm infants by six weeks of age (<LINK REF="REF-Stockman-1978" TYPE="REFERENCE">Stockman 1978</LINK>). This process is called physiologic anaemia of infancy (<LINK REF="REF-Strauss-1986" TYPE="REFERENCE">Strauss 1986</LINK>). In very low birth weight (VLBW) infants, the hematocrit falls to approximately 24% in infants weighing 1.0 to 1.5 kg and to 21% in infants weighing less than 1.0 kg at birth (<LINK REF="REF-Stockman-1986" TYPE="REFERENCE">Stockman 1986</LINK>). In extremely low birth weight (ELBW) infants, this decline in hematocrit is not 'physiologic', as it may be associated with clinical findings that prompt red blood cell transfusions. To our knowledge, the diagnostic accuracy of different clinical signs and laboratory findings has not been studied (<LINK REF="REF-Cohen-1998" TYPE="REFERENCE">Cohen 1998</LINK>). It is still unknown how low hematocrit levels can fall before clinical signs of anaemia occur and what is the minimum hematocrit level acceptable in infants requiring supplemental oxygen (<LINK REF="REF-Ohls-2002" TYPE="REFERENCE">Ohls 2002</LINK>). Nevertheless, 'top-up' transfusions to treat low haemoglobin or low hematocrit levels are frequently used. As many as 80% of VLBW infants and 95% of ELBW infants receive blood transfusions during their hospitalisations (<LINK REF="REF-Widness-1996" TYPE="REFERENCE">Widness 1996</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2014-04-16 12:07:28 -0400" MODIFIED_BY="[Empty name]">
<P>Erythropoietin (EPO) and iron effectively stimulate erythropoiesis. Plasma erythropoietin levels in neonates are lower than those of older children and adults. <LINK REF="REF-Brown-1983" TYPE="REFERENCE">Brown 1983</LINK> reported that between two and 30 days of life the mean EPO concentration was 10 mU/mL, as compared to 15 mU/mL in concurrently studied adults. A low plasma EPO level is a key reason that nadir hematocrit values of preterm infants are lower than those of term infants (<LINK REF="REF-Dallman-1981" TYPE="REFERENCE">Dallman 1981</LINK>; <LINK REF="REF-Stockman-1986" TYPE="REFERENCE">Stockman 1986</LINK>). Low plasma EPO levels provide a rationale for the use of EPO in the prevention or treatment of anaemia of prematurity. Studies in newborn monkeys and sheep have demonstrated that neonates have a large volume of distribution and more rapid elimination of EPO, necessitating the use of higher doses than are required for adults (<LINK REF="REF-Ohls-2000" TYPE="REFERENCE">Ohls 2000</LINK>). A systematic review of EPO administration noted a wide range of doses used, from 90 to 1400 IU/kg/week (<LINK REF="REF-Kotto_x002d_Kome-2004" TYPE="REFERENCE">Kotto-Kome 2004</LINK>). Side effects reported in adults include hypertension, bone pain, rash and (rarely) seizures. Only transient neutropenia has been reported in neonates (<LINK REF="REF-Ohls-2000" TYPE="REFERENCE">Ohls 2000</LINK>).</P>
</INTERVENTION>
<THEORY MODIFIED="2013-11-23 11:27:58 -0500" MODIFIED_BY="[Empty name]">
<P>The primary goal of EPO therapy is to reduce transfusions. Most transfusions are given during the first three to four weeks of life. The larger or stable preterm infants who respond best to EPO receive few transfusions. ELBW infants, who are sick and have the greatest need for red blood cell (RBC) transfusions shortly after birth, have not consistently responded to EPO. This suggests that EPO is a more effective erythropoietic stimulator in more mature neonates. ELBW neonates are more likely to need transfusions even if their erythropoiesis is stimulated (<LINK REF="REF-Kotto_x002d_Kome-2004" TYPE="REFERENCE">Kotto-Kome 2004</LINK>). In addition, ELBW neonates have a smaller blood volume and the relatively larger phlebotomy volumes that are required during hospital stay often necessitate 'early' transfusions. In contrast, 'late' transfusions are more often given because of anaemia of prematurity (<LINK REF="REF-Garcia-2002" TYPE="REFERENCE">Garcia 2002</LINK>). Most preterm infants who require blood transfusions will receive their first transfusion in the first two weeks of life (<LINK REF="REF-Zipursky-2000" TYPE="REFERENCE">Zipursky 2000</LINK>). Reducing the number of RBC transfusions reduces the risk of transmission of viral infections and may reduce costs. Frequent RBC transfusions may be associated with retinopathy of prematurity (ROP) (<LINK REF="REF-Hesse-1997" TYPE="REFERENCE">Hesse 1997</LINK>) and bronchopulmonary dysplasia (BPD).</P>
<P>In preterm infants, iron is needed for erythropoiesis. As neonatal blood volume expands with rapid growth, infants produce large amounts of haemoglobin. Several studies have observed a decrease in serum ferritin concentration (an indication of iron deficiency (<LINK REF="REF-Finch-1982" TYPE="REFERENCE">Finch 1982</LINK>) during erythropoietin treatment). The use of higher, more effective doses of erythropoietin might be expected to increase iron demand and the risk of iron deficiency. Iron supplementation during erythropoietin treatment has been observed to reduce the risk of the development of iron deficiency (<LINK REF="STD-Shannon-1995" TYPE="STUDY">Shannon 1995</LINK>). The range of iron doses used in EPO-treated infants is between 1 mg/kg/day to 10 mg/kg/day (<LINK REF="REF-Kotto_x002d_Kome-2004" TYPE="REFERENCE">Kotto-Kome 2004</LINK>).</P>
<P>EPO has been found to have important non-hematopoietic functions in the brain and other organs during development (<LINK REF="REF-Juul-2002" TYPE="REFERENCE">Juul 2002</LINK>). Administration of EPO could potentially have a neuro protective effect in preterm infants, especially in perinatal asphyxia (<LINK REF="REF-Dame-2001" TYPE="REFERENCE">Dame 2001</LINK>; <LINK REF="REF-Juul-2002" TYPE="REFERENCE">Juul 2002</LINK>). This aspect of EPO use in neonates will be systematically reviewed separately (<LINK REF="REF-Yu-2010" TYPE="REFERENCE">Yu 2010</LINK>).</P>
<P>It is likely that additional studies of EPO in preterm or LBW infants have been published since the reviews noted above, which included reports up to October 2002. We have performed a series of Cochrane reviews on the use of EPO in preterm infants, including: <I>Early erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants (</I>
<LINK REF="REF-Ohlsson-2012" TYPE="REFERENCE">Ohlsson 2012</LINK>), this review (Late erythropoietin; <LINK REF="REF-Aher-2012a" TYPE="REFERENCE">Aher 2012a</LINK>), and <I>Early versus late erythropoietin to prevent red blood cell transfusion in preterm and/or low birth weight infants</I> (<LINK REF="REF-Aher-2012b" TYPE="REFERENCE">Aher 2012b</LINK>). The cut-off of seven days of age or less for 'early' and more than seven days for 'late' treatment with EPO, although somewhat arbitrary, was chosen based on previously published meta-analyses (<LINK REF="REF-Garcia-2002" TYPE="REFERENCE">Garcia 2002</LINK>; <LINK REF="REF-Kotto_x002d_Kome-2004" TYPE="REFERENCE">Kotto-Kome 2004</LINK>), and allowed us to compare the results between our reviews and previously published reviews.</P>
</THEORY>
<IMPORTANCE MODIFIED="2013-11-04 10:04:33 -0500" MODIFIED_BY="[Empty name]">
<P>This review concerns late administration of EPO (starting in infants between eight and 28 days of age, after reaching 40 weeks postmenstrual age (PMA)). The main rationale for such EPO therapy is to avoid exposure of neonates to multiple blood donors and the risks associated with this exposure. It is likely that many sick neonates would have received a transfusion prior to entry into trials enrolling infants more than seven days of age. We carried out a systematic review to evaluate all available studies where EPO was begun after seven days of life, to assess the effect on the use of one or more red blood cell transfusions in preterm/very low birth weight infants.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2013-11-08 05:39:36 -0500" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="5">Primary objective</HEADING>
<P>To assess the effectiveness and safety of late initiation of erythropoietin (EPO) between eight and 28 days after birth, in reducing red blood cell (RBC) transfusions in preterm and/or low birth weight infants.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Secondary objective</HEADING>
<P>Subgroup analyses of low (&#8804; 500 IU/kg/week) and high (&gt; 500 IU/kg/week) doses of EPO, and low (&#8804; 5 mg/kg/day) and high (&gt; 5 mg/kg/day) doses of supplemental iron in reducing red blood cell transfusions in preterm and/or low birth weight infants.</P>
</SUBSECTION>
</OBJECTIVES>
<METHODS MODIFIED="2013-11-23 11:07:51 -0500" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2013-11-08 05:59:32 -0500" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES>
<P>Randomised or quasi-randomised controlled trials.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2013-11-07 04:20:16 -0500" MODIFIED_BY="[Empty name]">
<P>Preterm (&lt; 37 weeks) and/or low birth weight (&lt; 2500 g) neonates between eight and 28 days of age.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2013-11-08 05:58:29 -0500" MODIFIED_BY="[Empty name]">
<P>Late initiation of EPO, at eight to 28 days of age, using any dose, route, or duration of treatment, versus placebo or no intervention. The use of any dose of supplemental iron.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2013-11-08 05:59:32 -0500" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2012-05-28 14:40:11 -0400" MODIFIED_BY="[Empty name]">
<OL>
<LI>Use of one or more red blood cell transfusions.</LI>
</OL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2013-11-08 05:59:32 -0500" MODIFIED_BY="[Empty name]">
<OL>
<LI>The total volume (mL/kg) of blood transfused per infant.</LI>
<LI>Number of transfusions per infant.</LI>
<LI>Number of donors to whom the infant was exposed.</LI>
<LI>Mortality during initial hospital stay (all causes of mortality).</LI>
<LI>Retinopathy of prematurity (ROP) (any stage and stage &#8805; 3).</LI>
<LI>Proven sepsis (clinical symptoms and signs of sepsis and positive blood culture for bacteria or fungi).</LI>
<LI>Necrotising enterocolitis (NEC) (Bell's stage II or more).</LI>
<LI>Intraventricular haemorrhage (IVH); all grades and grades III and IV.</LI>
<LI>Periventricular leukomalacia (PVL); cystic changes in the periventricular areas.</LI>
<LI>Bronchopulmonary dysplasia (BPD) (supplementary oxygen at 28 days of age or at 36 weeks postmenstrual age (PMA) and compatible X-ray).</LI>
<LI>Sudden infant death after discharge.</LI>
<LI>Long-term outcomes assessed at any age beyond one year of age by a validated cognitive, motor, language, or behavioural/school/social interaction/adaptation test.</LI>
<LI>Neutropenia.</LI>
<LI>Hypertension (as this outcome was frequently reported by trial authors, it has been added since the protocol was published).</LI>
<LI>Length of hospital stay (days).</LI>
<LI>Any side effects reported in the trials.</LI>
</OL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2013-11-21 16:45:17 -0500" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2013-11-21 16:45:17 -0500" MODIFIED_BY="[Empty name]">
<P>For the original review (<LINK REF="REF-Aher-2006b" TYPE="REFERENCE">Aher 2006b</LINK>), we searched the Cochrane Central Register of Controlled Trials (CENTRAL, <I>The Cochrane Library</I>, 2006, Issue 2) to identify relevant randomised and quasi-randomised controlled trials. We searched MEDLINE for relevant articles published from 1966 to November 2005 using the following MeSH terms or text words: (exp Erythropoietin/OR erythropoietin:.mp. OR rhuepo.mp.) AND (anaemia/OR exp anaemia, neonatal/) AND (blood transfusion/OR blood component transfusion/OR erythrocyte transfusion/) AND (infant, newborn/OR infant, low birth weight/OR infant, very low birth weight/OR infant, premature/OR exp Infant, Premature, Diseases) OR (neonate: OR prematur*: OR newborn:).mp. OR newborn infant [age limit]) AND (clinical trial.pt. OR Randomized Controlled Trials/OR (random: OR rct OR rcts OR blind OR blinded OR placebo:).mp. OR (review.pt. OR review, academic.pt.) AND human. We searched EMBASE from 1980 to November 2005 and CINAHL 1982 to November 2005 using the following MeSH terms or text words: (Erythropoietin/OR erythropoietin: OR epo OR epogen OR epoetin: OR (rhuepo).mp. AND (anaemia/OR exp anaemia, neonatal/) AND (blood transfusion/OR exp blood component transfusion/OR erythrocytes/) AND exp Infant, Premature, Diseases/OR infant, newborn/OR infant, low birth weight/OR infant, very low birth weight/OR infant, premature/OR (neonate: OR newborn: OR prematur*:).mp. OR newborn infant [age limit].</P>
<P>We ran the same search strategy in February 2010, March 2012 and in July 2013.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2013-11-07 04:35:32 -0500" MODIFIED_BY="[Empty name]">
<P>In addition, we performed manual searches of bibliographies and personal files, with no language restrictions. We handsearched abstracts published from the Pediatric Academic Societies' Meetings and the European Society of Pediatric Research Meetings (published in Pediatric Research or electronically) from 1980 to April 2006.</P>
<P>In July 2013 we conducted electronic searches of abstracts from the Annual Meetings of the Pediatric Academic Societies at Abstracts2View&#8482; from 2000 to 2013. Additional searches in July 2013 included clinical trials registries (www.clinicaltrials.gov; www.controlled-trials.com; and who.int/ictrp).</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2013-11-23 11:07:51 -0500" MODIFIED_BY="[Empty name]">
<P>We used the standard methods of the Cochrane Neonatal Review Group and the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>) for data collection and analysis.</P>
<STUDY_SELECTION MODIFIED="2013-11-08 06:02:00 -0500" MODIFIED_BY="[Empty name]">
<P>Two review authors assessed all abstracts and published studies identified as potentially relevant by the literature search for inclusion in the review. Each review author extracted data separately onto a data abstraction form. They then compared the information and resolved differences by consensus. One review author (AO) entered the data into Review Manager 5 (<LINK REF="REF-RevMan-2012" TYPE="REFERENCE">RevMan 2012</LINK>) and the other (SMA) cross-checked the printout against his own data abstraction forms, and corrected errors.</P>
<P>For studies identified as abstracts only, we had planned to contact the primary author to obtain further information. The two studies identified as abstracts did not provide enough information for us to be able to contact the authors (<LINK REF="STD-Ahmadpour-Kacho-2004" TYPE="STUDY">Ahmadpour Kacho 2004</LINK>; <LINK REF="STD-Amin-2004" TYPE="STUDY">Amin 2004</LINK>).</P>
<P>This update in 2013 was conducted by both review authors (SMA and AO).</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2013-11-07 04:40:58 -0500" MODIFIED_BY="[Empty name]">
<P>The review authors separately extracted, assessed and coded all data for each study using a form that was designed specifically for this review. We replaced any standard error of the mean by the corresponding standard deviation. </P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2013-11-08 06:04:20 -0500" MODIFIED_BY="[Empty name]">
<P>We used the standard methods of the Cochrane Neonatal Review Group. We assessed the methodological quality of the studies using the following key criteria: allocation concealment (blinding of randomisation), blinding of intervention, completeness of follow-up, and blinding of outcome measurement/assessment. For each criterion, the assessment was low risk, high risk, or unclear risk of bias. Two review authors separately assessed each study, resolving any disagreement by discussion. This information was added to the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table.</P>
<P>For the 2012 and 2013 updates, one review author (AO) evaluated the following issues and entered them into the 'Risk of bias' table, and in 2013 the other review author (SMA) checked the information.</P>
<P>
<B>Selection bias </B>(random sequence generation and allocation concealment).<BR/>For each included study, we categorised the risk of selection bias as:<BR/>
<BR/>
<I>Random sequence generation:</I>
<BR/>Low risk - adequate (any truly random process e.g. random number table; computer random number generator);<BR/>High risk - inadequate (any non-random process e.g. odd or even date of birth; hospital or clinic record number);<BR/>Unclear risk - no or unclear information provided.</P>
<P>
<I>Allocation concealment:</I>
<BR/>Low risk - adequate (e.g. telephone or central randomisation; consecutively numbered sealed opaque envelopes);<BR/>High risk - inadequate (open random allocation; unsealed or non-opaque envelopes, alternation; date of birth);<BR/>Unclear risk - no or unclear information provided.</P>
<P>
<B>Performance bias</B>
<BR/>For each included study, we categorised the methods used to blind study personnel from knowledge of which intervention a participant received. (As our study population consisted of neonates they would all be blinded to the study intervention).<BR/>Low risk - adequate for personnel (a placebo that could not be distinguished from the active drug was used in the control group);<BR/>High risk - inadequate - personnel aware of group assignment;<BR/>Uncelar risk - no or unclear information provided.</P>
<P>
<B>Detection bias</B>
<BR/>For each included study, we categorised the methods used to blind outcome assessors from knowledge of which intervention a participant received. (As our study population consisted of neonates they would all be blinded to the study intervention). Blinding was assessed separately for different outcomes or classes of outcomes. We categorised the methods used with regards to detection bias as:<BR/>Low risk - adequate; follow-up was performed with assessors blinded to group;<BR/>High risk - inadequate; assessors at follow-up were aware of group assignment;<BR/>Unclear risk - no or unclear information provided.</P>
<P>
<B>Attrition bias</B>
</P>
<P>For each included study and for each outcome, we describe the completeness of data including attrition and exclusions from the analysis. We noted whether attrition and exclusions were reported, the numbers included in the analysis at each stage (compared with the total randomised participants), reasons for attrition or exclusion where reported, and whether missing data were balanced across groups or were related to outcomes. Where sufficient information was reported or supplied by the trial authors, we re-included missing data in the analyses. We categorised the methods with respect to the risk attrition bias as:<BR/>Low risk - adequate (&lt; 10% missing data);<BR/>High risk - inadequate (&#8805; 10% missing data);<BR/>Unclear risk - no or unclear information provided.</P>
<P>
<B>Reporting bias</B>
</P>
<P>For each included study, we describe how we investigated the risk of selective outcome reporting bias and what we found. We assessed the methods as:<BR/>Low risk - adequate (where it is clear that all of the study's prespecified outcomes and all expected outcomes of interest to the review have been reported);<BR/>High risk - inadequate (where not all the study's prespecified outcomes have been reported; one or more reported primary outcomes were not prespecified; outcomes of interest are reported incompletely and so cannot be used; study fails to include results of a key outcome that would have been expected to have been reported);<BR/>Unclear risk - no or unclear information provided (the study protocol was not available).</P>
<P>
<B>Other bias</B>
</P>
<P>For each included study, we describe any important concerns we had about other possible sources of bias (for example, whether there was a potential source of bias related to the specific study design or whether the trial was stopped early due to some data-dependent process). We assessed whether each study was free of other problems that could put it at risk of bias as:<BR/>Low risk - no concerns of other bias raised;<BR/>High risk - concerns raised about multiple checks of the data with the results made known to the investigators, difference in number of infants enrolled in abstract and final publications of the paper;<BR/>Unclear - concerns raised about potential sources of bias that could not be verified by contacting the authors. If needed, we planned to explore the impact of the level of bias through undertaking sensitivity analyses.<BR/>
</P>
<P>For the original review, two review authors (SMA, AO) who were not blinded to authors, institution or journal of publication, conducted independent quality assessments.</P>
<P>The 2012 update was conducted by one author (AO) and the current update by both authors (SMA and AO).</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2013-11-07 04:57:26 -0500" MODIFIED_BY="[Empty name]">
<P>The statistical methods include (typical when applicable) risk ratio (RR), risk difference (RD), number needed to treat for an additional beneficial outcome (NNTB) or number needed to treat to treat for an additional harmful outcome (NNTH) for dichotomous outcomes, and mean difference (MD) for continuous outcomes, all reported with their 95% confidence interval (CI).</P>
</EFFECT_MEASURES>
<HETEROGENEITY_ASSESSMENT MODIFIED="2013-11-23 11:07:51 -0500" MODIFIED_BY="[Empty name]">
<P>We conducted heterogeneity tests including the I² statistic to assess the appropriateness of pooling the data (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). For the 2012 and 2013 updates we classified the different percentages of heterogeneity as up to 25 mild heterogeneity, 25 to 49 low heterogeneity, 50 to 74 moderate heterogeneity and 75 or more high heterogeneity.</P>
</HETEROGENEITY_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2013-11-08 05:02:21 -0500" MODIFIED_BY="[Empty name]">
<P>We performed meta-analysis using Review Manager 5 software (<LINK REF="REF-RevMan-2012" TYPE="REFERENCE">RevMan 2012</LINK>), supplied by The Cochrane Collaboration. For estimates of typical RR and RD, we used the Mantel-Haenszel method. For measured quantities, we used the inverse variance method. All meta-analyses were done using the fixed-effect model.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2013-11-07 05:21:36 -0500" MODIFIED_BY="[Empty name]">
<P>We performed subgroup analyses for low (&#8804; 500 IU/kg/week) and high (&gt; 500 IU/kg/week) doses of EPO, and in addition within those subgroups for no iron, low (&#8804; 5 mg/kg/day) and high (&gt; 5 mg/kg/day) doses of supplemental iron (co-intervention).</P>
</SUBGROUP_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2014-03-04 19:08:20 -0500" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2013-11-23 11:28:24 -0500" MODIFIED_BY="[Empty name]">
<P>For this feedback-initiated update the study by Romagnoli (<LINK REF="STD-Romagnoli-2000" TYPE="STUDY">Romagnoli 2000</LINK>) was moved from the early EPO review (<LINK REF="REF-Ohlsson-2012" TYPE="REFERENCE">Ohlsson 2012</LINK>) to this late EPO review as the infants were of a mean (SD) age of 10 (± 1) days at the initiation of EPO treatment. The study enrolled 230 infants. The 2012 update identified one new study for inclusion. As a result 30 studies (31 comparisons) including 1591 preterm and or low birth weight infants met the inclusion criteria. These studies were performed in 21 countries (Argentina, Australia, Austria, Belgium, Brazil, Canada, Finland, France, Germany, Greece, Israel, Italy, Japan, Norway, South Africa, Spain, Switzerland, Taiwan (Republic of China), the UK, Turkey, the USA). We decided to include studies that enrolled some infants who were less than 8 days at study entry. We made one further deviation from our protocol, as we included studies that enrolled infants beyond 28 days of age. Most of these studies enrolled some infants who were less than 28 days old but the inclusion criteria did not have 28 days of postnatal age as an upper limit. We could not separate data for infants that were under 28 days at enrolment. The inclusion of these studies makes our review more comprehensive. The age at enrolment is stated for each study in the table <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>.</P>
<P>
<B>Excluded studies</B>
</P>
<P>One study (<LINK REF="STD-Ohls-1991" TYPE="STUDY">Ohls 1991</LINK>) was excluded as it compared an EPO-treated group with a group receiving blood transfusions. Two studies (<LINK REF="STD-Messer-1993" TYPE="STUDY">Messer 1993</LINK>; <LINK REF="STD-Testa-1998" TYPE="STUDY">Testa 1998</LINK>) were excluded as they were not randomised controlled trials. Two studies reported only as abstracts were excluded as one study from Saudi Arabia lacked information to ascertain whether the study was a randomised controlled trial or not (<LINK REF="STD-Amin-2004" TYPE="STUDY">Amin 2004</LINK>) and the other study conducted in Iran did not provide the age of the infants at the time of enrolment (<LINK REF="STD-Ahmadpour-Kacho-2004" TYPE="STUDY">Ahmadpour Kacho 2004</LINK>). We were unable to contact the authors for additional information. <LINK REF="STD-Warwood-2005" TYPE="STUDY">Warwood 2005</LINK> was a dose-finding study of darepoetin (longer-acting and more potent than EPO). Infants were randomised to receive either one or four microgram/kg of a single dose of darepoetin, without an untreated control group. <LINK REF="STD-Meyer-1996" TYPE="STUDY">Meyer 1996</LINK>, <LINK REF="STD-Bechensteen-1997" TYPE="STUDY">Bechensteen 1997</LINK> and <LINK REF="STD-Pathak-2003" TYPE="STUDY">Pathak 2003</LINK> also lacked an untreated control group. There were no outcomes of interest in the study by <LINK REF="STD-Widness-2006" TYPE="STUDY">Widness 2006</LINK>. In the searches in February 2010, we identified two additional studies (<LINK REF="STD-Badiee-2006" TYPE="STUDY">Badiee 2006</LINK>; <LINK REF="STD-Pasha-2008" TYPE="STUDY">Pasha 2008</LINK>). However, as they did not report on any of our prespecified outcomes we excluded them. In the search conducted in 2012, we identified and excluded three additional studies. In <LINK REF="STD-Mohammadzadeh-2005" TYPE="STUDY">Mohammadzadeh 2005</LINK> both groups received EPO. <LINK REF="STD-Warwood-2011" TYPE="STUDY">Warwood 2011</LINK> reported that "only one of the 20 study subjects qualified for and received a subsequent rbc transfusion during the hospitalisation". The authors do not state if the infant who received the transfusion belonged to the darepoetin or the control group. <LINK REF="STD-Ohls-2012" TYPE="STUDY">Ohls 2012</LINK> compared two dosing schedules; once a week versus three times a week of EPO in infants aged seven days or more.<BR/>
<B>
<BR/>Included studies</B>
</P>
<P>We include 30<B> </B>studies (31 comparisons) in this review. We treated the report by Giannakopoulou as two separate studies; Under <LINK REF="STD-Giannakopoulou-1998a" TYPE="STUDY">Giannakopoulou 1998a</LINK> we report on the 32 infants weighing &lt; 1000 g and under <LINK REF="STD-Giannakopoulou-1998b" TYPE="STUDY">Giannakopoulou 1998b</LINK> we report on the 36 infants weighing 1000 to 1300g. The studies are detailed in the table <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> and are briefly discussed below.</P>
<P>The detailed guidelines used for transfusions are outlined in the Additional Table (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>: <I>Transfusion Guidelines</I>).</P>
<P>
<LINK REF="STD-Akisu-2001" TYPE="STUDY">Akisu 2001</LINK> was a single-centre study performed at University of Ege, Izmir Turkey.<BR/>
</P>
<UL>
<LI>Objective: To evaluate the effect of EPO on lipid peroxidation and the activities of erythrocyte antioxidant enzymes in very low birth weight (VLBW) infants.</LI>
<LI>Population: Appropriately grown preterm infants with gestational age (GA) &lt; 33 weeks and birthweight &lt; 1500 g.</LI>
<LI>Intervention: The EPO group received high dose of EPO from day 10 of life, totaling 750 IU/kg/week (high dose). Infants in the control group received no placebo. All infants received 3 mg/kg/day (low dose) of elemental iron.</LI>
<LI>Outcomes assessed: Use of one or more red blood cell transfusions.</LI>
</UL>
<P>
<LINK REF="STD-Al_x002d_Kharfy-1996" TYPE="STUDY">Al-Kharfy 1996</LINK> was a single-centre study performed in Canada.<BR/>
</P>
<UL>
<LI>Objective: To determine whether treatment with EPO reduces transfusion requirements in preterm neonates at risk of having bronchopulmonary dysplasia (BDP) and requiring multiple transfusions.</LI>
<LI>Population: Appropriately grown preterm infants with birth weight (BW) &lt; 1250 g and having a 75% probability of having BPD determined on day 10 of life and postnatal age 10 to 17 days.</LI>
<LI>Intervention: The EPO group received EPO 200 IU/kg body weight, by subcutaneous (sc) injection, on Monday, Wednesday and Friday for six weeks (600 IU/kg/week; high dose). The control group received sham injections. Oral ferrous sulphate solution was administered to the EPO group at 6 mg of elemental iron/kg/day (high dose) and the control group received 2 mg of elemental iron/kg/day (low dose).</LI>
<LI>Outcomes assessed: Number of transfusions per infant, mortality, sepsis, retinopathy of prematurity (ROP) (stage &#8805; 3), hypertension, BPD at 28 days of age.</LI>
</UL>
<P>
<LINK REF="STD-Atasay-2002" TYPE="STUDY">Atasay 2002</LINK> was a single-centre study performed in Turkey.<BR/>
</P>
<UL>
<LI>Objective: To investigate the effect of early EPO treatment on induction of erythropoiesis and the need for transfusion in VLBW infants with acute neonatal problems.</LI>
<LI>Population: Infants with BW &lt; 1500 g and GA &lt; 32 weeks.</LI>
<LI>Intervention: The EPO group received EPO 600 IU/kg/week (high dose) sc, at seven to ten days and continued over seven to eight weeks. The control group received no EPO, placebo or iron. The EPO group was supplemented with oral iron (ferroglycine sulphate) at the dose of 3 mg/kg/day (low dose).</LI>
<LI>Outcomes assessed: Use of one or more red blood cell transfusion(s).</LI>
</UL>
<P>
<LINK REF="STD-Bader-1996" TYPE="STUDY">Bader 1996</LINK> was a two-centre study performed in Israel.<BR/>
</P>
<UL>
<LI>Objective: To assess whether an iron dose of 6 mg/kg/day is sufficient to maintain serum ferritin at adequate levels (as per authors).</LI>
<LI>Population: Preterm infants with GA &lt; 34 weeks and BW &lt; 1750 g and postnatal age three to five weeks.</LI>
<LI>Intervention: The EPO group received EPO 300 IU/kg/day sc three times a week (900 IU/kg/week; high dose), for a total duration of four weeks. The control group received no placebo or other intervention. Two weeks into the study elemental iron supplementation was begun in both groups at a dose of 6 mg/kg/day (high dose).</LI>
<LI>Outcomes assessed: Use of one or more red blood cell transfusions, side effects, sudden infant death syndrome (SIDS).</LI>
</UL>
<P>
<LINK REF="STD-Bechensteen-1993" TYPE="STUDY">Bechensteen 1993</LINK> was a four-centre study performed in Norway.<BR/>
</P>
<UL>
<LI>Objective: To determine whether VLBW infants respond to EPO with increased erythropoiesis.</LI>
<LI>Population: Preterm infants with BW 900 g to 1400 g at three weeks of age.</LI>
<LI>Intervention: The EPO group received EPO 100 IU/kg three times a week (300 IU/kg/week; low dose) sc from three to seven weeks of age. The control group received neither EPO nor placebo. Oral iron 18 mg/day (high dose) regardless of weight, began at the start of the study (three weeks). If serum iron concentration fell below 16 micromol/L, the dose was increased to 36 mg/day.</LI>
<LI>Outcomes assessed: Use of one or more red blood cell transfusions, mortality, hypertension, neutropenia, side effects.</LI>
</UL>
<P>
<LINK REF="STD-Bierer-2009" TYPE="STUDY">Bierer 2009</LINK> was a single-centre study performed in the USA.</P>
<UL>
<LI>Objective: To determine if EPO administration to neonates requiring surgery would stimulate erythropoiesis.</LI>
<LI>Population: Neonates requiring surgery. Post-natal age &lt; 28 days. The majority of infants were preterm and/or low birth weight.</LI>
<LI>Intervention: The EPO group received EPO 200 IU/kg per day or 400 IU/kg sc three times weekly (high dose). The placebo group received an equal volume of normal saline if the infant was on total parenteral nutrition and if not a sham dose was given sc and a BandAid was placed over the sham injection site. Infants received oral iron supplementation when enteral feeds reached 60 mL/kg/day.</LI>
<LI>Outcomes assessed: Volume transfused during hospitalisation (mL/kg), number of donors the infants was exposed to.</LI>
</UL>
<P>
<LINK REF="STD-Chen-1995" TYPE="STUDY">Chen 1995</LINK> was a single-centre study performed in Taiwan, Republic of China.<BR/>
</P>
<UL>
<LI>Objective: To evaluate the safety and efficacy of EPO for the treatment of anaemia of prematurity.</LI>
<LI>Population: Preterm infants with GA &#8804; 33 weeks and BW &#8804; 1750 g, haemoglobin (Hb) &lt; 10 g/dL and hematocrit (Hct) &lt; 30%.</LI>
<LI>Intervention: The EPO group (A) received 150 IU/kg iv twice a week (300 IU/kg/week; low dose); Group B) received packed washed erythrocyte transfusion, when their Hb levels were &lt; 10 g/dL with signs and symptoms attributed to anaemia or who had a Hb level &lt; 8 g/dL even if asymptomatic; group C did not received EPO or erythrocyte transfusions (three infants excluded from total 19, as they received erythrocyte transfusion later because of frequent episodes of apnoea). All infants received oral elemental iron 3 mg/kg/day (low dose). Group A and C are included in this review.</LI>
<LI>Outcomes assessed: Mortality, adverse effects.</LI>
</UL>
<P>
<LINK REF="STD-Corona-1998" TYPE="STUDY">Corona 1998</LINK> was a single-centre study performed in Italy.<BR/>
</P>
<UL>
<LI>Objective: To evaluate the efficacy of EPO, establish the optimal dose, the age at which to start, the duration of the treatment, any adverse effects and the reduction in red blood cell transfusions.</LI>
<LI>Population: Preterm infants (BW &lt; 1500 g and &lt; 33 weeks GA).</LI>
<LI>Intervention: EPO group A received EPO 150 IU/kg/week sc low dose) ; EPO group B received 300 IU/kg/week sc low dose); the control group (group C) received no treatment. All groups received oral iron 4 mg/kg/day (low dose).</LI>
<LI>Outcomes assessed: Use of one or more red blood cell transfusions, total volume (mL/kg) of blood transfused per infant (means but no standard deviation (SD) provided), side effects.</LI>
</UL>
<P>
<LINK REF="STD-Donato-1996" TYPE="STUDY">Donato 1996</LINK> was a single-centre study performed in Argentina.<BR/>
</P>
<UL>
<LI>Objective: To assess the efficacy of three different doses of recombinant human EPO (rHuEPO) to reduce the need for transfusion in premature infants with BW &lt; 1500 g.</LI>
<LI>Population: Preterm infants with GA &lt; 34 weeks and BW &lt; 1500 g.</LI>
<LI>Intervention: The placebo group (A) received human seroalbumin. The three EPO groups; Group B received EPO 50 IU/kg (150 IU/kg/week; low dose), Group C received EPO 100 IU/kg (300 IU/kg/week; low dose) and Group D received EPO 250 IU/kg (750 IU/kg/week; high dose) sc during eight consecutive weeks. All participants were given oral iron 6 mg/kg/day (high dose) and folic acid (2 mg/day) supplements, starting on day 15 of age and continuing during whole treatment period.</LI>
<LI>Outcomes assessed: Use of one or more red blood cell transfusions, average number of transfusions per infant during treatment, mortality, mean length of hospitalisation time, side effects, hypertension, SIDS.</LI>
</UL>
<P>
<LINK REF="STD-Emmerson-1993" TYPE="STUDY">Emmerson 1993</LINK> was a single-centre study performed in the UK.<BR/>
</P>
<UL>
<LI>Objective: To investigate the safety and efficacy of EPO for the prevention of anaemia of prematurity.</LI>
<LI>Population: Infants with GA between 27 and 33 weeks.</LI>
<LI>Intervention: The EPO group received low dose EPO (between 50 and 150 IU) twice a week from seven days of age and the placebo group received 4% albumin from seven days of age until discharge home. All infants received iron (6.25 mg) in the form of ferrous glycine sulphate from four weeks of age (high dose).</LI>
<LI>Outcomes assessed: Use of one or more red blood cell transfusions, volume transfused (mL/kg), mortality, hospital stay, SIDS, neutropenia.</LI>
</UL>
<P>
<LINK REF="STD-Giannakopoulou-1998a" TYPE="STUDY">Giannakopoulou 1998a</LINK> and <LINK REF="STD-Giannakopoulou-1998b" TYPE="STUDY">Giannakopoulou 1998b</LINK> was a single-centre study performed in Greece.<BR/>
</P>
<UL>
<LI>Objective: To stimulate erythrocyte production by the use of EPO and thereby decrease the requirement for red blood cell transfusions.</LI>
<LI>Population: Preterm infants with birth weights &#8804; 1300 g, postnatal age &gt; 20 days.</LI>
<LI>Intervention: The EPO group received EPO 300 IU/kg body weight, three times a week (900 IU/kg/week; high dose) from 20 days of age for six to eight weeks. The control group did not received any placebo. All infants received oral elemental iron 10 mg/kg/day (high dose).</LI>
<LI>Outcomes assessed: Mortality, side effects, hypertension, neutropenia.</LI>
<LI>We treated this report as two separate studies; Under <LINK REF="STD-Giannakopoulou-1998a" TYPE="STUDY">Giannakopoulou 1998a</LINK> we report on the 32 infants weighing &lt; 1000 g and under <LINK REF="STD-Giannakopoulou-1998b" TYPE="STUDY">Giannakopoulou 1998b</LINK> we report on the 36 infants weighing 1000 to 1300g.</LI>
</UL>
<P>
<LINK REF="STD-Griffiths-1997" TYPE="STUDY">Griffiths 1997</LINK> was a study conducted in four neonatal intensive care units (NICU) in Yorkshire, England.<BR/>
</P>
<UL>
<LI>Objective: To evaluate the role of EPO in reducing iron supplementation, which may exacerbate free radical change, leading to lung disease.</LI>
<LI>Population: Preterm infants with GA &#8804; 32 weeks and/or BW &#8804; 1500 g, requirement for mechanical ventilation and/or supplemental oxygen at birth. Postnatal age seven to 14 days.</LI>
<LI>Intervention: The EPO group received 480 IU/kg/week (low dose) and the control group received placebo (4% human albumin) starting at seven to 14 days of age. All infants received oral iron (3.0 mg/kg/day) (low dose) from four weeks after birth.</LI>
<LI>Outcomes assessed: Mortality, BPD (at 36 weeks PMA), number of blood transfusions per infant (medians provided), SIDS</LI>
</UL>
<P>
<BR/>
<LINK REF="STD-Javier-Manchon-1997" TYPE="STUDY">Javier Manchon 1997</LINK> was a multi-centre study involving three centres in Barcelona, Spain.<BR/>
</P>
<UL>
<LI>Objective: To test the therapeutic effect of EPO on anaemia of prematurity.</LI>
<LI>Population: Preterm infants &lt; 34 weeks GA, who at 28 days after birth had Hb levels &lt; 10.5 g/dL.</LI>
<LI>Intervention: The EPO group received high dose EPO (200 IU/kg/day) three days a week for four weeks and ferrous sulphate 4 mg/kg/day (low dose). The control infants did not receive placebo, EPO or iron.</LI>
<LI>Outcomes assessed: Use of one or more red blood cell transfusions between 30 and 60 days of age.</LI>
</UL>
<P>
<LINK REF="STD-Juul-2003" TYPE="STUDY">Juul 2003</LINK> was a single-centre study performed in the USA.<BR/>
</P>
<UL>
<LI>Objective: To determine whether enterally dosed EPO stimulates erythropoiesis in preterm infants.</LI>
<LI>Population: Preterm infants with BW between 700 to 1500 g and receiving at least 30 mL/kg per day of enteral feeding.</LI>
<LI>Intervention: The EPO group received 1000 IU/kg (enterally) per day divided into two daily feedings (7000 IU/kg/week; high dose), for 14 days. The placebo group received 5% dextrose in water for 14 days. All participants received supplemental iron (iron dextran, 1.0 mg/kg/day, or enteral ferrous sulphate 6 mg/kg/day (high dose)).</LI>
<LI>Outcomes assessed: Phlebotomy loss (mL) and packed red blood cell transfusion volume (mL). Evidence of feeding intolerance and other adverse effects.</LI>
</UL>
<P>
<LINK REF="STD-Kivivuori-1999" TYPE="STUDY">Kivivuori 1999</LINK> was a four-centre study performed in Helsinki and Espoo, Finland.<BR/>
</P>
<UL>
<LI>Objective: To compare oral and intramuscular routes of administration of iron in EPO treated VLBW infants.</LI>
<LI>Population: VLBW infants (birthweight ranged from 625 to 1470 g).</LI>
<LI>Intervention: One EPO group received EPO 300 IU/kg sc three times/week, 900 IU/kg/week (high dose) sc and oral iron 6 mg/kg/day (high dose). Another EPO group received EPO 900 IU/kg/week and weekly im iron 12 mg/kg (high dose). The control group received im iron 12 mg/kg/week but no EPO.</LI>
<LI>Outcomes assessed: Use of one or more red blood cell transfusions. Adverse effects.</LI>
</UL>
<P>
<LINK REF="STD-Kumar-1998" TYPE="STUDY">Kumar 1998</LINK> was a single-centre study performed in the USA.<BR/>
</P>
<UL>
<LI>Objective: To evaluate the efficacy and safety of EPO in VLBW infants with anaemia of prematurity.</LI>
<LI>Population: Preterm infants (GA &lt; 32 weeks, BW &lt; 1250 g with anaemia of prematurity.</LI>
<LI>Intervention: The EPO group received 300 IU/kg/dose of EPO sc twice a week (600 IU/kg/week; high dose) for six weeks. The control group received identical volume of placebo suspension (normal saline). All infants received elemental iron 6 mg/kg/day (high dose).</LI>
<LI>Outcomes assessed: Use of one or more red blood cell transfusions, number of erythrocyte transfusions (per infant), entry to discharge duration (days), side effects.</LI>
</UL>
<P>
<LINK REF="STD-Maier-2002" TYPE="STUDY">Maier 2002</LINK> was a multi-centre study performed in 14 centres in four European countries (Belgium, France, Germany, Switzerland).<BR/>
</P>
<UL>
<LI>Objective: To investigate whether EPO reduces the need for transfusions in extremely low birth weight (ELBW) infants and to determine the optimal dose of treatment.</LI>
<LI>Population: Preterm infants with BW 500 to 999 g.</LI>
<LI>Intervention: The EPO group received EPO 200 IU/kg/dose three times a week sc (600 IU/kg/week, high dose). The volume was increased by the equivalent of 50 IU/kg per dose if the hematocrit declined by 6% during any two-week period during the trial, but was withheld if the hematocrit was &gt; 45%. The control group 40 received an identical volume of placebo. Enteral iron 3 mg/kg/day (low dose) was given to all infants from days three to five and was increased at days 12 to 14 to 6 mg/kg/day (high dose) and to 9 mg/kg/day (high dose) at days 24 to 26 of life.</LI>
<LI>Outcomes assessed: Use of one or more red blood cell transfusions, donor exposure, mortality during hospital stay, necrotising enterocolitis (NEC), IVH, periventricular leukomalacia (PVL), ROP, days in oxygen, days in NICU, days in hospital.</LI>
</UL>
<P>
<LINK REF="STD-Meyer-1994" TYPE="STUDY">Meyer 1994</LINK> was a single-centre study performed in South Africa.<BR/>
</P>
<UL>
<LI>Objective: To assess the efficacy of EPO in the treatment of anaemia of prematurity.</LI>
<LI>Population: Preterm infants (&#8804; 32 weeks GA, weight &#8804; 1500 g, postnatal age two to eight weeks, central hematocrit Hct &#8804; 35%).</LI>
<LI>Intervention: The EPO group received high dose EPO (200 IU/kg three times a week; 600 IU/kg/week). The control group received an identical volume of placebo. All infants received 3 mg/kg/day of iron (low dose).</LI>
<LI>Outcomes assessed: Use of one or more red blood cell transfusions, sepsis, NEC, SIDS.</LI>
</UL>
<P>
<LINK REF="STD-Pollak-2001" TYPE="STUDY">Pollak 2001</LINK> was a single-centre study conducted in Vienna, Austria.<BR/>
</P>
<UL>
<LI>Objective: To test the efficacy and safety of combining intravenous iron in amounts approximately the in-utero accretion rate and the postnatal iron loss with EPO in VLBW infants.</LI>
<LI>Population: Preterm infants &lt; 31 weeks gestation and &lt; 1300 g birthweight not treated with red blood cell transfusions during the study period.</LI>
<LI>Intervention: During a three-day run-in baseline period 9 mg/kg/day of iron poly maltose complex (high dose) was administered to all participants in all groups. This was followed by a treatment period during which participants received: 1) the same oral iron supplementation dose alone (oral iron group - control group); 2) 300 IU/kg/day of EPO iv at three-day intervals (600 IU/kg/week, high dose) along with the same oral iron supplement as the oral iron group (EPO + oral iron group); or 3) 2 mg of intravenous iron sucrose/kg/day + EPO as in group two (iv iron + EPO group). To maintain comparability of iron intake among the three groups, this last group also received EPO and oral iron in an identical manner to the EPO + oral iron group.</LI>
<LI>Outcomes assessed: Mortality, sepsis, ROP, BPD (oxygen dependency at 36 weeks PMA).</LI>
</UL>
<P>
<LINK REF="STD-Reiter-2005" TYPE="STUDY">Reiter 2005</LINK> was a single-centre study performed in the USA.<BR/>
</P>
<UL>
<LI>Objective: To determine the effectiveness of a 10-day EPO course in preterm infants.</LI>
<LI>Population: Preterm infants &lt; 32 weeks gestation, hematocrit &#8804; 28%, post-conceptual age of &lt; 48 weeks or five months chronological age.</LI>
<LI>Intervention: The EPO group received 300 IU/kg/day (high dose) and 6 mg/kg/day of enteral iron (high dose) versus iron only. Both groups received the intervention for 10 days.</LI>
<LI>Outcomes assessed: Use of one or more red blood cell transfusions, volume of red blood cells required (mL/kg).</LI>
</UL>
<P>
<LINK REF="STD-Rocha-2001" TYPE="STUDY">Rocha 2001</LINK> was a single-centre study performed in Brazil.<BR/>
</P>
<UL>
<LI>Objective: To assess the efficacy of EPO for the prevention and treatment of anaemia of prematurity.</LI>
<LI>Population: Preterm infants with GA up to 33 weeks, BW up to 1550 g and postnatal age between 10 and 35 days.</LI>
<LI>Intervention: The two EPO groups received either daily doses of 100 IU/kg of EPO or twice weekly doses of 350 IU/kg (700 IU/kg/week, high dose). The EPO groups were given iron (ferrous sulphate) 3 mg/kg/day enterally, and increased to 6 mg/kg/day in the second week of treatment. In the control group iron supplementation was initiated around the 30th day of life. The control group did not receive any placebo.</LI>
<LI>Outcomes assessed: Mean number of blood transfusions per participant (no SD provided), two or more blood transfusions per participant.</LI>
</UL>
<P>
<LINK REF="STD-Romagnoli-2000" TYPE="STUDY">Romagnoli 2000</LINK> was a single-centre study performed in Italy.</P>
<UL>
<LI>Objective: To assess the effectiveness of rhEPO.</LI>
<LI>Population: Infants with PMA &#8804; 30 weeks and those infants of 31 - 34 weeks PMA suffering from respiratory distress syndrome and requiring mechanical ventilation.</LI>
<LI>Intervention: Treated infants received rhEPO doses of 300 IU/kg body weight sc on each Monday, Wednesday and Friday from the 2nd to the 7th week of life (high dose). Iron supplementation (Intrafer-Geymonat) was given at a dose of 1 mg/kg per day iv from the 2nd to the 4th week (low dose); thereafter 12 mg/kg/day orally until the 7th week of life.</LI>
<LI>Outcomes assessed: Retinopathy of prematurity (stage 1 - 2 and stage 3 - 4), IVH (&gt; grade 2), sepsis, NEC, number of infants transfused, number of transfusions per infant.</LI>
</UL>
<P>
<LINK REF="STD-Ronnestad-1995" TYPE="STUDY">Ronnestad 1995</LINK> was a single-centre study performed in Norway.<BR/>
</P>
<UL>
<LI>Objective: To investigate whether EPO given to infants &lt; 32 weeks GA, fed their own mother's milk supplemented with a bovine milk protein and electrolyte fortifier together with moderate iron supplementation, would ameliorate the anaemia and thus reduce the need for bred blood cell transfusions after the second week of life.</LI>
<LI>Population: Preterm infants, &lt; 32 weeks. Age 14 - 22 days.</LI>
<LI>Intervention: The EPO group received EPO 150 IU/kg three times per week (450 IU/kg/week; low dose) or placebo. All infants received 4 mg/kg/day of iron (low dose) as ferrous fumarase.</LI>
<LI>Outcomes assessed: Neutropenia.</LI>
</UL>
<P>
<LINK REF="STD-Samanci-1996" TYPE="STUDY">Samanci 1996</LINK> was a single-centre study performed in Turkey.<BR/>
</P>
<UL>
<LI>Objective: To determined whether EPO would prevent anaemia of prematurity and reduce the need for transfusion in infants with VLBW.</LI>
<LI>Population: Preterm infants with GA &#8804; 32 weeks, BW of &#8804; 1250 g. Post-natal age at the first dose was two to four weeks.</LI>
<LI>Intervention: The EPO group received 200 IU/kg sc three times weekly (600 IU/kg/week, high dose), for four weeks. The control group received an equivalent volume of placebo sc, three times weekly, for four weeks. All infants received oral supplements of elemental iron (3 mg/kg/day) (low dose) during the study period.</LI>
<LI>Outcomes assessed: Use of one or more red blood cell transfusions, number of blood transfusions per infant, NEC, IVH, major adverse events.</LI>
</UL>
<P>
<LINK REF="STD-Shannon-1991" TYPE="STUDY">Shannon 1991</LINK> was a three-centre study performed in the USA.<BR/>
</P>
<UL>
<LI>Objective: Not stated.</LI>
<LI>Population: Preterm infants with birth weights &#8804; 1250 g.</LI>
<LI>Intervention: The EPO group received EPO 100 IU/kg, twice each week (200 IU/kg/week; low dose) for six weeks. The control group intravenous injections of identical volume of placebo twice each week for six weeks. All infants received 3 mg/kg/day of oral iron (low dose) and continued at the discretion of the attending physician.</LI>
<LI>Outcomes assessed: Use of one or more red blood cell transfusions, mortality, NEC, hypertension, neutropenia, side effects.</LI>
</UL>
<P>
<LINK REF="STD-Shannon-1992" TYPE="STUDY">Shannon 1992</LINK> was a single-centre study performed in the USA.<BR/>
</P>
<UL>
<LI>Objective: Not stated.</LI>
<LI>Population: Preterm infants with GA &lt; 33 weeks and BW &lt; 1250 g</LI>
<LI>Intervention: The EPO group received EPO 100 IU/kg, 5 times a week (500 IU/kg/week; high dose. The control group received an identical volume of placebo suspension, five times a week. Oral iron was started in all infants at 3 mg/kg/day (low dose), divided in three doses and given between feedings. The iron dose was increased to 6 mg/kg/day (high dose) for infants who were tolerating full caloric feedings.</LI>
<LI>Outcomes assessed: Use of one or more red blood cell transfusions, major adverse events.</LI>
</UL>
<P>
<LINK REF="STD-Shannon-1995" TYPE="STUDY">Shannon 1995</LINK> was a multi-centre study at 11 centres in the USA.<BR/>
</P>
<UL>
<LI>Objective: To assess whether treatment with EPO would stimulate erythropoiesis and thereby reduce the need for erythrocyte transfusions in preterm infants.</LI>
<LI>Population: Preterm infants with GA &lt; 31 weeks with BW of &#8804; 1250 g.</LI>
<LI>Intervention: The EPO group received 100 IU/kg/day [from Monday through Friday (500 IU/kg/week; high dose)] for six weeks or until the infants were ready to be discharged home. Doses EPO (or placebo) were adjusted weekly according to changes in body weight. The control group received an identical volume of placebo suspension. Participants received oral iron supplements at study entry to achieve a total enteral intake of 3 mg/kg/day of elemental iron (low dose). Total iron intake was increased to 6 mg/kg/day (high dose) when the infants tolerated full caloric feeding enterally.</LI>
<LI>Outcomes assessed: Use of one or more red blood cell transfusions, mean number of erythrocyte transfusions per infant, mortality, sepsis, NEC, ROP, hypertension, SIDS, side effects.</LI>
</UL>
<P>
<LINK REF="STD-Whitehall-1999" TYPE="STUDY">Whitehall 1999</LINK> was a single-centre study conducted in Australia.<BR/>
</P>
<UL>
<LI>Objective: To evaluate safety and efficacy of EPO in reducing the need for red cell transfusions in anaemia of prematurity.</LI>
<LI>Population: Infants with GA &#8804; 32 weeks.</LI>
<LI>Intervention: Infants in the EPO group received 400 IU/kg every second day x 10 doses (high dose). Infants in the control group received no placebo. Both groups received 3 mg/kg/day of iron (low dose) increased to 6 mg/kg/day (high dose) as tolerated.</LI>
<LI>Outcomes assessed: Total volume (mL/kg) of blood transfused, number of transfusions per infant, mortality during hospital stay.</LI>
</UL>
<P>
<LINK REF="STD-Yamada-1999a" TYPE="STUDY">Yamada 1999a</LINK> was a single-centre study conducted in Japan.<BR/>
</P>
<UL>
<LI>Objective: To assess the efficacy of EPO in the treatment of anaemia of prematurity.</LI>
<LI>Population: Infants with BW 1000 to 1499 g, GA &lt; 33 weeks, haemoglobin &lt; 12 g/dL and oral milk intake &gt; 50 mL/kg/day.</LI>
<LI>Intervention: The EPO group received EPO (200 IU/kg twice a week, low dose) for eight weeks and the control group received no study drug or placebo. All infants received 3 mg/kg/day of oral iron (low dose).</LI>
<LI>Outcomes assessed: Use of one or more red blood transfusions, total volume of blood transfused (mL/infant), number of transfusions per infant, side effects.</LI>
</UL>
<P>
<LINK REF="STD-Yamada-1999b" TYPE="STUDY">Yamada 1999b</LINK> was a single-centre study conducted in Japan.<BR/>
</P>
<UL>
<LI>Objective: To assess the efficacy of EPO in the treatment of anaemia of prematurity.</LI>
<LI>Population: Infants with BW 500 to 999 g, GA &lt; 33 weeks, haemoglobin &lt; 13 g/dL and oral milk intake &gt; 50 mL/kg/day.</LI>
<LI>Intervention: The EPO group received low dose EPO (200 IU/kg twice a week) for eight weeks and the control group received no study drug or placebo. All infants received 3 mg/kg/day of oral iron (low dose).</LI>
<LI>Outcomes assessed: Use of one or more red blood transfusions, total volume of blood transfused (mL/infant), number of transfusions per infant, side effects.</LI>
</UL>
<P>Three different routes of administration were used; subcutaneous (sc) (<LINK REF="STD-Shannon-1992" TYPE="STUDY">Shannon 1992</LINK>; <LINK REF="STD-Bechensteen-1993" TYPE="STUDY">Bechensteen 1993</LINK>; <LINK REF="STD-Emmerson-1993" TYPE="STUDY">Emmerson 1993</LINK>; <LINK REF="STD-Meyer-1994" TYPE="STUDY">Meyer 1994</LINK>; <LINK REF="STD-Yamada-1999a" TYPE="STUDY">Yamada 1999a</LINK>; <LINK REF="STD-Yamada-1999b" TYPE="STUDY">Yamada 1999b</LINK>; <LINK REF="STD-Ronnestad-1995" TYPE="STUDY">Ronnestad 1995</LINK>; <LINK REF="STD-Shannon-1995" TYPE="STUDY">Shannon 1995</LINK>; <LINK REF="STD-Al_x002d_Kharfy-1996" TYPE="STUDY">Al-Kharfy 1996</LINK>; <LINK REF="STD-Bader-1996" TYPE="STUDY">Bader 1996</LINK>; <LINK REF="STD-Donato-1996" TYPE="STUDY">Donato 1996</LINK>; <LINK REF="STD-Samanci-1996" TYPE="STUDY">Samanci 1996</LINK>; <LINK REF="STD-Griffiths-1997" TYPE="STUDY">Griffiths 1997</LINK>; <LINK REF="STD-Javier-Manchon-1997" TYPE="STUDY">Javier Manchon 1997</LINK>; <LINK REF="STD-Corona-1998" TYPE="STUDY">Corona 1998</LINK>; <LINK REF="STD-Giannakopoulou-1998a" TYPE="STUDY">Giannakopoulou 1998a</LINK>; <LINK REF="STD-Giannakopoulou-1998b" TYPE="STUDY">Giannakopoulou 1998b</LINK>; <LINK REF="STD-Kumar-1998" TYPE="STUDY">Kumar 1998</LINK>; <LINK REF="STD-Kivivuori-1999" TYPE="STUDY">Kivivuori 1999</LINK>; <LINK REF="STD-Whitehall-1999" TYPE="STUDY">Whitehall 1999</LINK>; <LINK REF="STD-Romagnoli-2000" TYPE="STUDY">Romagnoli 2000</LINK>; <LINK REF="STD-Akisu-2001" TYPE="STUDY">Akisu 2001</LINK>; <LINK REF="STD-Rocha-2001" TYPE="STUDY">Rocha 2001</LINK>; <LINK REF="STD-Atasay-2002" TYPE="STUDY">Atasay 2002</LINK>; <LINK REF="STD-Reiter-2005" TYPE="STUDY">Reiter 2005</LINK>; <LINK REF="STD-Bierer-2009" TYPE="STUDY">Bierer 2009</LINK>), intravenous (iv) (<LINK REF="STD-Pollak-2001" TYPE="STUDY">Pollak 2001</LINK>; <LINK REF="STD-Shannon-1991" TYPE="STUDY">Shannon 1991</LINK>; <LINK REF="STD-Chen-1995" TYPE="STUDY">Chen 1995</LINK>;) and oral (<LINK REF="STD-Juul-2003" TYPE="STUDY">Juul 2003</LINK>), iv or sc (<LINK REF="STD-Maier-2002" TYPE="STUDY">Maier 2002</LINK>). The dose of EPO varied from 150 IU/kg/week (<LINK REF="STD-Donato-1996" TYPE="STUDY">Donato 1996</LINK>; <LINK REF="STD-Corona-1998" TYPE="STUDY">Corona 1998</LINK>) to 2100 IU/kg/week (<LINK REF="STD-Reiter-2005" TYPE="STUDY">Reiter 2005</LINK>) when given subcutaneously. When given intravenously, the dose varied from 200 IU/kg/week (<LINK REF="STD-Shannon-1991" TYPE="STUDY">Shannon 1991</LINK>) to 300 IU/kg/week (<LINK REF="STD-Chen-1995" TYPE="STUDY">Chen 1995</LINK>). <LINK REF="STD-Juul-2003" TYPE="STUDY">Juul 2003</LINK> provided 7000 IU/kg/week enterally.</P>
<P>Different EPO preparations were used; Recormon, Boehringer-Mannheim, Germany (<LINK REF="STD-Akisu-2001" TYPE="STUDY">Akisu 2001</LINK>); Eprex (provided by Cilag Zug, Switzerland, Ortho Pharmaceutical Canada Ltd., Janssen-Cilag or Guler Pharmaceutical Corp, Istanbul, Turkey) (<LINK REF="STD-Bechensteen-1993" TYPE="STUDY">Bechensteen 1993</LINK>; <LINK REF="STD-Emmerson-1993" TYPE="STUDY">Emmerson 1993</LINK>; <LINK REF="STD-Meyer-1994" TYPE="STUDY">Meyer 1994</LINK>; <LINK REF="STD-Chen-1995" TYPE="STUDY">Chen 1995</LINK>; <LINK REF="STD-Ronnestad-1995" TYPE="STUDY">Ronnestad 1995</LINK>; <LINK REF="STD-Al_x002d_Kharfy-1996" TYPE="STUDY">Al-Kharfy 1996</LINK>; <LINK REF="STD-Bader-1996" TYPE="STUDY">Bader 1996</LINK>; <LINK REF="STD-Samanci-1996" TYPE="STUDY">Samanci 1996</LINK>; <LINK REF="STD-Griffiths-1997" TYPE="STUDY">Griffiths 1997</LINK>; <LINK REF="STD-Giannakopoulou-1998a" TYPE="STUDY">Giannakopoulou 1998a</LINK>; <LINK REF="STD-Giannakopoulou-1998b" TYPE="STUDY">Giannakopoulou 1998b</LINK>; <LINK REF="STD-Kivivuori-1999" TYPE="STUDY">Kivivuori 1999</LINK>; <LINK REF="STD-Whitehall-1999" TYPE="STUDY">Whitehall 1999</LINK>; <LINK REF="STD-Atasay-2002" TYPE="STUDY">Atasay 2002</LINK> ); Amgen (<LINK REF="STD-Shannon-1991" TYPE="STUDY">Shannon 1991</LINK>), Eogen alpha, Amgen, Inc. Thousand Oaks, CA, USA (<LINK REF="STD-Reiter-2005" TYPE="STUDY">Reiter 2005</LINK>); unnamed products (<LINK REF="STD-Shannon-1992" TYPE="STUDY">Shannon 1992</LINK>; <LINK REF="STD-Shannon-1995" TYPE="STUDY">Shannon 1995</LINK>; <LINK REF="STD-Javier-Manchon-1997" TYPE="STUDY">Javier Manchon 1997</LINK>; <LINK REF="STD-Corona-1998" TYPE="STUDY">Corona 1998</LINK>; <LINK REF="STD-Kumar-1998" TYPE="STUDY">Kumar 1998</LINK>; <LINK REF="STD-Yamada-1999a" TYPE="STUDY">Yamada 1999a</LINK>; <LINK REF="STD-Yamada-1999b" TYPE="STUDY">Yamada 1999b</LINK>; <LINK REF="STD-Romagnoli-2000" TYPE="STUDY">Romagnoli 2000</LINK>; <LINK REF="STD-Rocha-2001" TYPE="STUDY">Rocha 2001</LINK>; <LINK REF="STD-Juul-2003" TYPE="STUDY">Juul 2003</LINK>; <LINK REF="STD-Bierer-2009" TYPE="STUDY">Bierer 2009</LINK>), NeoRecormon, F. Hofman-La Roche, Basel, Switzerland (<LINK REF="STD-Maier-2002" TYPE="STUDY">Maier 2002</LINK>), Erypo, Janssen-Cilag Pharma, Vienna, Austria (<LINK REF="STD-Pollak-2001" TYPE="STUDY">Pollak 2001</LINK>), and Hemax, Bio Sidus, S. A. (<LINK REF="STD-Donato-1996" TYPE="STUDY">Donato 1996</LINK>).</P>
<P>Three studies did not state that guidelines for red blood cell transfusions were in place (<LINK REF="STD-Shannon-1991" TYPE="STUDY">Shannon 1991</LINK>; <LINK REF="STD-Chen-1995" TYPE="STUDY">Chen 1995</LINK>; <LINK REF="STD-Akisu-2001" TYPE="STUDY">Akisu 2001</LINK>). In only one study was it explicit that infants who had received erythrocyte transfusions prior to study entry were excluded (<LINK REF="STD-Samanci-1996" TYPE="STUDY">Samanci 1996</LINK>). For transfusion guidelines see Additional Table (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>: <I>Transfusion Guidelines</I>).</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2013-11-21 14:59:00 -0500" MODIFIED_BY="[Empty name]">
<P>The assessment of individual studies is presented in the table '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>'. All studies were reported as randomised controlled trials. Information on which to base our judgements on whether a study used concealed allocation or not was often not clearly reported. We considered the concealment of allocation to be appropriate in 10 studies (<LINK REF="STD-Shannon-1992" TYPE="STUDY">Shannon 1992</LINK>; <LINK REF="STD-Bechensteen-1993" TYPE="STUDY">Bechensteen 1993</LINK>; <LINK REF="STD-Emmerson-1993" TYPE="STUDY">Emmerson 1993</LINK>; <LINK REF="STD-Shannon-1995" TYPE="STUDY">Shannon 1995</LINK>; <LINK REF="STD-Samanci-1996" TYPE="STUDY">Samanci 1996</LINK>; <LINK REF="STD-Al_x002d_Kharfy-1996" TYPE="STUDY">Al-Kharfy 1996</LINK>; <LINK REF="STD-Griffiths-1997" TYPE="STUDY">Griffiths 1997</LINK>; <LINK REF="STD-Romagnoli-2000" TYPE="STUDY">Romagnoli 2000</LINK>; <LINK REF="STD-Pollak-2001" TYPE="STUDY">Pollak 2001</LINK>; <LINK REF="STD-Maier-2002" TYPE="STUDY">Maier 2002</LINK>). In general, the studies were of small sample size ranging from eight (<LINK REF="STD-Shannon-1992" TYPE="STUDY">Shannon 1992</LINK>) to 230 infants (<LINK REF="STD-Romagnoli-2000" TYPE="STUDY">Romagnoli 2000</LINK>). The studies often lacked a sample size calculation. Most studies did not use a placebo or sham injection, precluding blinding of the intervention and the outcome measure assessment (<LINK REF="STD-Bechensteen-1993" TYPE="STUDY">Bechensteen 1993</LINK>; <LINK REF="STD-Yamada-1999a" TYPE="STUDY">Yamada 1999a</LINK>; <LINK REF="STD-Yamada-1999b" TYPE="STUDY">Yamada 1999b</LINK>; <LINK REF="STD-Chen-1995" TYPE="STUDY">Chen 1995</LINK>; <LINK REF="STD-Bader-1996" TYPE="STUDY">Bader 1996</LINK>; <LINK REF="STD-Javier-Manchon-1997" TYPE="STUDY">Javier Manchon 1997</LINK>; <LINK REF="STD-Corona-1998" TYPE="STUDY">Corona 1998</LINK>; <LINK REF="STD-Giannakopoulou-1998a" TYPE="STUDY">Giannakopoulou 1998a</LINK>; <LINK REF="STD-Giannakopoulou-1998b" TYPE="STUDY">Giannakopoulou 1998b</LINK>; <LINK REF="STD-Kivivuori-1999" TYPE="STUDY">Kivivuori 1999</LINK>; <LINK REF="STD-Whitehall-1999" TYPE="STUDY">Whitehall 1999</LINK>; <LINK REF="STD-Romagnoli-2000" TYPE="STUDY">Romagnoli 2000</LINK>; <LINK REF="STD-Akisu-2001" TYPE="STUDY">Akisu 2001</LINK>; <LINK REF="STD-Pollak-2001" TYPE="STUDY">Pollak 2001</LINK>; <LINK REF="STD-Rocha-2001" TYPE="STUDY">Rocha 2001</LINK>; <LINK REF="STD-Atasay-2002" TYPE="STUDY">Atasay 2002</LINK>; <LINK REF="STD-Reiter-2005" TYPE="STUDY">Reiter 2005</LINK>).</P>
<P>We performed two post hoc secondary analyses for the primary outcome 'Use of one or more red blood cell transfusions'. In the first, we compared those studies that used concealed allocation (a placebo or sham-injection to blind the intervention) and in which there was blinding of outcome measure assessment to those studies in which this was not evident from the published report. In the second post hoc analysis, we compared the studies that used strict criteria for red blood cell transfusions with those that used no or less strict criteria.<BR/>
</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2014-03-04 19:08:20 -0500" MODIFIED_BY="[Empty name]">
<P>For this update one study (<LINK REF="STD-Romagnoli-2000" TYPE="STUDY">Romagnoli 2000</LINK>) was moved from the early EPO review (<LINK REF="REF-Ohlsson-2012" TYPE="REFERENCE">Ohlsson 2012</LINK>) to this late EPO review. This added 230 infants to the review. The review now includes thirty studies (31 comparisons) that randomised 1591 infants. For details of results, see <LINK TAG="ANALYSES_AND_DATA" TYPE="SECTION">Data and analyses</LINK>.</P>
<P>
<B>Primary Outcome:</B>
</P>
<P>
<I>
<B>Late initiation of erythropoietin (EPO) (8 - 28 days) versus placebo or no intervention (Comparison 1)<BR/>
</B>
</I>
<B>
<BR/>
<I>The use of one or more red blood cell transfusions </I>
</B>(<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>)<B> (<I>
<U>Outcome 1.1</U>)</I>
</B>
<BR/>A total of 20 studies including 1142 infants reported on the use of one or more red blood cell transfusions following the use of either low or high dose of EPO. There was a significant reduction in the use of one or more red blood cell transfusions (typical risk ratio (RR) 0.71, 95% confidence interval (CI) 0.64 to 0.79; typical risk difference (RD); -0.17, 95% CI -0.22 to -0.12; number needed to treat for an additional beneficial outcome (NNTB); 6, 95% CI 5 to 8). There was moderate heterogeneity for this outcome (for RR; I²<SUP> </SUP>= 68.0%; for RD; I²<SUP> </SUP>= 60.0%).</P>
<P>
<B>Subgroup analyses:</B>
<BR/>We conducted further analyses including studies that used a <B>high dose of EPO</B> (&gt; 500 IU/kg/week) or a <B>low dose of EPO</B> (&#8804; 500 IU/kg/week).<BR/>
</P>
<P>
<I>
<B>High dose of EPO (<U>Outcome 1.2</U>)</B>
</I>
<BR/>The summary estimates for 14 studies including 912 infants testing a <B>high dose of EPO</B> <B>(<U>Outcome 1.2</U>)</B> were statistically significant with a typical RR of 0.76 (95% CI 0.68 to 0.86), a typical RD of -0.14 (95% CI -0.19 to -0.08) and a NNTB of 7 (95% CI 5 to 13). There was moderate heterogeneity for this outcome for RR (I² = 66%) and for RD (I² = 62%).</P>
<P>We conducted a subgroup analysis for <B>high dose of EPO in combination with high dose of iron</B> <B>(<U>Outcome 1.2.1</U>)</B>. Six studies (n = 318) showed a typical RR of 0.74 (95% CI 0.62 to 0.88), a typical RD of -0.16 (95% CI -0.24 to -0.08) and NNTB of 6 (95% CI 4 to 13). There was high heterogeneity for both RR (I² = 79%) and for RD (I² = 78%).</P>
<P>Eight studies of <B>high EPO and low dose of iron</B> <B>(<U>Outcome 1.2.2</U>)</B> (n = 594) showed a typical RR of 0.78 (95% CI 0.67 to 0.91), a typical RD of -0.13 (95% CI -0.20 to -0.05) and NNTB of 8 (95% CI 5 to 20). There was moderate heterogeneity for RR (I²<SUP> </SUP>= 58%) and low heterogeneity for RD (I = 38%).</P>
<P>
<BR/>
<I>
<B>Low dose of EPO (<U>Outcome 1.3</U>)</B>
</I>
</P>
<P>The summary estimates for seven studies including 239 infants testing a <B>low dose of EPO (<U>Outcome 1.3</U>) </B>were statistically significant with a typical RR of 0.53 (95% CI 0.42 to 0.67), a typical RD of -0.34 (95% CI -0.45 to -0.23) and a NNTB of 3 (95% CI 2 to 4). There was moderate heterogeneity for RR (I² = 59%) and minimal heterogeneity for RD (I² = 14%).</P>
<P>We conducted a subgroup analysis for l<B>ow dose of EPO in combination with high dose of iron (<U>Outcome 1.3.1</U>)</B>. Three studies (n = 77) showed a typical RR of 0.50 (95% CI 0.31 to 0.79), a typical RD of -0.31 (95% CI -0.49 to -0.13) and a NNTB of 3 (95% CI 2 to 8). There was no significant heterogeneity for this outcome for RR (I² = 0%) and RD (I²<SUP> </SUP>= 0%).</P>
<P>Four studies (n = 162) evaluated the effectiveness of <B>low dose of EPO in combination with low dose of iron (<U>Outcome 1.3.2</U>)</B>. The typical RR was 0.54 (95% CI 0.41 to 0.71), the typical RD was -0.36 (95% CI -0.49 to - 0.22) and the NNTB was 3 (95% CI 2 to 5). There was high heterogeneity (I² = 76%) for RR and moderate heterogeneity for RD (I² = 53%).</P>
<P>
<B>Secondary outcomes:</B>
</P>
<P>
<I>
<B>The total volume (mL/kg) of blood transfused per infant (<U>Outcome 1.4</U>)</B>
</I>
<B>
<BR/>
</B>Five studies including 197 infants reported on the total volume of blood transfused per infant. The typical mean difference (MD) between the groups was not statistically significant, with a typical MD of -1.61 mL/kg (95% CI -5.78 to 2.57) transfused per infant. There was high heterogeneity (I² = 92%). <LINK REF="STD-Corona-1998" TYPE="STUDY">Corona 1998</LINK> (n = 60) reported on this outcome but provided only the means with no standard deviation (SD). In the two EPO groups combined the mean was 20 mL/kg and in the control group it was 32 mL/kg (P &lt; 0.01, according to the authors).<BR/>
</P>
<P>
<I>
<B>Number of red blood cell transfusions per infant (<U>Outcome 1.5</U>)</B>
</I>
<B>
<BR/>
</B>The number of red blood cell transfusions per infant was reported in 11 studies enrolling 817 infants. The significant typical MD was -0.22 (95% CI -0.38 to -0.06) favouring the EPO group. There was high heterogeneity (I² = 94%). In <LINK REF="STD-Griffiths-1997" TYPE="STUDY">Griffiths 1997</LINK> (n = 42), the median number of blood transfusions was lower for the infants in the EPO group (difference in medians -2 (95% CI -4 to 0)).<BR/>
<BR/>
<I>
<B>Number of donors to whom the infant was exposed </B>
</I>(<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>) <B>(<I>
<U>Outcome 1.6</U>)</I>
</B>
<BR/>Two studies reported on donor exposure in 165 enrolled infants. The significant MD was 0.45 (95% CI 0.20 to 0.69) indicating a higher donor exposure number in the EPO group. There was high heterogeneity for this outcome (I² = 93%).<BR/>
<BR/>
<I>
<B>Mortality during initial hospital stay (all causes of mortality) (<U>Outcome 1.7</U>)</B>
</I>
<B>
<BR/>
</B>Thirteen studies (14 comparisons) including 767 infants reported on mortality during initial hospital stay. The non significant typical RR was 0.82 (95% CI 0.49 to 1.39) and the typical RD was -0.01 (95% CI -0.05 to 0.02). There was no statistically significant heterogeneity for this outcome for either RR (I² = 0%) or RD (I² = 0%).<BR/>
<BR/>
<I>
<B>Retinopathy of prematurity (ROP) (all stages or stage not reported) (</B>
</I>
<LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>) <I>
<B>(<U>Outcome 1.8</U>) </B>
<BR/>
</I>Three<I> </I>studies including 404 infants reported on ROP (all stages), with a non significant typical RR 1.27 (95% CI 0.99 to 1.64) and a typical RD of 0.09 (95% CI -0.00 to 0.18). There was high heterogeneity for this outcome for both RR (I² = 83%) and RD (I² = 82%).<BR/>
<BR/>
<I>
<B>Retinopathy of prematurity (ROP) stage </B>&#8805;<B> 3 (</B>
</I>
<LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>) <I>
<B>(<U>Outcome 1.9</U>) </B>
</I>
<BR/>Three trials enrolling 442 infants reported on severe ROP (stage &#8805; 3). The typical RR was 1.73 (95% CI 0.92 to 3.24) and the typical RD was 0.05 (95% CI -0.01 to 0.10); neither was statistically significant. There was unimportant heterogeneity for this outcome for RR (I² = 18%) but high heterogeneity for RD (I² = 79%).<BR/>
<BR/>
<I>
<B>Proven sepsis (Clinical symptoms and signs of sepsis and positive blood culture) (Outcome 1.10)</B>
</I>
<BR/>Five studies including 551 infants reported on this outcome. The typical RR was 0.75 (95% CI 0.52 to 1.09) and the typical RD was -0.05 (95% CI -0.11 to 0.01), neither statistically significant. There was no heterogeneity for this outcome for either RR (I²<SUP> </SUP>= 0%) or RD (I² = 0%).<BR/>
<BR/>
<I>
<B>Necrotising enterocolitis (NEC) (Bell's stage II or higher) (Outcome 1.11)</B>
</I>
<BR/>Six studies including 656 infants reported on NEC. In some studies the stage was not reported but the results are included in the meta-analyses. The typical RR was 0.88 (95% CI 0.46 to 1.69) and the typical RD -0.01(95% CI -0.04 to 0.03).Neither estimate was statistically significant. There was no heterogeneity for this outcome for either RR (I² = 0%) or RD (I² = 0%).<BR/>
<BR/>
<I>
<B>Intraventricular haemorrhage (IVH); all grades (<U>Outcome 1.12</U>)</B>
</I>
<BR/>Four studies including 454 infants reported on intraventricular haemorrhage (all grades). In <LINK REF="STD-Samanci-1996" TYPE="STUDY">Samanci 1996</LINK> there were no events in either group and that study is therefore disregarded for the RR. The non-significant typical RR was 0.87 (95% CI 0.53 to 1.42) and typical RD was -0.02 (95% CI -0.07 to 0.04). There was no heterogeneity for either RR (I² = 0%) or RD (I² = 0%). IVH is probably not a relevant outcome in this review as most haemorrhages occur during the first few days of life and infants were enrolled later in these studies.<BR/>
<BR/>
<I>
<B>Periventricular leukomalacia (PVL); cystic changes in the periventricular areas (<U>Outcome 1.13</U>)</B>
</I>
<BR/>One study enrolling 145 infants reported on PVL. The non-significant RR was 4.80 (95% CI 0.57 to 40.05) and the RD was 0.05 (95% CI -0.01 to 0.12). Test for heterogeneity not applicable.<BR/>
<BR/>
<I>
<B>Bronchopulmonary dysplasia (BPD) (supplemental oxygen at 28 days of age) (</B>
</I>
<LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>) <I>
<B>(<U>Outcome 1.14</U>)</B>
</I>
<BR/>Two studies (n = 285) reported on BPD at 28 days. In <LINK REF="STD-Al_x002d_Kharfy-1996" TYPE="STUDY">Al-Kharfy 1996</LINK> all infants in both groups had BPD. The typical RR was 1.25 (95% CI; 1.00 to 1.55) and the RD was 0.10 (95% CI 0.00 to 0.20). There was very high heterogeneity for both RR (I² = 97%) and RD (I² = 88%). Both results were of borderline statistical significance [test for overall effect: Z = 1.99 (P = 0.05)]. The extremely high heterogeneity for this analysis may relate to the fact that in one study all the infants had BPD at 28 days of age. The results should be interpreted with caution.</P>
<P>
<BR/>
<I>
<B>Bronchopulmonary dysplasia (BPD) (supplemental oxygen at 36 weeks postmenstrual age (PMA)) (<U>Outcome 1.15</U>)</B>
</I>
<BR/>Three studies enrolling 216 infants reported on the use of supplemental oxygen at 36 weeks PMA. The typical RR was 0.89 (95% CI 0.59 to 1.35) and the typical RD was -0.03 (95% CI-0.15 to 0.08); neither was statistically significant. There was moderate heterogeneity for RR (I² = 56%) and for RD (I² = 59%).<BR/>
<BR/>
<I>
<B>Sudden infant death (SIDS) after discharge (<U>Outcome 1.16</U>)</B>
</I>
<BR/>Six studies including 363 infants reported on SIDS. The typical RR was 1.06 (95% CI 0.25 to 4.52) and the typical RD was 0.00 (95% CI -0.03 to 0.04). Neither was statistically significant. There was no heterogeneity for either RR (I² = 0%) or RD (I² = 0%).<BR/>
<BR/>
<I>
<B>Neutropenia (<U>Outcome 1.17</U>)</B>
</I>
<BR/>Five studies (six comparisons) enrolling 164 infants reported on neutropenia. The typical RR was 0.28 (95% CI 0.05 to 1.54) (in only two studies did the outcome of interest occur), and the typical RD was -0.04 (-0.11 to 0.03); neither was statistically significant. There was no heterogeneity for RR (I² = 0%) and for RD (I² = 0%).<BR/>
<B>
<BR/>
<I>Hypertension (<U>Outcome 1.18</U>)</I>
</B>
<BR/>Seven studies (eight comparisons) including 363 infants reported on hypertension. The RR was 1.20 (95% CI 0.46 to 3.14) and the RD 0.01 (95% CI -0.04 to 0.05); neither was statistically significant. There was no statistically significant heterogeneity for either RR (I² = 21%) or RD (I² = 0%).<BR/>
<BR/>
<I>
<B>Length of hospital stay (days) (<U>Outcome 1.19</U>)</B>
</I>
<BR/>Length of hospital stay was reported in two studies enrolling 55 infants. There was no significant difference between the groups with a typical MD of -0.35 days (95% CI -12.83 to 12.13). There was no heterogeneity (I² = 0%).<BR/>
<BR/>
<I>
<B>Long-term outcomes assessed at any age beyond one year of age by a validated cognitive, motor, language, or behavioural/school/social interaction/adaptation test</B>
</I>
<BR/>Long-term neurodevelopmental outcomes were not reported in any study.<BR/>
<BR/>
<I>
<B>Any side effects reported in the trials</B>
</I>
<BR/>There were no serious side effects reported in most of the trials that specifically reported on adverse events (<LINK REF="STD-Shannon-1991" TYPE="STUDY">Shannon 1991</LINK>; <LINK REF="STD-Shannon-1992" TYPE="STUDY">Shannon 1992</LINK>; <LINK REF="STD-Bechensteen-1993" TYPE="STUDY">Bechensteen 1993</LINK>; <LINK REF="STD-Yamada-1999a" TYPE="STUDY">Yamada 1999a</LINK>; <LINK REF="STD-Yamada-1999b" TYPE="STUDY">Yamada 1999b</LINK>; <LINK REF="STD-Chen-1995" TYPE="STUDY">Chen 1995</LINK>; <LINK REF="STD-Shannon-1995" TYPE="STUDY">Shannon 1995</LINK>; <LINK REF="STD-Bader-1996" TYPE="STUDY">Bader 1996</LINK>; <LINK REF="STD-Donato-1996" TYPE="STUDY">Donato 1996</LINK>; <LINK REF="STD-Samanci-1996" TYPE="STUDY">Samanci 1996</LINK>; <LINK REF="STD-Corona-1998" TYPE="STUDY">Corona 1998</LINK>; <LINK REF="STD-Giannakopoulou-1998a" TYPE="STUDY">Giannakopoulou 1998a</LINK>; <LINK REF="STD-Giannakopoulou-1998b" TYPE="STUDY">Giannakopoulou 1998b</LINK>; <LINK REF="STD-Kumar-1998" TYPE="STUDY">Kumar 1998</LINK>; <LINK REF="STD-Kivivuori-1999" TYPE="STUDY">Kivivuori 1999</LINK>; <LINK REF="STD-Rocha-2001" TYPE="STUDY">Rocha 2001</LINK>; <LINK REF="STD-Juul-2003" TYPE="STUDY">Juul 2003</LINK>). <LINK REF="STD-Griffiths-1997" TYPE="STUDY">Griffiths 1997</LINK> reported a total of 41 different types of adverse events, with infection (positive blood cultures), pneumonia, and patent ductus arteriosus being the most common.<BR/>
<BR/>
<B>Secondary (post hoc) analyses:</B>
<BR/>In an attempt to further explore the heterogeneity observed in the primary outcome and subgroup analyses, we performed a post hoc<I> </I>analysis comparing the results of studies that we judged as high quality with those that we identified as of lower quality or could not precisely define their quality because of lack of information. We also compared the results of studies that used strict criteria for red blood cell transfusions to those that used no criteria or less strict criteria.<BR/>
</P>
<P>
<I>
<B>Use of one or more blood transfusions (secondary analysis based on quality) (<U>Outcome 1.20</U>)</B>
</I>
<BR/>For five high-quality studies enrolling 357 infants, the typical RR was 0.84 (95% CI 0.73 to 0.96); the typical RD was -0.12 (95% CI -0.21 to -0.03). For 15 studies of uncertain quality enrolling 785 infants, the typical RR was 0.63 (95% CI 0.54 to 0.73) and the typical RD was -0.20 (-0.26 to -0.14). The summary effect size was larger in the studies of poor quality. There was moderate heterogeneity for the high-quality studies (I² = 58% for both RR and RD) as well as for the studies of uncertain quality which had higher heterogeneity (I²<SUP> </SUP>= 71% for RR and 61% for RD).<BR/>
<BR/>
<I>
<B>Use of one or more blood transfusions (secondary analysis based on criteria for red blood cell transfusions) (<U>Outcome 1.21</U>)</B>
</I>
<BR/>We considered 15 studies enrolling 963 infants to have used strict (although variable) guidelines for red blood cell transfusions, and three studies enrolling 97 infants to have used no criteria or less strict criteria. We excluded two studies for which we were unable to translate the text regarding possible transfusion guidelines (<LINK REF="STD-Yamada-1999a" TYPE="STUDY">Yamada 1999a</LINK>; <LINK REF="STD-Yamada-1999b" TYPE="STUDY">Yamada 1999b</LINK>). For the 15 studies using strict red blood cell transfusion guidelines, the typical RR was 0.76 (95% CI 0.68 to 0.85) and the typical RD was -0.15 (95% CI -0.20 to -0.09); NNTB 7 (95% CI 5 to 11). There was moderate heterogeneity for RR (I² = 64%) and RD (I² = 56%). For the studies using no criteria or less strict criteria, the typical RR was 0.25 (95% CI 0.08 to 0.77) and the typical RD was -0.21 (95% CI -0.36 to -0.07); NNTB 5 (95% CI 3 to 14). There was no heterogeneity for the studies using no criteria or less strict criteria for RR (I² = 0%) and RD (I² = 0%). The summary effect size was larger for the studies that did not use strict guidelines for red blood cell transfusions compared to those that did.<BR/>
<BR/>
<I>
<B>Funnel plot</B>
</I>
<BR/>A funnel plot for the primary outcome 'Use of one or more red blood cell transfusions' was asymmetric, with a relative absence of smaller studies not having a protective effect (see <LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>).<BR/>
<BR/>
<B>Enterally-dosed EPO</B>
<BR/>One study (<LINK REF="STD-Juul-2003" TYPE="STUDY">Juul 2003</LINK>) using enterally-dosed EPO found that the intervention did not significantly influence erythropoiesis or iron utilisation when given for a two-week period, nor did it elevate the serum EPO concentration in preterm or term infants. The authors concluded that enterally-dosed EPO is not an effective substitute for parenteral administration (<LINK REF="STD-Juul-2003" TYPE="STUDY">Juul 2003</LINK>).</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2014-04-16 12:08:19 -0400" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2014-04-16 12:07:57 -0400" MODIFIED_BY="[Empty name]">
<P>In this update we have moved the study <LINK REF="STD-Romagnoli-2000" TYPE="STUDY">Romagnoli 2000</LINK> from the early erythropoietin (EPO) review (<LINK REF="REF-Ohlsson-2012" TYPE="REFERENCE">Ohlsson 2012</LINK>) to this late EPO review as infants started treatment with EPO at a mean (SD) age of 10 (± 1) days. The literature searches in March/May 2012 identified one additional trial (<LINK REF="STD-Bierer-2009" TYPE="STUDY">Bierer 2009</LINK>) and a few for exclusion (See <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>). The searches in 2013 did not identify any new trials. The current review includes 30 studies (31 comparisons) meeting our inclusion criteria. These studies included a total of 1591 preterm and/or low birth weight infants and reported on at least one of the outcomes of interest for this systematic review.</P>
<P>The results show that late administration of erythropoietin reduces the use of one or more blood transfusions following study entry. These results were quite consistent (overlapping confidence intervals) when including studies that used both low and high doses of EPO in combination with low and high doses of iron.</P>
<P>With the inclusion of <LINK REF="STD-Romagnoli-2000" TYPE="STUDY">Romagnoli 2000</LINK> in which there was a statistically significant increase in retinopathy of prematurity (ROP) at all stages and at stage 3 or higher, the overall estimates in the meta-analyses now show a trend towards increase for both these outcomes. Three studies including 404 infants reported on ROP (all stages), with a typical RR 1.27 (95% CI 0.99 to 1.64) and a typical RD of 0.09 (95% CI -0.00 to 0.18). This outcome was not statistically significantly different between the groups. There was high heterogeneity for this outcome for both RR ( I² = 83%) and RD (I² = 82%). Three trials enrolling 442 infants reported on severe ROP (stage 3 or higher). The typical RR was 1.73 (95% CI 0.92 to 3.24) and the typical RD was 0.05 (95% CI -0.01 to 0.10); neither was statistically significant. There was minimal heterogeneity for this outcome for RR (I² = 18%) but high heterogeneity for RD (I² = 79%). As the cut-off for early EPO treatment versus late EPO treatment was set arbitrarily at 8 completed days of initiation of treatment, we thought it justified to include all studies that have reported on ROP in secondary analyses. Details of these analyses are presented in the 2014 update of the early EPO review (<LINK REF="REF-Ohlsson-2012" TYPE="REFERENCE">Ohlsson 2012</LINK>). We combined all studies that reported on ROP at stage 3 or higher regardless of at what age the EPO treatment was initiated. We included seven studies from the early EPO review and three studies from the late EPO review that reported on this outcome. A total of 10 studies enrolling 1303 infants reported on this outcome. There was a significantly increased risk of ROP stage 3 or higher [typical RR 1.48 (95% CI 1.02 to 2.13); typical RD 0.03 (95% CI 0.00 to 0.06) (P = 0.04 for RR and 0.03 for RD); number needed to treat for an additional harmful outcome (NNTH) 33 (95% CI 17 to infinity)]. There was no heterogeneity for RR (1² = 0%) and moderate (I² = 50%) for RD.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2014-04-16 12:08:12 -0400" MODIFIED_BY="[Empty name]">
<P>The number needed to treat for an additional beneficial outcome (NNTB) to avoid one red blood cell transfusion was low (range 3 to 8, for different combinations of EPO and iron). The clinical importance of this finding is lessened by the fact that any donor exposure was not avoided, as many infants required red blood cell transfusions prior to study entry. Only two studies reported on donor exposure. In the study by <LINK REF="STD-Bierer-2009" TYPE="STUDY">Bierer 2009</LINK> there was a statistically significant increase in the number of donors the infants were exposed to but not in the study by <LINK REF="STD-Maier-2002" TYPE="STUDY">Maier 2002</LINK>. In the meta analysis of the two studies a significant difference in the typical mean difference for number of transfusions was noted indicating a higher donor exposure number in the EPO group. There was very high heterogeneity for this outcome (I²<SUP> </SUP>= 93% ), reducing the importance of the finding. In addition, in the 2012 and 2013 updates there was no statistically significant reduction in the total volume (mL/kg) of blood transfused per infant. There was a small reduction in the mean number of transfusions (0.2) per infant.</P>
<P>The need for intravenous, intramuscular or subcutaneous injections with EPO/iron treatment in the neonatal period is associated with repeated painful stimuli and could potentially have adverse long-term effects. This has not been addressed in any study.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2013-11-23 12:01:39 -0500" MODIFIED_BY="[Empty name]">
<P>The study quality varied and important information regarding the random sequence generation and whether the allocation was concealed or not was often missing. No study was reported according to the 'Consort' statement (<LINK REF="REF-CONSORT-2012" TYPE="REFERENCE">CONSORT 2012</LINK>). Sample sizes were small and long-term outcomes (18 to 24 months corrected age) were not reported. In only one study (<LINK REF="STD-Samanci-1996" TYPE="STUDY">Samanci 1996</LINK>) did the authors state that infants were not eligible to enter the study if they had previously received a red blood cell transfusion. Most studies followed guidelines for red blood cell transfusions, although these varied between the studies.</P>
<P>For the primary outcome of 'use of one or more blood transfusions' the typical risk ratio (RR) for five high quality studies was 0.84 (95% CI 0.73 to 0.96). For 15 studies of uncertain quality, the typical RR was 0.63 (95% CI 0.54 to 0.73). The CIs for these analyses are not overlapping, indicating that there are statistically significant differences in the effect sizes between studies that could be ascertained as being of high quality and studies of uncertain quality. There was a reduction in heterogeneity when the high quality studies were analysed separately. Studies of higher quality often show lower effect sizes (<LINK REF="REF-Schulz--1995" TYPE="REFERENCE">Schulz 1995</LINK>). Judging the quality of a study depends to a large extent on the information published, and obtaining additional information from the authors may change the evaluations. The typical effect size for studies that used strict red blood cell transfusion guidelines was smaller (RR 0.76) than for studies that used no or less strict criteria (RR 0.25).</P>
<P>Of concern is the finding of moderate heterogeneity for the primary outcome, including all combinations of low and high EPO and low and high iron treatment. The heterogeneity remained for individual combinations of EPO and iron. The heterogeneity could possibly be explained by the fact that the studies were conducted in 21 countries, with presumably different care practices. Of note, the control rates for red blood cell transfusions varied markedly between studies. As noted in the Additional <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>, there was large variation in the guidelines for red blood cell transfusions. The results of these post hoc analyses should therefore be interpreted with caution.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2014-04-16 12:08:19 -0400" MODIFIED_BY="[Empty name]">
<P>As outlined in Figure 5; Funnel plot of comparison: 1 Late initiation of EPO (8 - 28 days) vs placebo or no intervention, outcome: 1.1 Use of one or more red blood cell transfusions (low and high dose of EPO) there is a paucity of smaller studies not having a protective effect. It is possible that such studies have been conducted and that the results have not been published.</P>
<P>Several studies were supported by pharmaceutical companies and some authors were employed by such companies.</P>
<P>We are not aware of any potential biases in our own review process.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2013-11-23 10:14:49 -0500" MODIFIED_BY="[Empty name]">
<P>Systematic reviews of the efficacy of EPO in anaemia of prematurity have been published (<LINK REF="REF-Vamvakas-2001" TYPE="REFERENCE">Vamvakas 2001</LINK>; <LINK REF="REF-Garcia-2002" TYPE="REFERENCE">Garcia 2002</LINK>; <LINK REF="REF-Kotto_x002d_Kome-2004" TYPE="REFERENCE">Kotto-Kome 2004</LINK>). <LINK REF="REF-Vamvakas-2001" TYPE="REFERENCE">Vamvakas 2001</LINK> concluded that there is extreme variation in the results, and until this variation is better understood it is too early to recommend EPO as standard treatment for the anaemia of prematurity. <LINK REF="REF-Garcia-2002" TYPE="REFERENCE">Garcia 2002</LINK> concluded that administering EPO to VLBW neonates can result in a modest reduction in late erythrocyte transfusions and that this effect is dependent on the dose of EPO used. <LINK REF="REF-Kotto_x002d_Kome-2004" TYPE="REFERENCE">Kotto-Kome 2004</LINK> concluded that if EPO is begun in the first week of life, a moderate reduction can be expected in the proportion of VLBW neonates transfused. The reduction is less significant for early transfusion than for late transfusion. Direct comparisons regarding the results of this systematic overview and previous reviews (<LINK REF="REF-Vamvakas-2001" TYPE="REFERENCE">Vamvakas 2001</LINK>; <LINK REF="REF-Garcia-2002" TYPE="REFERENCE">Garcia 2002</LINK>; <LINK REF="REF-Kotto_x002d_Kome-2004" TYPE="REFERENCE">Kotto-Kome 2004</LINK>) are not appropriate as our review includes a much larger sample of studies.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2013-11-07 09:58:20 -0500" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2013-11-07 09:57:18 -0500" MODIFIED_BY="[Empty name]">
<P>Late EPO administration results in a reduction in the use of one or more red blood cell transfusions following initiation of therapy. It minimally reduces the number of red blood cell transfusions per infant. It is not associated with reductions in mortality or other neonatal morbidities. The use of late EPO is not associated with any short-term serious side effects except for a possible association with retinopathy of prematurity (ROP) stage 3 or higher. A large proportion of extremely low birth weight/preterm neonates require red blood cell transfusions during the first few days of life, when neither early nor late EPO administration could possibly have an impact. The decision to use late EPO will depend on the baseline rate of red blood cell transfusions in this population in a specific neonatal intensive care unit, the costs, the associated pain, and the values assigned to the clinical outcomes. Other means of reducing the need for red blood cell transfusions should be considered, including reduced blood sampling and the use of 'satellite packs' from directed or universal donors.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2013-11-07 09:58:20 -0500" MODIFIED_BY="Heather Maxwell">
<P>There is no need for further research to assess the effectiveness of the late use of EPO in reducing red blood cell transfusions. Its effectiveness has been established in populations that were exposed to donor blood prior to study entry, minimising the clinical importance of this effect. Future research should focus on strategies to minimise red blood cell donor exposure (using multiple aliquots from a properly tested single donor) during the first week of life, when the likelihood of need for red blood cell transfusions is at its peak. Such strategies in combination with late EPO treatment may reduce further donor exposure in early infancy. All ongoing and planned studies should monitor the incidence of retinopathy of prematurity.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2013-11-08 06:29:44 -0500" MODIFIED_BY="[Empty name]">
<P>We are thankful to Dr Rolf Maier, Zentrum für Kinder und Jugendmedizin, Philipps-Universität, Marburg, who provided us with additional information regarding his study.<BR/>We would like to thank Ms Elizabeth Uleryk, Chief Librarian, the Hospital for Sick Children (SickKids), Toronto, Ontario, Canada, for developing the search strategy.<BR/>We express our gratitude to Ms Marie Sirdevan, Perinatal Pharmacist, Pharmacy, Mount Sinai Hospital, Toronto, Ontario, Canada, who helped interpreting two papers written in Japanese. We are thankful to Dr Jaques Belik, the Hospital for Sick Children (SickKids), Toronto, Ontario, Canada, who translated part of one paper from Spanish to English. We are thankful to Dr Robin Ohls, University of New Mexico, Albuquerque, New Mexico, USA, who drew to our attention our misclassification of the study by Romagnoli and co-workers. We are thankful to Dr Constantion Romagnoli, Division of Neonatology, Catholic University of Rome, Rome, Italy, who provided us with additional information regarding his study.<BR/>
</P>
<P>Ms Yolanda R Brosseau, Managing Editor, Cochrane Neonatal Review Group conducted the literature searches in 2012. She and Ms Colleen M Ovelman, Trials Search Co-ordinator and Webmaster, Cochrane Neonatal Review Group, conducted the literature searches in July 2013.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2013-11-19 15:28:12 -0500" MODIFIED_BY="[Empty name]">
<P>Sanjay M Aher (SMA) and Arne Ohlsson (AO) contributed equally to all sections of the protocol for this review. The literature search of databases was conducted with the help of an experienced librarian. Both review authors identified potentially eligible studies from the printouts and agreed on which trials to include; designed and agreed upon data collection forms; conducted quality assessments and abstracted and compared data independently. One review author (AO) entered the data into RevMan 5 and the other review author (SMA) checked for accuracy. One review author (AO) wrote the full review and the other review author (SMA) read and made changes. Both review authors made changes following feedback from the editors of the review group. </P>
<P>Sanjay M Aher (SMA) and Arne Ohlsson (AO) wrote the original review.<BR/>
</P>
<P>The February 2010 update was conducted centrally by the Cochrane Neonatal Review Group staff (Yolanda Montagne, Diane Haughton, and Roger Soll). That update was reviewed and approved by AO, who completed the 'Risk of bias' tables. </P>
<P>The 2012 update was conducted by AO and approved by SMA.</P>
<P>The current update in 2013 was conducted by both authors (SMA and AO).</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2013-11-23 11:28:34 -0500" MODIFIED_BY="[Empty name]">
<P>In our objectives we state that neonates enrolled between eight and 28 days of age were to be included. In the studies that we identified some infants were less than 8 days at study entry and some were older than 28 days. When most of the enrolled infants were 8 days or older we included the studies in this Late EPO review and not in the Early EPO review. The inclusion of these studies makes our review more comprehensive. The age at enrolment is stated for each study in the table <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>. Hypertension was frequently reported by trial authors, and therefore it has been added as an outcome since the protocol was published.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2013-11-25 15:19:41 -0500" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2013-11-21 14:59:00 -0500" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2013-11-21 14:59:00 -0500" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Akisu-2001" MODIFIED="2013-09-11 10:21:04 -0400" MODIFIED_BY="[Empty name]" NAME="Akisu 2001" YEAR="2001">
<REFERENCE MODIFIED="2013-09-11 10:21:04 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Akisu M, Tuzun S, Arslanoglu S, Yalaz M, Kultursay N</AU>
<TI>Effect of recombinant human erythropoietin administration on lipid peroxidation and antioxidant enzyme(s) activities in preterm infants</TI>
<SO>Acta Medica Okayama</SO>
<YR>2001</YR>
<VL>55</VL>
<NO>6</NO>
<PG>357-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Al_x002d_Kharfy-1996" MODIFIED="2013-09-11 10:25:30 -0400" MODIFIED_BY="[Empty name]" NAME="Al-Kharfy 1996" YEAR="1996">
<REFERENCE MODIFIED="2013-09-11 10:21:47 -0400" MODIFIED_BY="Heather Maxwell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Al-Kharfy T, Smyth JA, Wadsworth L, Krystal G, Fitzgerald C, Davis J et al</AU>
<TI>Erythropoietin therapy in neonates at risk of having bronchopulmonary dysplasia and requiring multiple transfusions</TI>
<SO>Journal of Pediatrics</SO>
<YR>1996</YR>
<VL>129</VL>
<NO>1</NO>
<PG>89-96</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-09-11 10:25:30 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Smyth JA, Ainsworth L, Krystal G, Wadsworth L</AU>
<TI>Effect of erythropoietin therapy on oxygen dependency in premature infants</TI>
<SO>Pediatric Research</SO>
<YR>2002</YR>
<VL>51</VL>
<NO>3</NO>
<PG>330 A</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Atasay-2002" MODIFIED="2013-09-11 10:26:55 -0400" MODIFIED_BY="Heather Maxwell" NAME="Atasay 2002" YEAR="2002">
<REFERENCE MODIFIED="2013-09-11 10:26:55 -0400" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Atasay B, Gunlemez A, Akar N, Arsan S</AU>
<TI>Does early erythropoietin therapy decrease transfusions in anemia of prematurity?</TI>
<SO>Indian Journal of Pediatrics</SO>
<YR>2002</YR>
<VL>69</VL>
<NO>5</NO>
<PG>389-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bader-1996" MODIFIED="2013-09-11 10:28:14 -0400" MODIFIED_BY="[Empty name]" NAME="Bader 1996" YEAR="1996">
<REFERENCE MODIFIED="2013-09-11 10:28:14 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bader D, Blondheim O, Jonas R, Admoni O, Abend-Winge M, Reich D et al</AU>
<TI>Decreased ferritin levels, despite iron supplementation, during erythropoietin therapy in anaemia of prematurity</TI>
<SO>Acta Paediatrica</SO>
<YR>1996</YR>
<VL>85</VL>
<NO>4</NO>
<PG>496-501</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bechensteen-1993" MODIFIED="2013-09-11 11:06:17 -0400" MODIFIED_BY="Heather Maxwell" NAME="Bechensteen 1993" YEAR="1993">
<REFERENCE MODIFIED="2013-09-11 11:06:17 -0400" MODIFIED_BY="Heather Maxwell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bechensteen AG, Haga P, Halvorsen S, Whitelaw A, Liestol K, Lindemann R et al</AU>
<TI>Erythropoietin, protein, and iron supplementation and the prevention of anaemia of prematurity</TI>
<SO>Archieves of Disease in Childhood</SO>
<YR>1993</YR>
<VL>69</VL>
<NO>1 Spec No</NO>
<PG>19-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-09-11 10:31:19 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bechensteen AG, Halvorsen S, Haga P, Cotes PM, Liestol K</AU>
<TI>Erythropoietin (Epo), protein and iron supplementation and the prevention of anaemia of prematurity: effects on serum immunoreactive Epo, growth and protein and iron metabolism</TI>
<SO>Acta Paediatrica</SO>
<YR>1996</YR>
<VL>85</VL>
<NO>4</NO>
<PG>490-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bechensteen AG, Halvorsen S, Haga P</AU>
<TI>Erythropoiesis during rapid growth. Role of erythropoietin and nutrition</TI>
<SO>Annals of the New York Academy of Sciences</SO>
<YR>1994</YR>
<VL>718</VL>
<PG>339-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-09-11 10:32:41 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bechensteen AG, Refsum HE, Halvorsen S, Haga P, Liestol K</AU>
<TI>Effects of recombinant human erythropoietin on fetal and adult hemoglobin in preterm infants</TI>
<SO>Pediatric Research</SO>
<YR>1995</YR>
<VL>38</VL>
<NO>5</NO>
<PG>729-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bierer-2009" MODIFIED="2013-09-11 10:33:45 -0400" MODIFIED_BY="[Empty name]" NAME="Bierer 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-09-11 10:33:45 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bierer R, Roohi M, Peceny C, Ohls RK</AU>
<TI>Erythropoietin increases reticulocyte counts and maintains hematocrit in neonates requiring surgery</TI>
<SO>Journal of Pediatric Surgery</SO>
<YR>2009</YR>
<VL>44</VL>
<NO>8</NO>
<PG>1540-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chen-1995" MODIFIED="2013-09-11 10:34:46 -0400" MODIFIED_BY="[Empty name]" NAME="Chen 1995" YEAR="1995">
<REFERENCE MODIFIED="2013-09-11 10:34:46 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chen JY, Wu TS, Chanlai SP</AU>
<TI>Recombinant human erythropoietin in the treatment of anemia of prematurity</TI>
<SO>American Journal of Perinatology</SO>
<YR>1995</YR>
<VL>12</VL>
<NO>5</NO>
<PG>314-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Corona-1998" MODIFIED="2013-09-11 10:45:34 -0400" MODIFIED_BY="[Empty name]" NAME="Corona 1998" YEAR="1998">
<REFERENCE MODIFIED="2013-09-11 10:45:34 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Corona G, Fulia F, Liotta C, Barberi I</AU>
<TI>Clinical use of recombinant human erythropoietin (rHuEPO) in the treatment of preterm anaemia</TI>
<TO>Uso clinico dell'eritropoietina umana ricombinante (rHuEPO) nell'anemia della prematurita</TO>
<SO>Rivista Italiana Pediatria</SO>
<YR>1998</YR>
<VL>24</VL>
<PG>442-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Donato-1996" NAME="Donato 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Donato H, Rendo P, Vivas R, Schvartzman G, Digregorio J, Vain N</AU>
<TI>Recombinant human erythropoietin in the treatment of anemia of prematurity: a randomized, double-blind, placebo-controlled trial comparing three different doses</TI>
<SO>International Journal of Pediatric Hematology/Oncology</SO>
<YR>1996</YR>
<VL>3</VL>
<PG>279-85</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Emmerson-1993" MODIFIED="2013-09-11 11:05:50 -0400" MODIFIED_BY="[Empty name]" NAME="Emmerson 1993" YEAR="1993">
<REFERENCE MODIFIED="2013-09-11 11:05:50 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Emmerson AJ, Coles HJ, Stern CM, Pearson TC</AU>
<TI>Double blind trial of recombinant human erythropoietin in preterm infants</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>1993</YR>
<VL>68</VL>
<NO>3 Spec No</NO>
<PG>291-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Giannakopoulou-1998a" MODIFIED="2013-11-21 14:58:27 -0500" MODIFIED_BY="[Empty name]" NAME="Giannakopoulou 1998a" YEAR="1998">
<REFERENCE MODIFIED="2013-11-08 04:31:56 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Giannakopoulou C, Bolonaki I, Stiakaki E, Dimitriou H, Galanaki H, Hatzidaki E et al</AU>
<TI>Erythropoietin (rHuEPO) administration to premature infants for the treatment of their anemia</TI>
<SO>Pediatric Hematology and Oncology</SO>
<YR>1998</YR>
<VL>15</VL>
<NO>1</NO>
<PG>37-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Giannakopoulou-1998b" MODIFIED="2013-11-21 14:59:00 -0500" MODIFIED_BY="Kate Cahill" NAME="Giannakopoulou 1998b" YEAR="1998">
<REFERENCE MODIFIED="2013-11-08 04:32:14 -0500" MODIFIED_BY="Kate Cahill" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Giannakopoulou C, Bolonaki I, Stiakaki E, Dimitriou H, Galanaki H, Hatzidaki E et al</AU>
<TI>Erythropoietin (rHuEPO) administration to premature infants for the treatment of their anemia</TI>
<SO>Pediatric Hematology and Oncology</SO>
<YR>1998</YR>
<VL>15</VL>
<NO>1</NO>
<PG>37-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Griffiths-1997" MODIFIED="2013-11-08 04:32:37 -0500" MODIFIED_BY="[Empty name]" NAME="Griffiths 1997" YEAR="1997">
<REFERENCE MODIFIED="2013-11-08 04:32:37 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Griffiths G, Lall R, Chatfield S, Short A, MacKay P, Williamson P et al</AU>
<TI>Randomised controlled double blind study of the role of recombinant erythropoietin in the prevention of chronic lung disease</TI>
<SO>Archives of Disease in Childhood. Fetal and Neonatal Edition</SO>
<YR>1997</YR>
<VL>76</VL>
<NO>3</NO>
<PG>F190-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Javier-Manchon-1997" MODIFIED="2013-11-08 04:33:26 -0500" MODIFIED_BY="[Empty name]" NAME="Javier Manchon 1997" YEAR="1997">
<REFERENCE MODIFIED="2013-11-08 04:33:26 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Javier Manchon G, Natal Pujol A, Coroleu Lletget W, Zuasnabar Cotro A, Badia Barnusell J, Junca Piera J et al</AU>
<TI>Randomized multi-centre trial of the administration of erythropoietin in anemia of prematurity</TI>
<TO>Estudio multicentrico aleatorizado de administracion de eritropoyetina en la anemia de la prematuridad</TO>
<SO>Anales Espanoles de Pediatria</SO>
<YR>1997</YR>
<VL>46</VL>
<NO>6</NO>
<PG>587-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Juul-2003" MODIFIED="2013-09-11 11:18:40 -0400" MODIFIED_BY="[Empty name]" NAME="Juul 2003" YEAR="2003">
<REFERENCE MODIFIED="2013-09-11 11:18:40 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Juul SE</AU>
<TI>Enterally dosed recombinant human erythropoietin does not stimulate erythropoiesis in neonates</TI>
<SO>Journal of Pediatrics</SO>
<YR>2003</YR>
<VL>143</VL>
<NO>3</NO>
<PG>321-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kivivuori-1999" MODIFIED="2013-09-11 13:20:02 -0400" MODIFIED_BY="[Empty name]" NAME="Kivivuori 1999" YEAR="1999">
<REFERENCE MODIFIED="2013-09-11 13:20:02 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kivivuori SM, Virtanen M, Raivio KO, Viinikka L, Siimes MA</AU>
<TI>Oral iron is sufficient for erythropoietin treatment of very low birth-weight infants</TI>
<SO>European Journal of Pediatrics</SO>
<YR>1999</YR>
<VL>158</VL>
<NO>2</NO>
<PG>147-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kumar-1998" MODIFIED="2013-09-11 13:20:08 -0400" MODIFIED_BY="[Empty name]" NAME="Kumar 1998" YEAR="1998">
<REFERENCE MODIFIED="2013-09-11 13:20:08 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kumar P, Shankaran S, Krishnan RG</AU>
<TI>Recombinant human erythropoietin therapy for treatment of anemia of prematurity in very low birth weight infants: a randomized, double-blind, placebo-controlled trial</TI>
<SO>Journal of Perinatology</SO>
<YR>1998</YR>
<VL>18</VL>
<NO>3</NO>
<PG>173-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Maier-2002" MODIFIED="2013-09-11 13:23:25 -0400" MODIFIED_BY="[Empty name]" NAME="Maier 2002" YEAR="2002">
<REFERENCE MODIFIED="2013-09-11 13:23:25 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Maier RF, Obladen M, Muller-Hansen I, Kattner E, Merz U, Arlettaz R et al</AU>
<TI>Early treatment with erythropoietin beta ameiliorates anemia and reduces transfusion requirements in infants with birth weights below 1000 g</TI>
<SO>Journal of Pediatrics</SO>
<YR>2002</YR>
<VL>141</VL>
<NO>1</NO>
<PG>8-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Meyer-1994" MODIFIED="2013-09-11 13:25:01 -0400" MODIFIED_BY="Heather Maxwell" NAME="Meyer 1994" YEAR="1994">
<REFERENCE MODIFIED="2013-09-11 13:24:10 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Meyer MP, Haworth C, McNeill L</AU>
<TI>Is the use of recombinant human erythropoietin in anemia of prematurity cost-effective?</TI>
<SO>South African Medical Journal</SO>
<YR>1996</YR>
<VL>86</VL>
<NO>3</NO>
<PG>251-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-09-11 13:25:01 -0400" MODIFIED_BY="Heather Maxwell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Meyer MP, Meyer JH, Commerford A, Hann FM, Sive AA, Moller G et al</AU>
<TI>Recombinant human erythropoietin in the treatment of the anemia of prematurity: results of a double-blind, placebo-controlled study</TI>
<SO>Pediatrics</SO>
<YR>1994</YR>
<VL>93</VL>
<NO>6 Pt 1</NO>
<PG>918-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pollak-2001" MODIFIED="2013-09-11 13:26:50 -0400" MODIFIED_BY="[Empty name]" NAME="Pollak 2001" YEAR="2001">
<REFERENCE MODIFIED="2013-09-11 13:26:04 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kasper DC, Widness JA, Haiden N, Berger A. Hayde M, Pollak A et al</AU>
<TI>Characterization and differentiation of iron status in anemic very low birth weight infants using a diagnostic nomogram</TI>
<SO>Neonatology</SO>
<YR>2009</YR>
<VL>95</VL>
<NO>2</NO>
<PG>164-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-09-11 13:26:50 -0400" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Pollak A, Hayde M, Hayn M, Herkner K, Lombard KA, Lubec G et al</AU>
<TI>Effect of intravenous iron supplementation on erythropoiesis in erythropoietin-treated premature infants</TI>
<SO>Pediatrics</SO>
<YR>2001</YR>
<VL>107</VL>
<NO>1</NO>
<PG>78-85</PG>
<IDENTIFIERS MODIFIED="2012-03-25 11:26:01 -0400" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Reiter-2005" MODIFIED="2013-09-11 13:27:25 -0400" MODIFIED_BY="[Empty name]" NAME="Reiter 2005" YEAR="2005">
<REFERENCE MODIFIED="2013-09-11 13:27:25 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Reiter PD, Rosenberg AA, Valuck R, Novak K</AU>
<TI>Effect of short-term erythropoietin therapy in anemic premature infants</TI>
<SO>Journal of Perinatology</SO>
<YR>2005</YR>
<VL>25</VL>
<NO>2</NO>
<PG>125-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rocha-2001" MODIFIED="2013-09-11 13:28:42 -0400" MODIFIED_BY="[Empty name]" NAME="Rocha 2001" YEAR="2001">
<REFERENCE MODIFIED="2013-09-11 13:28:42 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rocha VL, Benjamin AC, Procianoy RS</AU>
<TI>The effect of recombinant human erythropoietin on the treatment of anemia of prematurity</TI>
<SO>Journal de Pediatria</SO>
<YR>2001</YR>
<VL>77</VL>
<NO>2</NO>
<PG>75-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Romagnoli-2000" MODIFIED="2013-09-11 13:30:16 -0400" MODIFIED_BY="[Empty name]" NAME="Romagnoli 2000" YEAR="2000">
<REFERENCE MODIFIED="2013-09-11 13:30:16 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Romagnoli C, Zecca E, Gallini F, Girlando P, Zuppa AA</AU>
<TI>Do recombinant human erythropoitetin and iron supplementation increase the risk of retinopathy of prematurity?</TI>
<SO>European Journal of Pediatrics</SO>
<YR>2000</YR>
<VL>159</VL>
<NO>8</NO>
<PG>627-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ronnestad-1995" MODIFIED="2013-09-11 13:31:12 -0400" MODIFIED_BY="[Empty name]" NAME="Ronnestad 1995" YEAR="1995">
<REFERENCE MODIFIED="2013-09-11 13:31:12 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ronnestad A, Moe PJ, Breivik N</AU>
<TI>Enhancement of erythropoiesis by erythropoietin, bovine protein and energy fortified mother's milk during anaemia of prematurity</TI>
<SO>Acta Paediatrica</SO>
<YR>1995</YR>
<VL>84</VL>
<NO>7</NO>
<PG>809-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Samanci-1996" MODIFIED="2013-09-11 13:32:05 -0400" MODIFIED_BY="[Empty name]" NAME="Samanci 1996" YEAR="1996">
<REFERENCE MODIFIED="2013-09-11 13:32:05 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Samanci N, Ovali F, Dagoglu</AU>
<TI>Effects of recombinant human erythropoietin in infants with very low birth weights</TI>
<SO>The Journal of International Medical Research</SO>
<YR>1996</YR>
<VL>24</VL>
<NO>2</NO>
<PG>190-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shannon-1991" MODIFIED="2013-09-11 13:33:43 -0400" MODIFIED_BY="Heather Maxwell" NAME="Shannon 1991" YEAR="1991">
<REFERENCE MODIFIED="2013-09-11 13:32:59 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Newton NR, Leonard CH, Piecuch RE, Phibbs RH</AU>
<TI>Neurodevelopmental outcome of prematurely born children treated with recombinant erythropoietin in infancy</TI>
<SO>Journal of Perinatology</SO>
<YR>1999</YR>
<VL>19</VL>
<NO>6 Pt 1</NO>
<PG>403-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-09-11 13:33:43 -0400" MODIFIED_BY="Heather Maxwell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Shannon KM, Mentzer WC, Abels RI, Freeman P, Newton N, Thompson D et al</AU>
<TI>Recombinant human erythropoietin in the anemia of prematurity: results of a placebo-controlled pilot study</TI>
<SO>Journal of Pediatrics</SO>
<YR>1991</YR>
<VL>118</VL>
<NO>6</NO>
<PG>949-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shannon-1992" MODIFIED="2013-09-11 13:34:25 -0400" MODIFIED_BY="Heather Maxwell" NAME="Shannon 1992" YEAR="1992">
<REFERENCE MODIFIED="2013-09-11 13:34:25 -0400" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shannon KM, Mentzer WC, Abels RI, Wertz M, Thayer-Moriyama J, Li WY et al</AU>
<TI>Enhancement of erythropoiesis by recombinant human erythropoietin in low birth weight infants: a pilot study</TI>
<SO>Journal of Pediatrics</SO>
<YR>1992</YR>
<VL>120</VL>
<NO>4 Pt 1</NO>
<PG>586-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shannon-1995" MODIFIED="2013-09-11 14:01:39 -0400" MODIFIED_BY="[Empty name]" NAME="Shannon 1995" YEAR="1995">
<REFERENCE MODIFIED="2013-09-11 13:37:56 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bard H, Widness JA</AU>
<TI>Effect of recombinant human erythropoietin on the switchover from fetal to adult hemoglobin synthesis in preterm infants</TI>
<SO>Journal of Pediatrics</SO>
<YR>1995</YR>
<VL>127</VL>
<NO>3</NO>
<PG>478-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-09-11 13:59:16 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Baxter LM, Vreman HJ, Ball B, Stevenson DK</AU>
<TI>Recombinant human erythropoietin (r-HuEPO) increases total bilirubin production in premature infants</TI>
<SO>Clinical Pediatrics</SO>
<YR>1995</YR>
<VL>34</VL>
<NO>4</NO>
<PG>213-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-09-11 13:59:55 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brown MS, Shapiro H</AU>
<TI>Effect of protein intake on erythropoiesis during erythropoietin treatment of anemia of prematurity</TI>
<SO>Journal of Pediatrics</SO>
<YR>1996</YR>
<VL>128</VL>
<NO>4</NO>
<PG>512-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-09-11 14:01:01 -0400" MODIFIED_BY="Heather Maxwell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Shannon KM, Keith JF 3rd, Mentzer WC, Ehrenkranz RA, Brown MS, Widness JA et al</AU>
<TI>Recombinant human erythropoietin stimulates erythropoiesis and reduces erythrocyte transfusions in very low birth weight preterm infants</TI>
<SO>Pediatrics</SO>
<YR>1995</YR>
<VL>95</VL>
<NO>1</NO>
<PG>1-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-09-11 14:01:39 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Widness JA, Lombard KA, Ziegler EE, Serfass RE, Carlson SJ, Johnson KJ et al</AU>
<TI>Erythrocyte incorporation and absorption of 58Fe in premature infants treated with erythropoietin</TI>
<SO>Pediatric Research</SO>
<YR>1997</YR>
<VL>41</VL>
<NO>3</NO>
<PG>416-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Whitehall-1999" MODIFIED="2013-09-11 14:03:04 -0400" MODIFIED_BY="[Empty name]" NAME="Whitehall 1999" YEAR="1999">
<REFERENCE MODIFIED="2013-09-11 14:03:04 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Whitehall JS, Patole SK, Campbell P</AU>
<TI>Recombinant human erythropoietin in anemia of prematurity</TI>
<SO>Indian Pediatrics</SO>
<YR>1999</YR>
<VL>36</VL>
<NO>1</NO>
<PG>17-27</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yamada-1999a" MODIFIED="2013-09-11 14:08:14 -0400" MODIFIED_BY="Heather Maxwell" NAME="Yamada 1999a" YEAR="1999">
<REFERENCE MODIFIED="2013-09-11 14:07:45 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yamada M, Takahashi R, Chiba Y, Ito T, Nakae N</AU>
<TI>Effects of recombinant human erythropoietin in infants with anemia of prematurity. I. Results in infants with birth weights between 1,000 and 1,499 gm</TI>
<SO>Acta Neonatologica Japonica</SO>
<YR>1999</YR>
<VL>35</VL>
<NO>4</NO>
<PG>755-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yamada-1999b" MODIFIED="2013-09-11 14:08:54 -0400" MODIFIED_BY="Heather Maxwell" NAME="Yamada 1999b" YEAR="1999">
<REFERENCE MODIFIED="2013-09-11 14:08:54 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yamada M, Takahashi R, Chiba Y, Ito T, Nakae N</AU>
<TI>Effects of recombinant human erythropoietin in infants with anemia of prematurity. II. Results in infants with birth weights between 500 and 999 gm</TI>
<SO>Acta Neonatologica Japonica</SO>
<YR>1999</YR>
<VL>35</VL>
<NO>4</NO>
<PG>762-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2013-11-08 04:48:05 -0500" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Ahmadpour-Kacho-2004" MODIFIED="2013-09-11 14:15:07 -0400" MODIFIED_BY="[Empty name]" NAME="Ahmadpour Kacho 2004" YEAR="2004">
<REFERENCE MODIFIED="2013-09-11 14:15:07 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ahmadpour Kacho M, Zahed Pasha YA, Esmaili MR, Hajian K, Moradi SH</AU>
<TI>The effect of human recombinant erythropoietin on prevention of anemia of prematurity</TI>
<SO>Pediatric Research</SO>
<YR>2003</YR>
<VL>54</VL>
<NO>4</NO>
<PG>564</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Amin-2004" MODIFIED="2013-09-11 14:16:15 -0400" MODIFIED_BY="[Empty name]" NAME="Amin 2004" YEAR="2004">
<REFERENCE MODIFIED="2013-09-11 14:16:15 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Amin A, Alzahrani D</AU>
<TI>Efficacy of erythropoietin in premature infants</TI>
<SO>Pediatric Research</SO>
<YR>2003</YR>
<VL>54</VL>
<NO>4</NO>
<PG>557</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Badiee-2006" MODIFIED="2013-09-11 14:17:26 -0400" MODIFIED_BY="[Empty name]" NAME="Badiee 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-09-11 14:17:26 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Badiee Z, Pourmirzaiee MA, Kelishadi R, Naseri F</AU>
<TI>Recombinant human erythropoietin and blood transfusion in low-birth weight preterm infants under restrictive transfusion guidelines</TI>
<SO>Saudi Medical Journal</SO>
<YR>2006</YR>
<VL>27</VL>
<NO>6</NO>
<PG>817-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bechensteen-1997" MODIFIED="2013-11-08 04:48:05 -0500" MODIFIED_BY="[Empty name]" NAME="Bechensteen 1997" YEAR="1997">
<REFERENCE MODIFIED="2013-11-08 04:48:05 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bechensteen AG, Hågå P, Halvorsen S, Liestøl K, Lindemann R, Whitelaw A et al</AU>
<TI>Effect of low and moderate doses of recombinant human erythropoietin on the haematological response in premature infants on high protein and iron intake</TI>
<SO>European Journal of Pediatrics</SO>
<YR>1997</YR>
<VL>156</VL>
<NO>1</NO>
<PG>56-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Messer-1993" MODIFIED="2013-09-11 14:35:38 -0400" MODIFIED_BY="[Empty name]" NAME="Messer 1993" YEAR="1993">
<REFERENCE MODIFIED="2013-09-11 14:35:38 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Messer J, Haddad J, Donato L, Astruc D, Matis J</AU>
<TI>Early treatment of premature infants with recombinant human erythropoietin</TI>
<SO>Pediatrics</SO>
<YR>1993</YR>
<VL>92</VL>
<NO>4</NO>
<PG>519-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Meyer-1996" MODIFIED="2013-09-11 14:36:17 -0400" MODIFIED_BY="[Empty name]" NAME="Meyer 1996" YEAR="1996">
<REFERENCE MODIFIED="2013-09-11 14:36:17 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Meyer MP, Haworth C, Meyer JH, Commerford A</AU>
<TI>A comparison of oral and intravenous iron supplementation in preterm infants receiving recombinant erythropoietin</TI>
<SO>Journal of Pediatrics</SO>
<YR>1996</YR>
<VL>129</VL>
<NO>2</NO>
<PG>258-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mohammadzadeh-2005" MODIFIED="2013-09-11 14:37:47 -0400" MODIFIED_BY="[Empty name]" NAME="Mohammadzadeh 2005" YEAR="2005">
<REFERENCE MODIFIED="2013-09-11 14:37:47 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mohammadzadeh A, Naseri F</AU>
<TI>Effect of high versus low doses of human recombinant erythropoietin on the anemia of prematurity</TI>
<SO>Acta Medica Iranica</SO>
<YR>2005</YR>
<VL>43</VL>
<NO>2</NO>
<PG>95-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ohls-1991" MODIFIED="2013-09-11 14:43:09 -0400" MODIFIED_BY="[Empty name]" NAME="Ohls 1991" YEAR="1991">
<REFERENCE MODIFIED="2012-04-29 10:01:07 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Bierer R, Roohi M, Ohls RK</AU>
<TI>A randomized, masked study of weekly erythropoietin dosing in neonates</TI>
<SO>Pediatric Academic Societies' Annual Meeting</SO>
<YR>2008</YR>
<PG>E-PAS2008:633749.3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-09-11 14:43:09 -0400" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ohls RK, Christensen RD</AU>
<TI>Recombinant erythropoietin compared with erythrocyte transfusion in the treatment of anemia of prematurity</TI>
<SO>Journal of Pediatrics</SO>
<YR>1991</YR>
<VL>119</VL>
<NO>5</NO>
<PG>781-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ohls-2012" MODIFIED="2013-09-11 14:39:22 -0400" MODIFIED_BY="[Empty name]" NAME="Ohls 2012" YEAR="2012">
<REFERENCE MODIFIED="2012-05-05 14:32:29 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Bierer R, Roohi M, Ohls RK</AU>
<TI>A randomized, masked study of weekly erythropoietin dosing in neonates</TI>
<SO>Pediatric Academic Societies' Annual Meeting</SO>
<YR>2008</YR>
<PG>E-PAS2008:633749.3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-09-11 14:39:22 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ohls RK, Roohi M, Peceny HM, Schrader R, Bierer R</AU>
<TI>A randomized, masked study of weekly erythropoietin dosing in preterm infants</TI>
<SO>Journal of Pediatrics</SO>
<YR>2012</YR>
<VL>160</VL>
<NO>5</NO>
<PG>790-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pasha-2008" MODIFIED="2013-09-11 14:44:03 -0400" MODIFIED_BY="[Empty name]" NAME="Pasha 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-09-11 14:44:03 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pasha YZ, Ahmadpour-Kacho M, Hajiahmadi M, Hosseini MB</AU>
<TI>Enteral erythropoietin increases plasma erythropoietin level in preterm infants: a randomized controlled trial</TI>
<SO>Indian Pediatrics</SO>
<YR>2008</YR>
<VL>45</VL>
<NO>1</NO>
<PG>25-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pathak-2003" MODIFIED="2013-09-11 14:44:51 -0400" MODIFIED_BY="[Empty name]" NAME="Pathak 2003" YEAR="2003">
<REFERENCE MODIFIED="2013-09-11 14:44:51 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pathak A, Roth P, Piscitelli J, Johnson L</AU>
<TI>Effects of vitamin E supplementation during erythropoietin treatment of the anemia of prematurity</TI>
<SO>Archives of Disease in Childhood. Fetal and Neonatal Edition</SO>
<YR>2003</YR>
<VL>88</VL>
<NO>4</NO>
<PG>F324-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Testa-1998" MODIFIED="2013-09-11 14:45:57 -0400" MODIFIED_BY="Heather Maxwell" NAME="Testa 1998" YEAR="1998">
<REFERENCE MODIFIED="2013-09-11 14:45:57 -0400" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Testa M, Reali A, Copula M, Pinna B, Birocchi F, Pisu C et al</AU>
<TI>Role of rHuEpo on blood transfusions in preterm infants after the fifteenth day of life</TI>
<SO>Pediatric Hematology and Oncology</SO>
<YR>1998</YR>
<VL>15</VL>
<NO>5</NO>
<PG>415-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Warwood-2005" MODIFIED="2013-09-11 14:47:13 -0400" MODIFIED_BY="[Empty name]" NAME="Warwood 2005" YEAR="2005">
<REFERENCE MODIFIED="2013-09-11 14:47:13 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Warwood TL, Ohls RK, Wiedmeier SE, Lambert DK, Jones C, Scoffield SH et al</AU>
<TI>Single-dose darbepoetin administration to anemic preterm neonates</TI>
<SO>Journal of Perinatology</SO>
<YR>2005</YR>
<VL>25</VL>
<NO>11</NO>
<PG>725-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Warwood-2011" MODIFIED="2013-09-11 14:48:10 -0400" MODIFIED_BY="[Empty name]" NAME="Warwood 2011" YEAR="2011">
<REFERENCE MODIFIED="2013-09-11 14:48:10 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Warwood TL, Lambert DK, Henry E, Christensen RD</AU>
<TI>Very low birth weight infants qualifying for a 'late' erythrocyte transfusion: does giving darbepoetin along with the transfusion counteract the transfusion's erythropoietic suppression?</TI>
<SO>Journal of Perinatology</SO>
<YR>2011</YR>
<VL>31</VL>
<NO>Suppl 1</NO>
<PG>S17-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Widness-2006" MODIFIED="2013-09-11 14:49:08 -0400" MODIFIED_BY="[Empty name]" NAME="Widness 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-09-11 14:49:08 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Widness JA, Serfass RE, Haiden N, Nelson SE, Lombard KA, Pollak A</AU>
<TI>Erythrocyte iron incorporation but not absorption is increased by intravenous iron administration in erythropoietin-treated premature infants</TI>
<SO>Journal of Nutrition</SO>
<YR>2006</YR>
<VL>136</VL>
<NO>7</NO>
<PG>1868-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2013-11-25 15:19:41 -0500" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2013-11-25 15:19:41 -0500" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Aher-2012b" MODIFIED="2013-11-08 04:55:02 -0500" MODIFIED_BY="[Empty name]" NAME="Aher 2012b" TYPE="COCHRANE_REVIEW">
<AU>Aher SM, Ohlsson A</AU>
<TI>Early versus late erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2012</YR>
<NO>10</NO>
<IDENTIFIERS MODIFIED="2013-11-04 09:45:15 -0500" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-11-04 09:45:15 -0500" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004865.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Brown-1983" MODIFIED="2013-09-11 14:51:32 -0400" MODIFIED_BY="[Empty name]" NAME="Brown 1983" TYPE="JOURNAL_ARTICLE">
<AU>Brown MS, Phibbs RH, Gracia JF, Dallman PR</AU>
<TI>Postnatal changes in erythropoietin levels in untransfused premature infants</TI>
<SO>Journal of Pediatrics</SO>
<YR>1983</YR>
<VL>103</VL>
<NO>4</NO>
<PG>612-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cohen-1998" MODIFIED="2013-09-11 14:52:00 -0400" MODIFIED_BY="[Empty name]" NAME="Cohen 1998" TYPE="JOURNAL_ARTICLE">
<AU>Cohen A, Manno C</AU>
<TI>Transfusion practices in infants receiving assisted ventilation</TI>
<SO>Clinics in Perinatology</SO>
<YR>1998</YR>
<VL>25</VL>
<NO>1</NO>
<PG>97-111</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-CONSORT-2012" MODIFIED="2013-11-08 04:58:17 -0500" MODIFIED_BY="Kate Cahill" NAME="CONSORT 2012" TYPE="JOURNAL_ARTICLE">
<AU>Altman DG, Moher D, Schultz KF</AU>
<TI>Improving the reporting of randomised trials: The CONSORT statement and beyond</TI>
<SO>Statistics in Medicine</SO>
<YR>2012</YR>
<VL>31</VL>
<NO>25</NO>
<PG>2985-97</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dallman-1981" NAME="Dallman 1981" TYPE="JOURNAL_ARTICLE">
<AU>Dallman PR</AU>
<TI>Anemia of prematurity</TI>
<SO>Annual Review of Medicine</SO>
<YR>1981</YR>
<VL>32</VL>
<PG>143-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dame-2001" MODIFIED="2013-09-11 14:53:12 -0400" MODIFIED_BY="[Empty name]" NAME="Dame 2001" TYPE="JOURNAL_ARTICLE">
<AU>Dame C, Juul SE, Christensen RD</AU>
<TI>The biology of erythropoietin in the central nervous system and its neurotrophic and neuroprotective potential</TI>
<SO>Biology of the Neonate</SO>
<YR>2001</YR>
<VL>79</VL>
<NO>3-4</NO>
<PG>228-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Finch-1982" NAME="Finch 1982" TYPE="JOURNAL_ARTICLE">
<AU>Finch CA</AU>
<TI>Erythropoiesis, erythropoietin and iron</TI>
<SO>Blood</SO>
<YR>1982</YR>
<VL>60</VL>
<PG>1241-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Garcia-2002" MODIFIED="2013-09-11 14:57:22 -0400" MODIFIED_BY="[Empty name]" NAME="Garcia 2002" TYPE="JOURNAL_ARTICLE">
<AU>Garcia MG, Hutson AD, Chrisensen RD</AU>
<TI>Effect of recombinant erythropoietin on "late" transfusions in the neonatal intensive care unit: a meta-analysis</TI>
<SO>Journal of Perinatology</SO>
<YR>2002</YR>
<VL>22</VL>
<NO>2</NO>
<PG>108-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hesse-1997" MODIFIED="2013-09-11 14:58:03 -0400" MODIFIED_BY="[Empty name]" NAME="Hesse 1997" TYPE="JOURNAL_ARTICLE">
<AU>Hesse L, Eberl W, Schlaud M, Poets CF</AU>
<TI>Blood transfusion. Iron load and retinopathy of prematurity</TI>
<SO>European Journal of Pediatrics</SO>
<YR>1997</YR>
<VL>156</VL>
<NO>6</NO>
<PG>465-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" MODIFIED="2013-11-08 04:59:34 -0500" MODIFIED_BY="[Empty name]" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JP, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<NO>7414</NO>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2013-09-11 15:01:13 -0400" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011], The Cochrane Collaboration</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<PB>The Cochrane Collaboration. Available from www.cochrane-handbook.org (updated March 2011)</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Juul-2002" MODIFIED="2013-09-11 15:01:59 -0400" MODIFIED_BY="[Empty name]" NAME="Juul 2002" TYPE="JOURNAL_ARTICLE">
<AU>Juul S</AU>
<TI>Erythropoietin in the central nervous system, and its use to prevent hypoxic-ischemic brain damage</TI>
<SO>Acta Paediatrica Supplement</SO>
<YR>2002</YR>
<VL>91</VL>
<NO>438</NO>
<PG>36-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kotto_x002d_Kome-2004" MODIFIED="2013-09-11 15:02:37 -0400" MODIFIED_BY="[Empty name]" NAME="Kotto-Kome 2004" TYPE="JOURNAL_ARTICLE">
<AU>Kotto-Kome AC, Garcia MG, Calhoun DA, Christensen RD</AU>
<TI>Effect of beginning recombinant erythropoietin treatment within the first week of life among very-low-birth-weight neonates, on "early" and "late" erythrocyte transfusions: a meta-analysis</TI>
<SO>Journal of Perinatology</SO>
<YR>2004</YR>
<VL>24</VL>
<NO>1</NO>
<PG>24-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ohls-2000" MODIFIED="2013-09-11 15:04:39 -0400" MODIFIED_BY="[Empty name]" NAME="Ohls 2000" TYPE="JOURNAL_ARTICLE">
<AU>Ohls RK</AU>
<TI>The use of erythropoietin in neonates</TI>
<SO>Clinics in Perinatology</SO>
<YR>2000</YR>
<VL>27</VL>
<NO>3</NO>
<PG>681-96</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ohls-2002" MODIFIED="2013-09-11 15:05:09 -0400" MODIFIED_BY="[Empty name]" NAME="Ohls 2002" TYPE="JOURNAL_ARTICLE">
<AU>Ohls RK</AU>
<TI>Erythropoietin treatment in extremely low birth weight infants: blood in versus blood out</TI>
<SO>Journal of Pediatrics</SO>
<YR>2002</YR>
<VL>141</VL>
<NO>1</NO>
<PG>3-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ohlsson-2012" MODIFIED="2013-10-18 13:28:01 -0400" MODIFIED_BY="[Empty name]" NAME="Ohlsson 2012" TYPE="COCHRANE_REVIEW">
<AU>Ohlsson A, Aher SM</AU>
<TI>Early erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2012</YR>
<NO>9</NO>
<IDENTIFIERS MODIFIED="2013-10-18 13:27:49 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-10-18 13:27:49 -0400" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004863.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2012" MODIFIED="2013-11-08 05:02:31 -0500" MODIFIED_BY="[Empty name]" NAME="RevMan 2012" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan) Version 5.1</TI>
<YR>2012</YR>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schulz--1995" MODIFIED="2013-11-08 05:03:26 -0500" MODIFIED_BY="[Empty name]" NAME="Schulz  1995" TYPE="JOURNAL_ARTICLE">
<AU>Schulz KF, Chalmers I, Hayes RJ, Altman DG</AU>
<TI>Empirical evidence of bias: Dimensions of methodological quality associated with estimates of treatment effects in controlled trials</TI>
<SO>JAMA</SO>
<YR>1995</YR>
<VL>273</VL>
<NO>5</NO>
<PG>408-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stockman-1978" MODIFIED="2013-09-11 15:06:56 -0400" MODIFIED_BY="[Empty name]" NAME="Stockman 1978" TYPE="JOURNAL_ARTICLE">
<AU>Stockman JA 3rd, Oski FA</AU>
<TI>Physiological anaemia of infancy and the anaemia of prematurity</TI>
<SO>Clinics in Hematology</SO>
<YR>1978</YR>
<VL>7</VL>
<NO>1</NO>
<PG>3-18</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stockman-1986" MODIFIED="2013-09-11 15:09:34 -0400" MODIFIED_BY="[Empty name]" NAME="Stockman 1986" TYPE="JOURNAL_ARTICLE">
<AU>Stockman JA 3rd</AU>
<TI>Anemia of prematurity. Current concept in the issue of when to transfuse</TI>
<SO>Pediatric Clinics of North America</SO>
<YR>1986</YR>
<VL>33</VL>
<NO>1</NO>
<PG>111-28</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Strauss-1986" MODIFIED="2013-09-11 15:10:27 -0400" MODIFIED_BY="[Empty name]" NAME="Strauss 1986" TYPE="JOURNAL_ARTICLE">
<AU>Strauss RG</AU>
<TI>Current issues in neonatal transfusions</TI>
<SO>Vox Sanguinis</SO>
<YR>1986</YR>
<VL>51</VL>
<NO>1</NO>
<PG>1-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vamvakas-2001" MODIFIED="2013-09-11 15:10:59 -0400" MODIFIED_BY="[Empty name]" NAME="Vamvakas 2001" TYPE="JOURNAL_ARTICLE">
<AU>Vamvakas EC, Strauss RG</AU>
<TI>Meta-analysis of controlled clinical trials studying the efficacy of rHuEPO in reducing blood transfusions in the anemia of prematurity</TI>
<SO>Transfusion</SO>
<YR>2001</YR>
<VL>41</VL>
<NO>3</NO>
<PG>406-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Widness-1996" MODIFIED="2013-09-11 15:11:36 -0400" MODIFIED_BY="[Empty name]" NAME="Widness 1996" TYPE="JOURNAL_ARTICLE">
<AU>Widness JA, Seward VJ, Kromer IJ, Burmeiser LF, Bell EF, Strauss RG</AU>
<TI>Changing patterns of red blood cell transfusion in very low birth weight infants</TI>
<SO>Journal of Pediatrics</SO>
<YR>1996</YR>
<VL>129</VL>
<NO>5</NO>
<PG>680-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yu-2010" MODIFIED="2013-11-08 05:09:07 -0500" MODIFIED_BY="[Empty name]" NAME="Yu 2010" TYPE="COCHRANE_PROTOCOL">
<AU>Yu Z, Guo X, Han S, Lu J, Sun Q, Ohlsson A</AU>
<TI>Erythropoietin for term and late preterm infants with hypoxic ischemic encephalopathy</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2010</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2013-07-17 10:18:38 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-07-17 10:18:38 -0400" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD008316"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Zipursky-2000" MODIFIED="2013-09-11 15:18:59 -0400" MODIFIED_BY="[Empty name]" NAME="Zipursky 2000" TYPE="JOURNAL_ARTICLE">
<AU>Zipursky A</AU>
<TI>Erythropoietin therapy for premature infants: cost without benefit?</TI>
<SO>Pediatric Research</SO>
<YR>2000</YR>
<VL>48</VL>
<NO>2</NO>
<PG>136</PG>
<IDENTIFIERS MODIFIED="2012-07-17 10:10:32 -0400" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2013-11-04 09:53:38 -0500" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Aher-2006b" MODIFIED="2010-02-26 13:24:00 -0500" MODIFIED_BY="[Empty name]" NAME="Aher 2006b" TYPE="COCHRANE_REVIEW">
<AU>Aher SM, Ohlsson A</AU>
<TI>Late erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2010-02-26 13:24:00 -0500" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-02-26 13:24:00 -0500" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004868.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Aher-2012a" MODIFIED="2013-11-04 09:53:38 -0500" MODIFIED_BY="[Empty name]" NAME="Aher 2012a" TYPE="COCHRANE_REVIEW">
<AU>Aher SM, Ohlsson A</AU>
<TI>Late erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2012</YR>
<NO>9</NO>
<IDENTIFIERS MODIFIED="2013-08-15 10:57:57 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-08-15 10:57:57 -0400" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004868.pub3"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2014-03-04 19:09:38 -0500" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2014-03-04 19:09:38 -0500" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2013-11-20 14:05:28 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Akisu-2001">
<CHAR_METHODS MODIFIED="2013-11-20 14:05:28 -0500" MODIFIED_BY="[Empty name]">
<P>Randomised controlled study, single centre, University of Ege, Izmir, Turkey</P>
<P>Study period: Not stated</P>
<P>Funding sources: Not stated</P>
<P>Declarations of interest: None reported<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-07 10:23:16 -0500" MODIFIED_BY="[Empty name]">
<P>40 AGA preterm infants with GA &lt; 33 weeks and birth weight &lt; 1500 g were enrolled on day 10 of life<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-08-09 16:25:15 -0400" MODIFIED_BY="[Empty name]">
<P>Infants assigned to the treatment group (n = 20) received r-HuEPO (Recormon, Boehringer-Mannheim, Germany) sc 3 times per week, totaling 750 IU/kg/week (high dose)<BR/>20 infants were assigned to the control group with no placebo given<BR/>All infants received 3 mg/kg/day (low dose) of elemental iron<BR/>All infants received poly-vitamin supplements, vitamin D and folate</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Exposure of a proportion of infants to one or more red blood cell transfusions</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-11-07 10:25:09 -0500" MODIFIED_BY="Kate Cahill">
<P>Unknown whether infants who had received blood transfusions prior to study entry were included or not<BR/>This study focused on lipid peroxidation and antioxidant enzyme activities in preterm infants<BR/>Guidelines for transfusion were not stated.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-20 14:08:12 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Al_x002d_Kharfy-1996">
<CHAR_METHODS MODIFIED="2013-11-20 14:08:12 -0500" MODIFIED_BY="[Empty name]">
<P>A double-blind (sham-injection in the placebo group), randomised, control trial, single centre, Canada</P>
<P>Study period: March 1992 to May 1994</P>
<P>Funding sources: Supported by a grant from the Vancouver Foundation</P>
<P>Declarations of interest: None reported<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-07 10:38:44 -0500" MODIFIED_BY="[Empty name]">
<P>55 preterm infants with birth weight &lt; 1250 g, appropriate for GA, postnatal age 10 - 17 days, Hct less than 45% and a &gt; 75% probability of having BPD, determined at 10 days of age by the predictive score of Sinkin et al. were included<BR/>Infants were randomly assigned, within 250 g birth weight strata and between 10 and 17 days of age<BR/>41 infants received the 6-week treatment schedule</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-07 10:34:09 -0500" MODIFIED_BY="[Empty name]">
<P>Infants assigned to the treatment group (n = 27) received r-HuEPO (Eprex, Ortho Pharmaceutical, Canada Ltd), in a dosage of 200 IU/kg body weight, by sc injection, on Monday, Wednesday and Friday for 6 weeks (600 IU/kg/week; high dose)<BR/>In control infants (n = 28), because of a desire to avoid repeated sc placebo injections, sham injections were given and an adhesive dressing was applied to the sham injection site. The care of the infant was then handed back to nursery personnel unaware of treatment assignment<BR/>Vitamin E (25 IU/day) and folic acid (0.05 mg/day) began when enteral feeding reached 50% of total fluid intake<BR/>Oral ferrous sulphate solution was administered to the treatment group at 6 mg of elemental iron/kg/day (high dose) and the control group received 2 mg of elemental iron/kg/day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-16 13:14:32 -0400" MODIFIED_BY="[Empty name]">
<P>Number of transfusions per infant<BR/>Mortality<BR/>Sepsis<BR/>ROP (stage = 3)<BR/>Hypertension<BR/>BPD (at 28 days)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-11-07 10:34:38 -0500" MODIFIED_BY="Kate Cahill">
<P>Unclear whether infants who had received blood transfusions prior to study entry were included or not<BR/>This study exclusively enrolled those infants, who were predicted to have &gt; 75% probability of having BPD and requiring multiple transfusions<BR/>All enrolled infants were included in the data analyses<BR/>Sham injections were given in the control group<BR/>Erythrocyte transfusions were in accordance with the guidelines developed by the Canadian Paediatric Society Fetus and Newborn Committee</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-20 14:15:34 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Atasay-2002">
<CHAR_METHODS MODIFIED="2013-11-20 14:15:34 -0500" MODIFIED_BY="[Empty name]">
<P>Prospective, randomised, placebo controlled trial, single centre, Turkey</P>
<P>Study period: October 1997 to February 1999</P>
<P>Funding sources: None stated</P>
<P>Declarations of interest: None reported<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-07 10:35:46 -0500" MODIFIED_BY="[Empty name]">
<P>27 VLBW infants, with birth weight &lt; 1500 g, GA &lt; 32 weeks and postnatal age 7 - 10 days<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-07 10:36:32 -0500" MODIFIED_BY="[Empty name]">
<P>14 infants received 600 IU/kg/week (high dose) rHuEPO (Cilag AG Schafhausen, Switzerland), by sc route, at 7 - 10 days and continued over 7 - 8 weeks<BR/>13 infants were assigned to control group (no EPO or placebo)<BR/>Infants in the study group were supplemented with oral iron (ferroglycine sulphate) at the dose of 3 mg/kg/day (low dose)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Exposure of a proportion of infants to one or more red blood cell transfusions</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-11-07 10:36:46 -0500" MODIFIED_BY="Kate Cahill">
<P>Infants were enrolled at age 7 - 10 days. We decided to include this study in the late EPO systematic review, although some infants may have been &lt; 8 days old at enrolment<BR/>Unknown if infants who had received blood transfusions prior to study entry were included or not<BR/>Transfusion guidelines were followed<BR/>The authors did not provide information on the mean age of the infants at enrolment<BR/>Strict transfusion criteria were used in this trial<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-20 14:23:39 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bader-1996">
<CHAR_METHODS MODIFIED="2013-11-20 14:23:39 -0500" MODIFIED_BY="[Empty name]">
<P>Randomised, controlled clinical trial, 2 centres, Israel, </P>
<P>Study period: January 1, 1992 to December 31, 1992</P>
<P>Funding sources: None stated</P>
<P>Declarations of interest: CILAG int. supplied rHuEPO<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-07 11:10:00 -0500" MODIFIED_BY="[Empty name]">
<P>29 preterm infants (birth weight &lt; 1750 g, GA &lt; 34 weeks and postnatal age of 3 - 5 weeks, mean postnatal age 34 ± 14 days)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-07-10 17:11:11 -0400" MODIFIED_BY="[Empty name]">
<P>15 infants received 300 IU/kg/day of rHuEPO (Eprex, Cilag Int.) sc to lateral aspect of right arm 3 times a week (900 IU/kg/week; high dose), for a total duration of 4 weeks<BR/>14 infants received no placebo or other intervention<BR/>All infants received enteral vitamin E (25 IU/day), vitamin A and D (400 and 1500 IU/day) and folic acid<BR/>Two weeks into the study elemental iron supplementation was begun in both groups at a dose of 6 mg/kg/day (high dose)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Exposure of a proportion of infants to one or more red blood cell transfusions<BR/>SIDS<BR/>Side effects<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Unclear whether infants who had received blood transfusions prior to study entry were included or not<BR/>Criteria for blood transfusion were in place</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-23 11:28:41 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bechensteen-1993">
<CHAR_METHODS MODIFIED="2013-11-23 11:28:41 -0500" MODIFIED_BY="[Empty name]">
<P>Randomised, open, controlled study, 4 participating centres</P>
<P>Study period: Dates not reported</P>
<P>Funding sources: Cilag provided financial support and provision of Eprex</P>
<P>Declarations of interest: One of the authors (AGB) was a recipient of a research fellow-ship from the Norwegian Cancer Society. The financial support of Semper AB, Sweden was acknowledged for the preparation of freeze dried human milk protein<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-07 10:40:49 -0500" MODIFIED_BY="[Empty name]">
<P>29 preterm infants (birth weight 900 - 1400 g, AGA) at 3 weeks of age<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-07 10:41:13 -0500" MODIFIED_BY="[Empty name]">
<P>14 infants received rHuEPO (Eprex, Cilag), 100 IU/kg 3 times a week (300 IU/kg/week; low dose) sc from 3 to 7 weeks of age<BR/>15 infants received neither EPO nor placebo<BR/>Oral iron 18 mg/day (high dose) regardless of weight, began at the start of the study (3 weeks). If serum iron concentration fell below 16 micromol/L, the dose was increased to 36 mg/day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Exposure of a proportion of infants to one or more red blood cell transfusions<BR/>Mortality<BR/>Hypertension<BR/>Neutropenia<BR/>Side effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-08-13 12:02:42 -0400" MODIFIED_BY="[Empty name]">
<P>Infants receiving blood transfusions &lt; 96 hours before start of study were excluded<BR/>Indications for blood transfusions were 1) Hb &lt; 80 g/L or 2) at the discretion of the clinician caring for the infant according to symptoms and signs<BR/>This study concentrates more on different haematological parameters rather than the need for RBC transfusions</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-20 14:27:50 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bierer-2009">
<CHAR_METHODS MODIFIED="2013-11-20 14:27:50 -0500" MODIFIED_BY="[Empty name]">
<P>Randomised, placebo controlled study, 1 centre, the USA</P>
<P>Study period: August 2001 to May 2005</P>
<P>Funding sources: Supported by grants from national Institues of Health HD00988 and M01 RR 00997</P>
<P>Declarations of interest: None reported<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-07 11:10:32 -0500" MODIFIED_BY="[Empty name]">
<P>20 infants; 10 infants in the EPO group (BW (SEM) 2034 ± 308 g, 8 ± 2 days old); 10 infants in the placebo group (BW (SEM) 2400 ±184 g, 7 ±2 days old)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-07 10:43:20 -0500" MODIFIED_BY="[Empty name]">
<P>The EPO group received EPO 200 IU/kg per day or 400 IU/kg sc 3 times weekly (high dose). The placebo group received an equal volume of normal saline if the infant was on total parenteral nutrition and if not a sham dose was given sc and a BandAid was placed over the sham injection site. Infants received oral iron supplementation (dose not specified) when enteral feeds reached 60 mL/kg/day. Dosing continued until the infant reached study day 14 unless the infant was discharged from the hospital or died before the end of the study period.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-11-07 10:44:10 -0500" MODIFIED_BY="[Empty name]">
<P>Volume transfused during hospitalisation (mL/kg) </P>
<P>Number of transfusion per infant </P>
<P>Number of donors the infants was exposed to</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-11-07 10:44:40 -0500" MODIFIED_BY="[Empty name]">
<P>We included this study in our Late EPO review as most infants would have been &gt; 7 days and would have weighed &lt; 2500g on study entry.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-20 14:31:07 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chen-1995">
<CHAR_METHODS MODIFIED="2013-11-20 14:31:07 -0500" MODIFIED_BY="[Empty name]">
<P>Randomised, controlled clinical trial, single centre, Taiwan, Republic of China</P>
<P>Study period: June 1992 to May 1994</P>
<P>Funding sources: None reported</P>
<P>Declarations of interest: none reported<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-07 11:10:44 -0500" MODIFIED_BY="[Empty name]">
<P>67 preterm infants (birth weight &#8804; 1750 g and GA &#8804; 33 weeks<BR/>Mean age at entry Group A 22.3 ± 6.6 days; Group C 22.3 ± 6.6. days<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-07 10:47:41 -0500" MODIFIED_BY="[Empty name]">
<P>26 infants (Group A) received rHuEPO (Eprex, Cilag Zug, Switzerland) 150 mg/kg iv twice a week (300 IU/kg/week; low dose) for 4 weeks<BR/>25 infants (Group B) received packed washed erythrocyte transfusion, 10 to 15 mL/kg, during a 2 - 4 hour period when their Hb levels were less than 10 g/dL with signs and symptoms attributed to anaemia or who had a Hb level less than 8 g/dL even if asymptomatic.<BR/>16 infants (Group C) did not receive rHuEPO or erythrocyte transfusions (3 infants excluded from total 19, as they received erythrocyte transfusion later because of frequent episodes of apnoea)<BR/>All infants received oral elemental iron 3 mg/kg/day (low dose) and vitamin E 5 mg/kg/d</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-08-09 16:26:53 -0400" MODIFIED_BY="[Empty name]">
<P>Mortality<BR/>Side effects<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-11-07 10:48:24 -0500" MODIFIED_BY="[Empty name]">
<P>Unknown whether infants who had received blood transfusions prior to study entry were included or not<BR/>Strict guidelines for transfusions were not in place (transfusions were given based on frequent episodes of apnoea)<BR/>We compared Groups A and C based on intention-to-treat in this systematic review</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-20 14:34:14 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Corona-1998">
<CHAR_METHODS MODIFIED="2013-11-20 14:34:14 -0500" MODIFIED_BY="[Empty name]">
<P>Randomised, controlled clinical trial, single centre, Italy</P>
<P>Study period: Not reported</P>
<P>Funding sources: None reported</P>
<P>Declarations of interest: None reported<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-07 11:11:01 -0500" MODIFIED_BY="[Empty name]">
<P>60 preterm infants (birth weight &lt; 1500 g and &lt; 33 weeks GA)<BR/>Postnatal age (days) group A 10.1 ± 2; group B 9.5 ± 3; Group C 9.8 ± 2<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-07-10 16:47:14 -0400" MODIFIED_BY="[Empty name]">
<P>20 infants (group A) received rHuEPO (unnamed product) 150 IU/kg/week sc (low dose)<BR/>22 infants (group B) received 300 IU/kg/week sc<BR/>18 infants (group C) received no treatment<BR/>All groups received oral iron 4 mg/kg/day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-08-13 12:04:04 -0400" MODIFIED_BY="[Empty name]">
<P>Exposure of a proportion of infants to one or more red blood cell transfusions<BR/>Total volume (mL/kg) of blood transfused per infant (no SD provided)<BR/>Side effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-11-20 10:10:35 -0500" MODIFIED_BY="[Empty name]">
<P>Unknown whether infants who had received blood transfusions prior to study entry were included or not<BR/>Infants were included after the first week of life the mean (SD) postnatal age was 10.1 (2) days in group A; 9.5 (3) in group B and 9.8 (2) in group C<BR/>Some infants my have been &lt; 8 days old, but we included this study in the Late EPO review as most infants were &#8805; 8 days<BR/>Transfusion guidelines were in place</P>
<P>We combined the two groups of infants that received EPO (n = 42) and compared that combined group to the group (n = 18 infants) that did not receive any treatment</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-23 11:28:45 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Donato-1996">
<CHAR_METHODS MODIFIED="2013-11-23 11:28:45 -0500" MODIFIED_BY="[Empty name]">
<P>Prospective, randomised, placebo-controlled trial, single centre</P>
<P>Study period: Argentina, July 1991 to June 1993</P>
<P>Funding sources: This work was supported by Bio Sidus S.A.</P>
<P>Declarations of interest: See funding resources<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-07 11:11:10 -0500" MODIFIED_BY="[Empty name]">
<P>32 preterm infants with GA &lt; 34 weeks and birth weight &lt; 1500 g<BR/>Age at enrolment was 21 to 35 days of life<BR/>Mean postnatal age at enrolment (days) group A. 27.0 ± 3.2; Group B 27.6 ± 3.6; Group C 29.7 ± 5.8; Group D 32.1 ± 7.7<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-07 11:11:53 -0500" MODIFIED_BY="[Empty name]">
<P>32 preterm infants were randomly assigned to receive:<BR/>1. Group A (n = 9) placebo (human seroalbumin) sc<BR/>2. Group B (n = 8) rHuEPO (HEMAX, Bio Sidus, S.A.) at dose of 50 IU/kg sc (150 IU/kg/week; low dose)<BR/>3. Group C (n = 8) rHuEPO at dose of 100 IU/kg sc (300 IU/kg/week; low dose) <BR/>4. Group D (n = 7) rHuEPO at dose of 250 IU/kg sc (750 IU/kg/week; high dose), sc 3 days per week during 8 consecutive weeks<BR/>All infants were given oral iron 6 mg/kg/day (high dose) and folic acid (2 mg/day) supplements, starting on day 15 of age and continuing during whole treatment period</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-11-07 11:12:08 -0500" MODIFIED_BY="[Empty name]">
<P>Exposure of a proportion of infants to one or more red blood cell transfusions</P>
<P>Average number of transfusions per infant during treatment<BR/>Mortality<BR/>Mean length of hospitalisation (days)<BR/>Side effects</P>
<P>Hypertension</P>
<P>SIDS</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-11-20 11:12:43 -0500" MODIFIED_BY="Kate Cahill">
<P>Transfusion criteria were followed in this study</P>
<P>We combined the results for the three EPO groups (Group B, Group C and Group D; total n = 23) regardless whether high or low dose of EPO was used and compared to the results for the placebo group (Group A; n = 9). In separate analyses we compared the low dose EPO groups (Group B; n = 8 and group C; n = 8) to the placebo group (Group A) and the high dose EPO group (Group D; n = 7) to the placebo group (Group A; n = 9). All infants were given high dose of iron. </P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-20 14:42:06 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Emmerson-1993">
<CHAR_METHODS MODIFIED="2013-11-20 14:42:06 -0500" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, placebo-controlled trial, 1 centre in the UK</P>
<P>Study period: Not stated</P>
<P>Funding sources: This study was supported by Cilag Ltd.</P>
<P>Declarations of interest: See founding sources<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-07 11:13:38 -0500" MODIFIED_BY="Kate Cahill">
<P>24 infants with GA between 27 and 33 weeks<BR/>Postnatal age &gt; 7 days<BR/>Mean (SE) age (days) at first dose; EPO group 9 (0.4); Placebo group 8 (0.6)<BR/>One infant in the EPO group was withdrawn at 14 days of age to enable transfer to another hospital for maternal reasons<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-07 11:14:28 -0500" MODIFIED_BY="[Empty name]">
<P>16 infants were randomly assigned to receive r-HuEpo sc (Eprex, Cilag, Ltd). The first 9 infants received 50 IU/Kg of EPO, the next 9 infants received 100 IU/kg, and the final 6 infants received 150 IU/kg of r-HuEpo or placebo (4% albumin) twice a week sc after 7 days of age twice weekly sc 300 IU/kg/week (low dose) into the buttock commencing after 7 days of age and administered until the infant was discharged home. All infants received iron (6.25 mg) in the form of ferrous glycine sulphate from four weeks of age (high dose).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-11-07 11:15:24 -0500" MODIFIED_BY="[Empty name]">
<P>Exposure of a proportion of infants to one or more red blood cell transfusions </P>
<P>Volume transfused (mL/kg) </P>
<P>Mortality </P>
<P>Hospital stay </P>
<P>SIDS </P>
<P>Neutropenia</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Transfusion guidelines were followed<BR/>Unknown if infants who had received transfusions prior to study entry were included or not<BR/>One infant in the EPO group was withdrawn at 14 days of age to enable transfer to another hospital for maternal reasons and was not included in the analyses</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-03-04 19:09:38 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Giannakopoulou-1998a">
<CHAR_METHODS MODIFIED="2013-11-20 14:45:10 -0500" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial, single centre, Greece, </P>
<P>Study period: Period not stated</P>
<P>Funding sources: None reported</P>
<P>Declarations of interest: None stated<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-20 11:30:14 -0500" MODIFIED_BY="[Empty name]">
<P>36 preterm infants with birth weights 1000 - 1300 g,<BR/>32 preterm infants with birth weight &lt; 1000 g<BR/>Postnatal age &gt; 20 days<BR/>Divided into 4 groups<BR/>Groups 1 and 3 were controls and Groups 2 and 4 were treatment groups<BR/>one infant in Group 2 died and one infant from Group 1 was excluded because of severe infection<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-07 11:17:24 -0500" MODIFIED_BY="[Empty name]">
<P>24 infants received rHuEPO (Eprex, Cilag, Schafhausen, Switzerland) from day 20 of life sc at a dose of 300 IU/kg body weight, 3 times a week (900 IU/kg/week; high dose) for 6 - 8 weeks (n = 24)<BR/>24 control infants did not received any treatment.<BR/>All received oral elemental iron 10 mg/kg/day (high dose), folic acid 1 mg/day and vitamin E 15 mg/day<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mortality<BR/>Hypertension<BR/>Neutropenia<BR/>Side effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-03-04 19:09:38 -0500" MODIFIED_BY="[Empty name]">
<P>Unknown whether infants who had received blood transfusions prior to study entry were included or not<BR/>Guidelines for blood transfusions were in place<BR/>
<B>Under Giannakopoulou 1998a we report on the 32 infants weighing &lt; 1000 g</B>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-07 11:19:09 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Giannakopoulou-1998b">
<CHAR_METHODS>
<P>See above</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>See above</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>See above</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>See above</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-11-07 11:19:09 -0500" MODIFIED_BY="[Empty name]">
<P>
<B>Under Giannakopoulou 1998b we report on the 36 infants weighing 1000 - 1300 g</B>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-23 11:28:48 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Griffiths-1997">
<CHAR_METHODS MODIFIED="2013-11-23 11:28:48 -0500" MODIFIED_BY="[Empty name]">
<P>A multi centre, randomised, placebo-controlled, double-blind study, 4 NICUs in Yorkshire, the UK</P>
<P>Study period: June 1993 - December 1994</P>
<P>Funding sources: One of the authors (GG) was funded by the Yorkshire Regional health Authority</P>
<P>Declarations of interest: None reported<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-22 14:46:59 -0500" MODIFIED_BY="[Empty name]">
<P>43 preterm infants with GA &lt; 32 weeks and/or birth weight &lt; 1500 g, requirement for mechanical ventilation and/or supplemental oxygen on day 7 to 14 after birth<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-07 11:21:00 -0500" MODIFIED_BY="[Empty name]">
<P>21 infants received R-HuEpo (Eprex; Cilag UK) EPO 480 IU/kg/week (low dose) sc and 21 infants received placebo (4% human albumin) sc<BR/>The first injection was given on the day of randomisation, and then twice weekly until the infant either (a) reached 40 weeks PMA, (b) was transferred to another hospital (not in the study), (c) did not require any mechanical ventilation/oxygen for a period of more than a week, (d) had local adverse reactions/complications related to the trial solution, or (e) had PCV &gt; 60%. All infants received oral iron (3.0 mL/kg/day) (low dose) from 4 week after birth.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-16 14:36:05 -0400" MODIFIED_BY="[Empty name]">
<P>Mortality, BPD (at 36 weeks PMA)</P>
<P>SIDS<BR/>Median number of blood transfusions<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Infants who received blood transfusions prior to study entry were not excluded<BR/>Transfusion guidelines were in place<BR/>One infant who received treatment was ineligible and was subsequently withdrawn and excluded from the analysis</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-23 11:28:55 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Javier-Manchon-1997">
<CHAR_METHODS MODIFIED="2013-11-23 11:28:55 -0500" MODIFIED_BY="[Empty name]">
<P>A multi centre, randomised, controlled study, 3 centres in Barcelona, Spain</P>
<P>Study period: Not stated</P>
<P>Funding sources: None reported</P>
<P>Declarations of interest: none reported<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-07 11:23:09 -0500" MODIFIED_BY="[Empty name]">
<P>Population: Preterm infants &lt; 34 weeks GA, who at 28 days after birth had haemoglobin levels &lt; 10.5 g/dL<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-07 11:23:35 -0500" MODIFIED_BY="[Empty name]">
<P>15 infants received 200 IU EPO/kg sc (unnamed product) 3 days a week for 4 weeks (600 IU/kg/week; high dose) and ferrous sulphate 4 mg/kg/day (low dose)<BR/>13 control infants did not receive placebo, EPO or iron</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Exposure of a proportion of infants to one or more red blood cell transfusions between 30 and 60 days of age</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-11-07 11:23:55 -0500" MODIFIED_BY="[Empty name]">
<P>Infants were included if they had received blood transfusions prior to randomisation<BR/>Transfusion guidelines were similar in all 3 centres (details not provided)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-23 11:29:01 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Juul-2003">
<CHAR_METHODS MODIFIED="2013-11-20 14:55:21 -0500" MODIFIED_BY="[Empty name]">
<P>A prospective, blinded, placebo-controlled study, single centre, USA</P>
<P>Study period: Period not stated</P>
<P>Funding sources: Supported by the National Institues of health, grants M01-RR-00037 and RR00082</P>
<P>Declarations of interest: None reported<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-23 11:29:01 -0500" MODIFIED_BY="[Empty name]">
<P>36 preterm infants with birth weight between 700 to 1500 g and receiving at least 30 mL/kg per day of enteral feeding. 32 infants completed the study<BR/>The mean (SD) GA (weeks) at birth was 27.8 ± 1.8 in the EPO group and 28.8 ± 2.1 in the placebo group<BR/>Mean (SD) corrected GA (weeks) at study entry was 31.6 ± 2.0 in the EPO group and 31.9 ± 1.6 in the placebo group</P>
<P>Infants in the EPO group ranged from 2 to 8 weeks postnatal age at study entry (with a median of 4 weeks), whereas placebo-treated infants ranged from 1 to 7.4weeks postnatal age (with a median of 2 weeks). Overall, the median age at study entry was 2.8 weeks of age.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-22 15:50:04 -0500" MODIFIED_BY="[Empty name]">
<P>15 infants received rEpo (unnamed product) 1000 IU/kg per day divided into 2 daily feedings (7000 IU/kg/week; high dose), for 14 days.<BR/>17 infants received placebo (D5W) for 14 days.<BR/>All subjects received supplemental iron (iron dextran, 1.0 mg/kg/day administered in the hyperalimentation solution, or enteral ferrous sulphate 6 mg/kg per day (high dose))</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-08-13 12:04:04 -0400" MODIFIED_BY="[Empty name]">
<P>Phlebotomy loss (mL) and PRBC transfusion volume (mL)<BR/>Evidence of feeding intolerance and other adverse effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>This is the only study which used oral EPO<BR/>The results of this study are not included in the meta-analyses</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-23 11:29:06 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kivivuori-1999">
<CHAR_METHODS MODIFIED="2013-11-23 11:29:06 -0500" MODIFIED_BY="[Empty name]">
<P>An open randomised study, four centres; three in Helsinki and one in Espoo, Finland</P>
<P>Study period: Not stated</P>
<P>Funding sources: None reported</P>
<P>Declarations of interest: Cilag A.G. supplied the erythropoietin and Vifor International supplied parenteral iron preparation<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-07 11:29:12 -0500" MODIFIED_BY="[Empty name]">
<P>45 VLBW infants (4 excluded - see notes)<BR/>41 infants included<BR/>Birthweight ranged from 625 - 1470 g<BR/>The infants were randomised to 3 groups<BR/>One group (n = 14) received rHuEPO and oral iron (mean GA 30.1 ± 0.7 weeks), one group (n = 14) received rHuEPO and im iron ( mean GA 28.8 ± 0.5 weeks), one group (n = 13) received no rHuEPO and im iron (mean GA 29.1 ± 0.6 weeks)<BR/>Infants who were weaned from the respirator by 2 weeks of age were eligible<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-08-09 16:28:23 -0400" MODIFIED_BY="[Empty name]">
<P>14 infants received rHuEPO (Cilag A.G., Schafhausen, Switzerland) 300 IU/kg sc 3 times/week, 900 IU/kg/week (high dose) sc and oral iron 6 mg/kg/day (high dose)<BR/>14 infants received 900 IU/kg/week of rhuEPO and weekly im iron 12 mg/kg (high dose)<BR/>13 infants received im iron 12 mg/kg/week but no rHuEPO</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-08-09 16:28:23 -0400" MODIFIED_BY="[Empty name]">
<P>Exposure of a proportion of infants to one or more red blood cell transfusions<BR/>Side effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-11-07 11:30:24 -0500" MODIFIED_BY="[Empty name]">
<P>Unknown whether infants who had received blood transfusion prior to study entry were included or not<BR/>4 infants were excluded after randomisation; 1 weighed &gt; 1500 g, 1 had intestinal "obstipation", 1 had highly elevated serum transferrin saturation (96%), 1 accidentally received a high dose of parenteral iron (43 mg/kg)<BR/>We include the infants in the im iron group in the high-dose iron analyses<BR/>The transfusion policies (not stated) were the same in all hospitals</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-20 15:15:07 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kumar-1998">
<CHAR_METHODS MODIFIED="2013-11-20 15:15:07 -0500" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, placebo- controlled trial, single centre, USA</P>
<P>Study period: Period not stated</P>
<P>Funding sources: None reported</P>
<P>Declarations of interest: None reported</P>
<P>
<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-07 11:31:56 -0500" MODIFIED_BY="[Empty name]">
<P>30 infants (GA &lt; 32 weeks, birth weight &lt; 1250 g with anaemia of prematurity)<BR/>Mean (SD) postnatal age (days) at entry was 40.3 (20.4) in the EPO group and 36.5 (16.6) in the placebo group)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-08-04 11:59:41 -0400" MODIFIED_BY="[Empty name]">
<P>300 IU/kg/dose of rHuEPO (unnamed product) sc injection twice a week (600 IU/kg/week; high dose) for 6 weeks (n = 15)<BR/>Identical volume of placebo suspension (normal saline) (n = 15)<BR/>Infants received elemental iron 6 mg/kg/d (high dose)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Exposure of a proportion of infants to one or more red blood cell transfusions<BR/>Number of erythrocyte transfusions (per infant)<BR/>Entry to discharge duration (days)<BR/>Side effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-05-10 16:21:06 -0400" MODIFIED_BY="[Empty name]">
<P>Infants who had received transfusions prior to randomisation were included<BR/>Transfusion guidelines were followed<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-22 15:01:40 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Maier-2002">
<CHAR_METHODS MODIFIED="2013-11-22 15:00:59 -0500" MODIFIED_BY="[Empty name]">
<P>Randomised controlled study, 14 centres in four European countries (Belgium, France, Germany, Switzerland)</P>
<P>Study period: May 1998 to June 1999</P>
<P>Funding sources: The study was supported by F. Hoffman-La Roche, Basel, Switzerland</P>
<P>Declarations of interest: One of the authors (FG) was employed by F. Hoffman-La Roche<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-07 11:35:22 -0500" MODIFIED_BY="[Empty name]">
<P>148 infants with BW 500 - 999 g<BR/>Exclusion criteria: cyanotic heart disease, major congenital malformation requiring surgery, administration of investigational drug during pregnancy, GA &#8805; 30 completed weeks<BR/>The early EPO group started treatment at 3 - 5 days of age and the late EPO group 3 weeks later (at 24 to 26 days of age)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-22 15:01:40 -0500" MODIFIED_BY="[Empty name]">
<P>Infants were randomised to 3 groups (see notes for the control group). In the early EPO group 74 infants (median and quartiles for GA; 26 (25 to 28) weeks for BW 778 (660, 880) g) received 250 IU/kg iv or sc of rHuEPO on Mondays, Wednesdays and Fridays (NeoRecormon, F. Hofman-La Roche, Basel Switzerland) (750 IU/week iv or sc, high dose) starting at days 3 - 5 of life.<BR/>In the late EPO group 74 infants received the same treatment 3 weeks later<BR/>Treatment in both groups continued until days 65 to 68 of life. rHEPO was given iv in both groups as long as the infant had an iv line in place and sc thereafter. The late EPO group received sham injections until EPO was given.<BR/>Enteral iron 3 mg/kg/day was given to all infants from days 3 - 5 and was increased at days 12 - 14 to 6 mg/kg/day and to 9 mg/kg/day at days 24 - 26 of life (high dose)</P>
<P>A third group (control group, n =71) was included in this trial.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Exposure of a proportion of infants to one or more red blood cell transfusions<BR/>Donor exposure <BR/>Mortality during hospital stay<BR/>NEC<BR/>IVH<BR/>PVL<BR/>ROP<BR/>Days in oxygen<BR/>Days in NICU<BR/>Days in hospital</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-11-22 14:59:36 -0500" MODIFIED_BY="[Empty name]">
<P>Sample size calculation was performed<BR/>Transfusion guidelines were followed<BR/>Industry funded (F. Hoffman-La Roche, Basel Switzerland)<BR/>24 (32%) of the infants in the early EPO group and 23 (31%) in the late EPO group received 1 - 3 transfusions before they entered the study.<BR/>A third group (control group, n =71) was included in this trial. One infant in the control group was excluded from all evaluations because the parents withdrew consent a few hours after randomisation before the start of the treatment phase.</P>
<P>We compared the late EPO group (n = 74) to the control group (n = 71).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-23 11:29:14 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Meyer-1994">
<CHAR_METHODS MODIFIED="2013-11-23 11:29:14 -0500" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, placebo-controlled study, single centre, South Africa</P>
<P>Study period: Not stated</P>
<P>Funding sources: Funding for the study was obtained from Janssen's Pharmaceutica</P>
<P>Declarations of interest: See funding resources<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-07 11:40:08 -0500" MODIFIED_BY="[Empty name]">
<P>80 preterm infants (&lt; 32 weeks GA, birth weight &lt; 1500 g, postnatal age 2 to 8 weeks.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-08-09 16:28:54 -0400" MODIFIED_BY="[Empty name]">
<P>40 infants received rHuEPO (Eprex) sc 3 times a week at a dose of 200 IU/kg/dose (600 IU/kg/week, high dose). The volume was increased by the equivalent of 50 IU/kg per dose if the Hct declined by 6% during any 2-week period during the trial, but was withheld if the Hct was &gt; 45%.<BR/>40 infants received an identical volume of placebo<BR/>Infants received 3 mg/kg/day of iron (low dose)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-08-09 16:28:54 -0400" MODIFIED_BY="[Empty name]">
<P>Exposure of a proportion of infants to one or more red blood cell transfusions<BR/>Sepsis<BR/>NEC<BR/>SIDS</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Previous blood transfusion was not an exclusion criterion<BR/>Transfusion guidelines were followed</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-20 15:33:33 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pollak-2001">
<CHAR_METHODS MODIFIED="2013-11-20 15:33:33 -0500" MODIFIED_BY="[Empty name]">
<P>Randomised, unmasked, controlled study, single centre study conducted in Vienna, Austria</P>
<P>Study period: August 1995 to May 1997</P>
<P>Funding sources: The study was supported by the March and Dimes Birth defects Foundation (Grant FY 95-0220); by Vifor International, St Gallen, Switzerland; by Janssen-Cilag Pharma, Vienna, Austria, by the Verein zur Förderung der wissenschaftlichen Forschung auf dem Gebiet der Neonatologie und Kinderintenzivmedicin; and by the red Bull Company, Salzburg, Austria</P>
<P>Declarations of interest: See funding resources<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-07 11:43:22 -0500" MODIFIED_BY="[Empty name]">
<P>38 preterm infants with GA &lt; 31 weeks and weight &lt; 1300 g at birth. <BR/>Infants who had received red blood cell transfusions 3 days before study entry or during the study were excluded. 9 infants were disqualified (see 'Notes'). Age at entry &gt; 7 days</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-08-09 16:29:16 -0400" MODIFIED_BY="[Empty name]">
<P>The 21-day study consisted of a 3-day run-in baseline period during which 9 mg/kg/day of iron poly maltose complex (IPC; Ferrum Hausmann Syrup, Vifor International, St Gallen, Switzerland) supplementation was administered to all participants in all groups. This was followed by an 18-day treatment period during which participants received: 1) the same oral iron supplementation dose alone (oral iron group, n = 9); 2) 300 IU/kg/day (&gt; 600 IU/kg/week; high dose) of r-HuEPO (Erypo, Janssen-Cilag Pharma, Vienna, Austria) as an iv bolus infusion administered at 3-day intervals along with the same oral iron supplement as the oral iron group (EPO + oral iron group, n = 10); or 3) 2 mg of iv iron sucrose/kg/day (Venofer, Vifor International) diluted in 0.9% of sodium chloride to a final concentration of 2 mg/mL and infused daily over 2 hours (iv iron + EPO group, n = 10). To maintain comparability of iron intake among the 3 groups, this last group also received EPO and oral iron in an identical manner as the EPO + oral iron group<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-11-07 11:44:47 -0500" MODIFIED_BY="Kate Cahill">
<P>Mortality </P>
<P>Sepsis </P>
<P>BPD at 36 weeks </P>
<P>ROP (stage not provided)<BR/>Hospital stay</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-11-07 11:45:16 -0500" MODIFIED_BY="[Empty name]">
<P>Transfusion guide lines were in place<BR/>Of the 38 study participants who began the study, 9 were disqualified during the treatment period (3 infants with sepsis or sepsis-like episodes, 2 with NEC, 2 who received blood transfusions, and 2 for a protocol violation)</P>
<P>In a secondary analysis a diagnostic nomogram was used by Kasper et al to characterise and differentiate iron status in anaemic very low birth weight infants (<LINK REF="STD-Pollak-2001" TYPE="STUDY">Pollak 2001</LINK>). In this secondary study no outcomes of interest for this review were included.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-20 15:37:22 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Reiter-2005">
<CHAR_METHODS MODIFIED="2013-11-20 15:37:22 -0500" MODIFIED_BY="[Empty name]">
<P>Randomised, controlled study, single centre, the USA</P>
<P>Study period: Not stated</P>
<P>Funding sources: Supported by Grant Number M01 RR000069 General Clinical Research Centers Program National Centers for Research Resources NIH</P>
<P>Declarations of interest: No conflict of interests with any of the authors<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-07 11:46:09 -0500" MODIFIED_BY="[Empty name]">
<P>60 preterm infants with GA at birth &lt; 32 week, Hct &#8804; 28%, &lt; 48 weeks conceptual age or 5 months chronological age<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-17 08:29:28 -0400" MODIFIED_BY="[Empty name]">
<P>30 infants received EPO (Eogen alpha, Amgen Inc., Thousand Oaks, CA) at 300 IU/kg per day sc for 10 days (2100 IU/kg/week; high dose) and oral elemental iron at 6 mg/kg/day (high dose). The control group (n = 30) received only supplemental iron in the same dose. 7 infants in the EPO group and 5 in the control group had received EPO prior to study entry.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-08-13 12:04:04 -0400" MODIFIED_BY="[Empty name]">
<P>Exposure of a proportion of infants to one or more red blood cell transfusions<BR/>Volume of red blood cells transfused (mL/kg)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-11-07 11:48:19 -0500" MODIFIED_BY="Kate Cahill">
<P>Transfusion guidelines were in place and followed</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-20 15:40:23 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rocha-2001">
<CHAR_METHODS MODIFIED="2013-11-20 15:40:23 -0500" MODIFIED_BY="[Empty name]">
<P>Randomised, controlled study, single centre study in Brazil</P>
<P>Study period: March 1995 to December 1996</P>
<P>Funding sources: None reported</P>
<P>Declarations of interest: None reported<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-07 11:48:58 -0500" MODIFIED_BY="[Empty name]">
<P>45 preterm infants with GA &#8804; 33 weeks, BW &#8804; 1550 g, postnatal age 10 - 35 days<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-07 11:49:55 -0500" MODIFIED_BY="[Empty name]">
<P>In Group 1) 15 infants received daily doses of 100 IU/kg of EPO sc (unnamed product) (700 IU/kg/week - high dose); in Group 2) 15 infants received 350 IU/kg of EPO sc twice weekly (700 IU/kg/week - high dose); in Group 3) 15 infants did not receive EPO<BR/>Groups 1 and 2 were given iron (ferrous sulphate) 3 mg/kg/day enterally and was increased to 6 mg/kg/day in the second week of treatment<BR/>In Group 3 iron supplementation was initiated around the 30th day of life<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-11-07 11:51:17 -0500" MODIFIED_BY="Heather Maxwell">
<P>Short-term side effects<BR/>Mean number of blood transfusions per infant, but no SD provided<BR/>Excessive blood transfusions defined as &#8805; 2 blood transfusions per infant (This was not an outcome identified in our protocol)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-11-07 11:54:37 -0500" MODIFIED_BY="[Empty name]">
<P>Although stated to be a randomised controlled trial in the abstract this is uncertain as in the text the authors write:"...each of the patients was systematically placed into on of the three existing groups...". Three infants (one from group 2 and two from group 3) were not included due to intercurrent diseases (2 cases of severe sepsis and one case of necrotizing enterocolitis). The authors do not state in which groups the specific diseases occurred.<BR/>The name of the manufacturer of EPO was not provided<BR/>"Data collection was interrupted after a sample size calculation revealed that the number of patients studied so far would have to be at least doubled in order to obtain a statistical difference between the two groups of preterm infants who used EPO in different posology"<BR/>The authors were satisfied when "a statistical difference regarding excessive blood transfusions was found between the two treated groups and the control group"<BR/>It is unknown whether infants who had received blood transfusions prior to study entry were included or not<BR/>Transfusion guidelines were followed</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-23 11:29:24 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Romagnoli-2000">
<CHAR_METHODS MODIFIED="2013-11-20 12:16:30 -0500" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, controlled clinical trial, single centre, Rome Italy, 3-year period ending December 1998<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-23 11:29:24 -0500" MODIFIED_BY="[Empty name]">
<P>230 infants with gestational age &lt; 30 weeks and 31 - 34 weeks with RDS and requiring mechanical ventilation. Infants were 7 days old, when randomised</P>
<P>Study period: Not reported</P>
<P>Funding sources: None reported</P>
<P>Declarations of interest: None declared<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-07 11:56:49 -0500" MODIFIED_BY="[Empty name]">
<P>115 infants received EPO (unnamed product) 300 IU/kg sc, 3 times a week (900 IU/kg/week, high dose) from the 2nd to the 7th week and iron 1 mg/kg/day iv (high dose)<BR/>115 infants did not receive EPO, placebo or iron</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-11-07 11:57:07 -0500" MODIFIED_BY="[Empty name]">
<P>Use of one or more red blood cell transfusions<BR/>Number of blood transfusions per infant<BR/>ROP (all stages, stages 1 - 2, 3 - 4, and the need for cryotherapy)<BR/>NEC<BR/>IVH &gt; grade III - IV<BR/>Chronic lung disease at 28 days<BR/>Sepsis<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-11-22 15:07:17 -0500" MODIFIED_BY="[Empty name]">
<P>It is not stated whether infants who had received blood transfusions prior to study entry were included<BR/>Protocol was used to administer transfusions during study period. We obtained information from Dr Romagnoli stating that the mean (SD) age when the treatment started was 10 (± 1) days. We therefore moved this study from the Early EPO to the Late EPO review</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-20 15:48:17 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ronnestad-1995">
<CHAR_METHODS MODIFIED="2013-11-20 15:48:17 -0500" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, placebo-controlled trial, single Centre, Norway</P>
<P>Study period: Period not stated</P>
<P>Funding sources: The study was financially supported by the National Public Health Society</P>
<P>Declarations of interest: Recombinant human erythropoietin was provided by Cilag, Norway<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-07 11:58:44 -0500" MODIFIED_BY="Kate Cahill">
<P>24 preterm infants, &lt; 32 weeks, between 14 and 22 days of age<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-07 11:59:38 -0500" MODIFIED_BY="[Empty name]">
<P>24 preterm infants were randomly assigned, to receive sc either rHuEPO (Eprex, Cilag) (n = 12) 150 IU/kg 3 times per week (450 IU/kg/week; low dose) or placebo (n = 12). Treatment was started between day 14 and 22 and continued for 6 weeks or alternatively until haemoglobin concentration exceeded 13.0 g/100 mL after 4 weeks of treatment.<BR/>All infants were fed their own mother's milk 150 - 180 mL/kg/day, supplemented with a bovine milk protein and electrolyte fortifier. Additionally, they received vitamin E 25 mg/kg/day, a multivitamin formula (Multibionata) 0.5 mL/day and folic acid 100 mcg/day<BR/>Iron supplementation 4 mg/kg/day (low dose) as ferrous fumarase was started at study entry</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Neutropenia</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-20 15:53:05 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Samanci-1996">
<CHAR_METHODS MODIFIED="2013-11-20 15:53:05 -0500" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, controlled clinical trial, single centre, University of Istanbul, Turkey </P>
<P>Study period: September 1993 to March 1994</P>
<P>Funding sources: None reported</P>
<P>Declarations of interest: Recombinant human erythropoietin was manufactured by Cilag AG, Switzerland and provided by Güler Pharmaceutical Corp, Instanbul, Turkey<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-07 12:00:55 -0500" MODIFIED_BY="[Empty name]">
<P>24 preterm infants with GA &#8804; 32 weeks, birth weight of &#8804; 1250 g and postnatal age at the first dose was 2 - 4 weeks.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-07 12:01:22 -0500" MODIFIED_BY="[Empty name]">
<P>12 infants received r-HuEPO (Cilag AG, Switzerland, provided by Guler Pharmaceutical Corp, Istanbul, Turkey) at a dose of 200 IU/kg, sc, 3 times weekly (600 IU/kg/week, high dose), for 4 weeks.<BR/>12 infants received an equivalent volume of placebo sc, 3 times weekly, for 4 weeks<BR/>All infants received oral supplements of elemental iron (3 mg/kg/day) (low dose) and vitamin E, 25 IU/day, during the study period</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-16 15:10:51 -0400" MODIFIED_BY="[Empty name]">
<P>Exposure of a proportion of infants to one or more red blood cell transfusions<BR/>Number of blood transfusions per infant<BR/>IVH</P>
<P>NEC<BR/>Side effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Infants who received erythrocyte transfusions before study entry were excluded<BR/>Guidelines for erythrocyte transfusions were developed and followed</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-20 16:00:03 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shannon-1991">
<CHAR_METHODS MODIFIED="2013-11-20 16:00:03 -0500" MODIFIED_BY="[Empty name]">
<P>Multicentre, randomised, double-blind, controlled clinical trial, 3 centres, USA, </P>
<P>Study period: Study period not stated</P>
<P>Funding sources: Supported by a grant from the R. W. Johnson Pharmaceutical Research Institute, and by grants from the National Institues of Health (DK 32094 and M01RR01271, Pediatric Clinical Research Center)</P>
<P>Declarations of interest: None reported<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-07 12:02:43 -0500" MODIFIED_BY="[Empty name]">
<P>20 preterm infants, including 2 pairs of twins<BR/>Participants were stratified at entry into 2 groups: a) "large" (birth weight 901 to 1250 g) and b) "small" (birth weight &#8804; 900 g)<BR/>10 small and 10 large babies were entered into the trial<BR/>Within these two subgroups 5 infants each were randomly assigned to receive either r-HuEPO or placebo<BR/>Postnatal age 10 to 35 days<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-10 16:21:32 -0400" MODIFIED_BY="[Empty name]">
<P>10 infants received iv injections of r-HuEPO (Amgen) at a dose of 100 IU/kg, twice each week (200 IU/kg/week; low dose) for 6 weeks.<BR/>10 infants received iv injections of identical volume of placebo twice each week for 6 weeks.<BR/>All infants received 3 mg/kg/day of oral iron (low dose) and continued at the discretion of the attending physician.<BR/>All infants received supplemental vitamin E (5 IU/day).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Exposure of a proportion of infants to one or more red blood cell transfusions<BR/>Mortality<BR/>NEC<BR/>Hypertension<BR/>Neutropenia<BR/>Side effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-05-10 16:21:32 -0400" MODIFIED_BY="[Empty name]">
<P>Unknown whether infants who had received transfusions prior to randomisation were included or not<BR/>Infants with more complicated courses had large amounts of blood removed for laboratory tests<BR/>Transfusions were administered at the discretion of the attending physician</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-20 16:01:30 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shannon-1992">
<CHAR_METHODS MODIFIED="2013-11-20 16:01:30 -0500" MODIFIED_BY="[Empty name]">
<P>A double-blind, randomised, pilot study, single centre, USA </P>
<P>Study period: October to December 1991</P>
<P>Funding sources: Supported by a grant from the R. W. Johnson Pharmaceutical Research Institute, and by grants from the National Institues of Health (DK 32094 and M01RR01271, Pediatric Clinical Research Center)</P>
<P>Declarations of interest: None reported<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-07 12:04:04 -0500" MODIFIED_BY="[Empty name]">
<P>8 preterm infants with GA &lt; 33 weeks and birth weight &lt;1250 g<BR/>Postnatal age (range) 8 - 28 days<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-08-13 12:04:04 -0400" MODIFIED_BY="[Empty name]">
<P>4 infants received sc injections of r-HuEPO (unnamed product) at a dose of 100 IU/kg, 5 times a week (500 IU/kg/week; high dose)<BR/>4 infants received identical volume of placebo suspension, 5 times a week.<BR/>Oral iron was started in all infants at 3 mg/kg/day (low dose), divided in 3 doses and given between feedings<BR/>The iron dose was increased to 6 mg/kg/day for infants who were tolerating full caloric feedings<BR/>Infants also received 1 mL/day of multivitamins and vitamin E (15 IU per day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Exposure of a proportion of infants to one or more red blood cell transfusions<BR/>Major adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-05-10 16:21:32 -0400" MODIFIED_BY="[Empty name]">
<P>This was a pilot study<BR/>Unclear if infants were included if they had received transfusions prior to randomisation<BR/>Guidelines for red blood cell transfusions were in place</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-22 15:51:18 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shannon-1995">
<CHAR_METHODS MODIFIED="2013-11-21 08:24:09 -0500" MODIFIED_BY="[Empty name]">
<P>Multicentre, randomised, double-blind, controlled clinical trial, 11 centres, USA</P>
<P>Study period: October 1991 to October 1993</P>
<P>Funding sources: This work was supported, in part, by the R.W. Johnson Pharmaceutical Research Institute. Additional support was provided by Clinical Research Center grants from the National Institutes of Health to the University of California, San Francisco (Grant M01-RR-01271), to Yale University (Grant M01-RR-06022), to the University of Iowa (Grant M01-RR-00059), to the University of New Mexico (Grant M01-RR-00997), and to Stanford University (Grant M01-RR-00070). Further support came from National Institutes of Health Grant HD-14426 at Stanford; from Presbyterian/St.Luke&#8217;s Community Foundation Grant 9017 to Dr. Brown; from the Children&#8217;s Miracle Network Telethon at the University of Iowa; and from the Chief, Navy Bureau of Medicine and Surgery, Washington, D.C., at the Naval Medical Center San Diego (Clinical Investigation Program S-91-083). </P>
<P>Declarations of interest: Marlene Brim and Robert I. Abels are employees of the R.W. Johnson Pharmaceutical Research Institute and own stock in its parent company, Johnson and Johnson, Inc.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-07 12:05:52 -0500" MODIFIED_BY="[Empty name]">
<P>157 preterm infants with GA &lt; 31 weeks with birth weight &#8804; 1250 g<BR/>Mean (SD) age (days) at study entry; EPO group 22.9 ± 10.1; Placebo group 24.1 ± 9.9<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-22 15:51:18 -0500" MODIFIED_BY="[Empty name]">
<P>Sc injection of rHuEPO (unnamed product) at a dose of 100 IU/kg, or an identical volume of placebo suspension, were given from Monday through Friday (500 IU/kg/week; high dose) for 6 weeks or until the infants were ready to be discharged home. Doses of rHuEPO (or placebo) were adjusted weekly according to changes in body weight<BR/>There were 77 infants in the rHuEPO group and 80 infants in the placebo group<BR/>Participants received oral iron supplements at study entry to achieve a total enteral intake of 3 mg/kg/day of elemental iron (low dose)<BR/>Total iron intake was increased to 6 mg/kg/day when the infants tolerated full caloric feeding enterally<BR/>Infants also received 15 IU of supplemental vitamin E and an additional 1 mL/day of an enteral multivitamin preparation</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-16 15:19:48 -0400" MODIFIED_BY="[Empty name]">
<P>Exposure of a proportion of infants to one or more red blood cell transfusions<BR/>Mean number of erythrocyte transfusions per infant<BR/>Mortality<BR/>Sepsis<BR/>NEC<BR/>Threshold ROP<BR/>Hypertension<BR/>SIDS<BR/>Side effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-11-07 12:07:20 -0500" MODIFIED_BY="Kate Cahill">
<P>Infants who had received blood transfusions prior to study entry were included<BR/>Guidelines for blood transfusions were developed<BR/>This study reports 4 post-discharge infants deaths among 125 infants followed until they were at least 6 months old. Three placebo-treated infants died; 2 of probable SIDS and one from aspiration pneumonia<BR/>The only late infant death in an EPO-treated infant occurred at 11 months of age from late NEC.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-20 16:05:28 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Whitehall-1999">
<CHAR_METHODS MODIFIED="2013-11-20 16:05:28 -0500" MODIFIED_BY="[Empty name]">
<P>Single centre, randomised controlled clinical trial, single-centre study in Australia</P>
<P>Study period: August 1992 to March 1993</P>
<P>Funding sources: None reported</P>
<P>Declarations of interest: None declared<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-07 12:08:10 -0500" MODIFIED_BY="[Empty name]">
<P>42 infants with GA &#8804; 32 weeks<BR/>Postnatal age 14 days<BR/>Exclusion criteria: major congenital anomaly, primary haematological disease, hypertension, seizures, failure to obtain consent<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-13 20:02:45 -0400" MODIFIED_BY="[Empty name]">
<P>10 infants with BW &#8804; 1000 g and 12 infants with BW &gt; 1000 g received 400 IU/kg of EPO (EPREX, Janssen-Cilag) sc every second day x 10 doses (high dose)<BR/>10 infants with BW &#8804; 1000 g and 10 infants with BW &gt; 1000 g received no placebo<BR/>Both groups received 3 mg/kg/day of iron (low dose) increased to 6 mg/kg/day (high dose) as tolerated</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-08-13 12:04:04 -0400" MODIFIED_BY="[Empty name]">
<P>Total volume (mL/kg) of blood transfused<BR/>Number of transfusions per infant<BR/>Mortality during hospital stay</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Unknown whether infants were included if they had received blood transfusion prior to study entry<BR/>Guidelines for blood transfusions were in place</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-22 15:51:55 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yamada-1999a">
<CHAR_METHODS MODIFIED="2013-11-20 16:06:58 -0500" MODIFIED_BY="[Empty name]">
<P>Single-centre, randomised controlled clinical trial, Japan</P>
<P>Study period: Not stated</P>
<P>Funding sources: Not stated</P>
<P>Declarations of interest: Not stated<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-07 12:09:16 -0500" MODIFIED_BY="[Empty name]">
<P>55 infants with BW 1000 - 1499 g and GA &lt; 33 weeks and postnatal age &lt; 40 days<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-22 15:51:55 -0500" MODIFIED_BY="[Empty name]">
<P>28 infants received 200 IU/kg of EPO (unnamed product) sc twice a week (400 IU/kg/week, low dose) for 8 weeks and oral iron (3 mg/kg/day). 27 infants in the control group received no treatment or placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-08-13 12:04:04 -0400" MODIFIED_BY="[Empty name]">
<P>Exposure of a proportion of infants to one or more red blood cell transfusions<BR/>The total volume (mL) of blood transfused per infant<BR/>Number of transfusions per infant</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Unknown if infants who had received transfusions prior to enrolment were excluded or not<BR/>Conservative red blood cell transfusion guidelines were followed</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-22 15:52:09 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yamada-1999b">
<CHAR_METHODS MODIFIED="2013-11-20 16:07:32 -0500" MODIFIED_BY="[Empty name]">
<P>Single-centre, randomised controlled clinical trial, Japan</P>
<P>Study period: Not reported</P>
<P>Funding sources: Not stated</P>
<P>Declarations of interest: Not stated<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-07 12:10:10 -0500" MODIFIED_BY="[Empty name]">
<P>27 infants with BW 500 to 999 g and GA &lt; 33 weeks and postnatal age &lt; 40 days<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-22 15:52:09 -0500" MODIFIED_BY="[Empty name]">
<P>15 infants received EPO 200 IU/kg of EPO (unnamed product) sc twice a week (400 IU/kg/week, low dose) sc for 8 weeks and oral iron (3 mg/kg/day). 12 infants in the control group received no treatment or placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-08-13 12:04:04 -0400" MODIFIED_BY="[Empty name]">
<P>Exposure of a proportion of infants to one or more red blood cell transfusions<BR/>The total volume (mL) of blood transfused per infant<BR/>Number of transfusions per infant</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Unknown if infants who had received transfusions prior to enrolment were excluded or not<BR/>Conservative red blood cell transfusion guidelines were followed</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>AGA = appropriate for gestational age<BR/>BPD = bronchopulmonary dysplasia<BR/>BW = birth weight<BR/>EPO = erythropoietin<BR/>GA = gestational age<BR/>Hb = haemoglobin<BR/>Hct = hematocrit<BR/>iv = intravenous (or intravenously)<BR/>im = intramuscular (or intra muscularly)<BR/>IU = units<BR/>IVH = intraventricular haemorrhage<BR/>NEC = necrotising enterocolitis<BR/>NICU = neonatal intensive care unit<BR/>PCV = packed cell volume (hematocrit)<BR/>PMA = postmenstrual age<BR/>PRBC = packed red blood cells<BR/>PVL = periventricular leukomalacia<BR/>RDS = respiratory distress syndrome<BR/>ROP = retinopathy of prematurity<BR/>rHuEPO = recombinant human erythropoietin<BR/>sc = subcutaneous (or subcutaneously)<BR/>SD = standard deviation<BR/>SEM = standard error of the mean<BR/>SIDS = sudden infant death syndrome<BR/>TPN: total parenteral nutrition<BR/>VLBW: very low birth weight</P>
<P>
<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2013-11-08 03:45:56 -0500" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2013-11-08 03:43:38 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ahmadpour-Kacho-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-11-08 03:43:38 -0500" MODIFIED_BY="[Empty name]">
<P>Published in abstract form only. Randomised controlled trial of erythropoietin vs no treatment in preterm low birth weight infants. The abstract lacks information on the age of the infants at the time of enrolment.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-11-08 03:43:54 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Amin-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-11-08 03:43:54 -0500" MODIFIED_BY="[Empty name]">
<P>Published in abstract form only. The authors state that this was a controlled clinical trial of erythropoietin vs conventional therapy in preterm very low birth weight infants. It is not clear if this was a randomised controlled trial or not.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-08-04 11:41:52 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Badiee-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-08-04 11:41:52 -0400" MODIFIED_BY="[Empty name]">
<P>No outcomes of interest.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-08-04 11:41:52 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bechensteen-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-08-04 11:41:52 -0400" MODIFIED_BY="[Empty name]">
<P>Both groups got EPO.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-08-09 16:31:37 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Messer-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-08-09 16:31:37 -0400" MODIFIED_BY="[Empty name]">
<P>This is not a randomised controlled trial. Non-randomised controls were used.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-08-09 16:31:37 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Meyer-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-08-09 16:31:37 -0400" MODIFIED_BY="[Empty name]">
<P>All infants were treated with EPO.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-08-04 11:42:39 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mohammadzadeh-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-08-04 11:42:39 -0400" MODIFIED_BY="[Empty name]">
<P>Both groups got EPO.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-08-09 16:31:37 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ohls-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-08-09 16:31:37 -0400" MODIFIED_BY="[Empty name]">
<P>This study compared EPO with erythrocyte transfusion and not placebo.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-11-08 03:44:58 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ohls-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-11-08 03:44:58 -0500" MODIFIED_BY="[Empty name]">
<P>This study compared 2 dosing schedules; once a week vs 3 times a week of EPO in infants &#8805; 7 days of age. It appears that this study was published as an abstract in 2008 when a lower number of infants had been enrolled (14 in the abstract vs 20 in the full publication).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-08-04 11:42:51 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pasha-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-08-04 11:42:51 -0400" MODIFIED_BY="[Empty name]">
<P>No outcomes of interest. "No subject from the study group required red blood cell transfusion". The authors do not state if any infant was transfused in the control group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-11-08 03:45:13 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pathak-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-11-08 03:45:13 -0500" MODIFIED_BY="[Empty name]">
<P>Both groups got EPO.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-08-04 11:42:54 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Testa-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-08-04 11:42:54 -0400" MODIFIED_BY="[Empty name]">
<P>The study used historical controls.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-11-08 03:45:42 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Warwood-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-11-08 03:45:42 -0500" MODIFIED_BY="[Empty name]">
<P>This study was a dose-finding study of darepoetin (longer-acting and more potent than EPO). Infants were randomised to 2 different doses of darepoetin.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-11-08 03:45:56 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Warwood-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-11-08 03:45:56 -0500" MODIFIED_BY="[Empty name]">
<P>No outcomes of interest for this review were presented apart from need for transfusion. One of the study subjects qualified for and received a blood transfusion. However, the authors do not state which group this infant belonged to.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-08-04 11:43:11 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Widness-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-08-04 11:43:11 -0400" MODIFIED_BY="[Empty name]">
<P>No outcomes of interest for this review were presented.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>EPO: erythropoietin</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2013-11-22 15:04:52 -0500" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2013-11-07 11:47:53 -0500" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-12 16:05:12 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Akisu-2001">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-12 16:10:03 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Al_x002d_Kharfy-1996">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-12 16:13:08 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Atasay-2002">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-13 08:04:04 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bader-1996">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-12 16:17:27 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bechensteen-1993">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-25 15:55:27 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bierer-2009">
<DESCRIPTION>
<P>A random number list was used. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-12 16:20:02 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chen-1995">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-12 16:23:53 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Corona-1998">
<DESCRIPTION>
<P>No information provided </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-12 16:26:31 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Donato-1996">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-12 16:29:24 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Emmerson-1993">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-12 16:33:04 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Giannakopoulou-1998a">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-12 16:34:57 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Giannakopoulou-1998b">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-13 08:09:43 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Griffiths-1997">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-13 08:16:34 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Javier-Manchon-1997">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-13 08:19:36 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Juul-2003">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-13 08:27:52 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kivivuori-1999">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-13 08:30:15 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kumar-1998">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-13 12:04:04 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Maier-2002">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-09 16:29:04 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Meyer-1994">
<DESCRIPTION>
<P>A computerised random numbers generator was used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-13 12:20:16 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pollak-2001">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-07 11:47:53 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Reiter-2005">
<DESCRIPTION>
<P>It is uncertain whether there was concealed allocation to the two study groups (A clinical research nurse assigned infants to a study group using a random number table)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-13 13:21:23 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rocha-2001">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-16 10:35:02 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Romagnoli-2000">
<DESCRIPTION>
<P>Random number</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-13 13:26:00 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ronnestad-1995">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-13 13:30:38 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Samanci-1996">
<DESCRIPTION>
<P>A random number table was used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-13 13:33:41 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Shannon-1991">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-13 13:37:15 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Shannon-1992">
<DESCRIPTION>
<P>No information provided </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-10 16:21:32 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shannon-1995">
<DESCRIPTION>
<P>Computer-generated randomisation was used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-04 12:07:33 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Whitehall-1999">
<DESCRIPTION>
<P>Computer-generated random numbers were used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-13 13:49:34 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yamada-1999a">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-13 13:52:40 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yamada-1999b">
<DESCRIPTION>
<P>No information provided<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2013-11-07 10:51:30 -0500" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-12 16:05:53 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Akisu-2001">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-15 11:27:07 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Al_x002d_Kharfy-1996">
<DESCRIPTION>
<P>Blinding of randomisation - yes (numbered sealed envelopes)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-12 16:13:38 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Atasay-2002">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-07 10:39:59 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bader-1996">
<DESCRIPTION>
<P>No information provided - infants were randomly assigned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-12 16:17:12 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bechensteen-1993">
<DESCRIPTION>
<P>Prenumbered sealed envelopes were used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-10 17:10:35 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bierer-2009">
<DESCRIPTION>
<P>EPO or placebo was dispensed from the pharmacy in total parenteral nutrition iv administration or in syringes for sc dosing. If iv access was not present, EPO was administered sc. For infants randomised to receive placebo, iv administration consisted of TPN with placebo (an equal volume of normal saline) added, whereas sc administration consisted of sham dosing, followed by placement of a BandAid over the sham injection site</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-12 16:21:33 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chen-1995">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-07 10:51:30 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Corona-1998">
<DESCRIPTION>
<P>No information provided - infants were divided into 3 groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-12 16:27:08 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Donato-1996">
<DESCRIPTION>
<P>No information provided - "randomly assigned"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-12 16:31:17 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Emmerson-1993">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-15 11:29:12 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Giannakopoulou-1998a">
<DESCRIPTION>
<P>No information provided </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-12 16:35:12 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Giannakopoulou-1998b">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-15 11:29:43 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Griffiths-1997">
<DESCRIPTION>
<P>Stratified randomisation was used. Blinding was maintained throughout the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-13 08:16:47 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Javier-Manchon-1997">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-13 08:19:45 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Juul-2003">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-13 08:28:04 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kivivuori-1999">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-13 08:30:46 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kumar-1998">
<DESCRIPTION>
<P>No information provided; infants were randomly assigned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-13 12:04:18 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Maier-2002">
<DESCRIPTION>
<P>Numbered sealed envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-13 12:07:33 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Meyer-1994">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-09 16:29:27 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pollak-2001">
<DESCRIPTION>
<P>Randomisation was performed by drawing sequentially numbered sealed envelopes in blocks of 6 for each stratification group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-13 14:13:56 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Reiter-2005">
<DESCRIPTION>
<P>A clinical research nurse assigned infants to a study group using a random number table</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-13 13:23:31 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rocha-2001">
<DESCRIPTION>
<P>"...each of the patients were systematically placed in one of the three existing groups" (for groups see interventions above)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-16 10:35:06 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Romagnoli-2000">
<DESCRIPTION>
<P>Opening of numbered, sealed envelopes, on the 7th day of life<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-13 13:26:33 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ronnestad-1995">
<DESCRIPTION>
<P>No information provided - infants were randomly assigned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-13 13:31:26 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Samanci-1996">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-13 13:34:15 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Shannon-1991">
<DESCRIPTION>
<P>No information provided; infants were randomly assigned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-13 13:37:50 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Shannon-1992">
<DESCRIPTION>
<P>No information provided; infants were randomly assigned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-13 13:42:42 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shannon-1995">
<DESCRIPTION>
<P>The personnel responsible for administrative support, oversight, and monitoring of the study, the study chair and all investigators were masked to treatment group assignments throughout the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-13 13:46:57 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Whitehall-1999">
<DESCRIPTION>
<P>Sealed coded envelopes were used<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-13 13:49:57 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yamada-1999a">
<DESCRIPTION>
<P>Randomly assigned </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-13 13:53:45 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yamada-1999b">
<DESCRIPTION>
<P>No information provided; randomly assigned<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2013-11-07 12:04:45 -0500" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-03-12 16:06:32 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Akisu-2001">
<DESCRIPTION>
<P>The control group did not receive a placebo</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-03-12 16:11:03 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Al_x002d_Kharfy-1996">
<DESCRIPTION>
<P>Sham-injection was given in the placebo group</P>
<P>Blinding of outcome measure assessment - yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-11-07 10:37:30 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Atasay-2002">
<DESCRIPTION>
<P>Blinding of intervention not stated<BR/>Blinding of outcome measure assessment not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-03-13 08:04:42 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bader-1996">
<DESCRIPTION>
<P>Blinding of intervention - no; no placebo was used<BR/>Blinding of outcome measure assessment - no</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-03-12 16:17:49 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bechensteen-1993">
<DESCRIPTION>
<P>Blinding of intervention - no<BR/>Blinding of outcome measure assessment -no</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-05-28 15:42:51 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bierer-2009">
<DESCRIPTION>
<P>Outcome data reported for all randomised infants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-03-12 14:33:18 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Chen-1995">
<DESCRIPTION>
<P>Blinding of intervention - no<BR/>Blinding of outcome measurement - no</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-03-12 14:34:37 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Corona-1998">
<DESCRIPTION>
<P>Blinding of intervention - no<BR/>Blinding of outcome measurement - no</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-11-07 11:12:58 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Donato-1996">
<DESCRIPTION>
<P>Blinding of intervention - yes - placebo-controlled<BR/>Blinding of outcome measure assessment - yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-11-07 11:15:44 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Emmerson-1993">
<DESCRIPTION>
<P>Blinding of intervention - yes - placebo-controlled<BR/>Blinding of outcome measure assessment - yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-03-12 14:35:28 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Giannakopoulou-1998a">
<DESCRIPTION>
<P>Blinding of intervention - no<BR/>Blinding of outcome measures - no</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-03-12 14:35:40 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Giannakopoulou-1998b">
<DESCRIPTION>
<P>Blinding of intervention - no<BR/>Blinding of outcome measures - no</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-03-12 14:35:51 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Griffiths-1997">
<DESCRIPTION>
<P>Blinding of intervention yes<BR/>Blinding of outcome measure assessment - yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-03-12 14:36:06 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Javier-Manchon-1997">
<DESCRIPTION>
<P>Blinding of intervention - no<BR/>Blinding of outcome measure assessment - no</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-03-12 14:36:27 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Juul-2003">
<DESCRIPTION>
<P>Blinding of intervention - yes<BR/>Blinding of outcome measure assessment - yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-03-13 14:31:50 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kivivuori-1999">
<DESCRIPTION>
<P>Blinding of intervention - no; open randomised study<BR/>Blinding of outcome measure assessment - no<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-03-12 14:37:06 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kumar-1998">
<DESCRIPTION>
<P>Blinding of intervention - yes<BR/>Blinding of outcome measure assessment - yes<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-03-12 14:37:25 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Maier-2002">
<DESCRIPTION>
<P>Blinding of intervention - yes<BR/>Blinding of outcome-measure assessment - yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-03-12 14:37:55 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Meyer-1994">
<DESCRIPTION>
<P>Blinding of intervention - yes<BR/>Blinding of outcome measure assessment - yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-03-13 12:22:30 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Pollak-2001">
<DESCRIPTION>
<P>Unmasked trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-03-13 14:14:07 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Reiter-2005">
<DESCRIPTION>
<P>There was no placebo</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-03-13 13:23:46 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Rocha-2001">
<DESCRIPTION>
<P>No placebo was used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-06-16 10:35:12 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Romagnoli-2000">
<DESCRIPTION>
<P>Blinding of intervention: no</P>
<P>Blinding of outcome-measure assessment: no (the outcome of ROP was)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-11-07 12:00:03 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ronnestad-1995">
<DESCRIPTION>
<P>Blinding of intervention - yes; a placebo-treated group was in place<BR/>Blinding of outcome measure assessment - yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-03-13 13:31:37 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Samanci-1996">
<DESCRIPTION>
<P>A placebo was used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-03-13 13:34:34 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shannon-1991">
<DESCRIPTION>
<P>A placebo was used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-11-07 12:04:45 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shannon-1992">
<DESCRIPTION>
<P>An identical-looking placebo was used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-03-13 13:43:08 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shannon-1995">
<DESCRIPTION>
<P>A placebo was used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-03-13 13:47:13 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Whitehall-1999">
<DESCRIPTION>
<P>No placebo was used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-03-13 13:50:08 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Yamada-1999a">
<DESCRIPTION>
<P>No placebo was used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-03-13 13:53:02 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Yamada-1999b">
<DESCRIPTION>
<P>No placebo was used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2013-11-07 11:48:09 -0500" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-05-10 16:20:56 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Akisu-2001">
<DESCRIPTION>
<P>Outcomes reported for all randomised infants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-05-04 09:16:33 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Al_x002d_Kharfy-1996">
<DESCRIPTION>
<P>Outcomes reported on all randomised infants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-05-10 16:20:56 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Atasay-2002">
<DESCRIPTION>
<P>Outcomes reported for all randomised infants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-05-10 16:20:56 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bader-1996">
<DESCRIPTION>
<P>Outcomes reported on all randomised infants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-05-10 16:20:56 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bechensteen-1993">
<DESCRIPTION>
<P>Outcomes reported on all randomised infants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-11-07 10:45:47 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bierer-2009">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-05-10 16:21:05 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chen-1995">
<DESCRIPTION>
<P>Outcomes reported for all randomised infants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-05-05 15:52:15 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Corona-1998">
<DESCRIPTION>
<P>Outcomes reported for all randomised infants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-05-10 16:21:05 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Donato-1996">
<DESCRIPTION>
<P>Outcomes reported on all randomised infants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-05-05 15:54:05 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Emmerson-1993">
<DESCRIPTION>
<P>Outcomes reported on all randomised infants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-05-10 16:21:05 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Giannakopoulou-1998a">
<DESCRIPTION>
<P>Outcomes reported for all randomised infants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-05-10 16:21:05 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Giannakopoulou-1998b">
<DESCRIPTION>
<P>Outcomes reported for all randomised infants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-11-07 11:22:46 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Griffiths-1997">
<DESCRIPTION>
<P>Outcomes reported on all randomised infants except 1 infant who received treatment but was ineligible and was subsequently withdrawn and excluded from the analysis<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-05-10 16:21:06 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Javier-Manchon-1997">
<DESCRIPTION>
<P>Outcomes reported on all randomised infants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-11-07 11:27:33 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Juul-2003">
<DESCRIPTION>
<P>Information on 4 infants is missing. 36 infants were enrolled and 32 completed the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-11-07 11:31:04 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kivivuori-1999">
<DESCRIPTION>
<P>Complete follow-up - no; 4 infants were excluded after randomisation (see above)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-05-10 16:21:06 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kumar-1998">
<DESCRIPTION>
<P>Outcomes reported for all infants randomised</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-03-13 14:32:12 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Maier-2002">
<DESCRIPTION>
<P>One infant in the control group was excluded from all evaluations because the parents withdrew consent a few hours after randomisation before the start of the treatment phase.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-11-07 11:42:21 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Meyer-1994">
<DESCRIPTION>
<P>Three infants were early withdrawals from the trial. One infant in the placebo group completed 4 days in the trial before features of necrotizing enterocolitis became apparent. The infant died one week later; the entry data were included in the analysis. A second infant from the placebo group completed 39 days in the study before dying from intraventricular haemorrhage associated with a previous ventriculoperitoneal shunt. One infant in the treatment group developed group B streptococcal septicaemia and meningitis at the age of 30 days; the symptoms began on day 19 of the study. The infant subsequently died of complications at one year of age. The observations obtained for the last 2 infants up to the time of the intercurrent event were included in the results.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-11-07 11:45:51 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pollak-2001">
<DESCRIPTION>
<P>Of the 38 study participants who began the study, 9 were disqualified during the treatment period (see above)</P>
<P>Disqualified infants were replaced by the next eligible infant in the stratification group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-11-07 11:48:09 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Reiter-2005">
<DESCRIPTION>
<P>Three infants were withdrawn from the initial data analysis: 1 from the EPO group and 2 from the control group because post-treatment laboratory variables were not obtained</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-03-15 11:33:33 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rocha-2001">
<DESCRIPTION>
<P>Three infants (one from group 2 and two from group 3) were not included due to intercurrent diseases (2 cases of severe sepsis and one case of necrotizing enterocolitis)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-06-16 10:35:16 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Romagnoli-2000">
<DESCRIPTION>
<P>Complete follow-up: yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-05-10 16:21:31 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ronnestad-1995">
<DESCRIPTION>
<P>Outcomes reported on all randomised infants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-05-10 16:21:32 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Samanci-1996">
<DESCRIPTION>
<P>Outcomes reported on all infants randomised</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-05-10 16:21:32 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shannon-1991">
<DESCRIPTION>
<P>Outcomes reported for all infants randomised</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-05-10 16:21:32 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shannon-1992">
<DESCRIPTION>
<P>Outcomes reported on all infants randomised</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-05-10 16:21:38 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shannon-1995">
<DESCRIPTION>
<P>Outcomes reported for all infants randomised</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-03-13 14:32:21 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Whitehall-1999">
<DESCRIPTION>
<P>Outcomes reported for all randomised infants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-05-10 16:21:38 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yamada-1999a">
<DESCRIPTION>
<P>Outcomes reported for all randomised infants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-05-10 16:21:38 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yamada-1999b">
<DESCRIPTION>
<P>Outcomes for all randomised infants were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2013-11-07 11:58:05 -0500" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-06 12:37:52 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Akisu-2001">
<DESCRIPTION>
<P>The protocol for the study was not available to us and therefore we can not ascertain if there were deviations from the protocol</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-05 15:47:10 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Al_x002d_Kharfy-1996">
<DESCRIPTION>
<P>The protocol for the study was not available to us so we could not judge if there were deviations from the protocol</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-05 15:48:14 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Atasay-2002">
<DESCRIPTION>
<P>The protocol for the study was not available to us so we could not judge if there were deviations from the protocol</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-05 15:49:01 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bader-1996">
<DESCRIPTION>
<P>The protocol for the study was not available to us so we could not judge if there were deviations from the protocol</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-05 15:49:39 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bechensteen-1993">
<DESCRIPTION>
<P>The protocol for the study was not available to us so we could not judge if there were deviations from the protocol</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-28 15:42:55 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bierer-2009">
<DESCRIPTION>
<P>The study was not entered into a trials registry and we cannot tell if there were any deviations from the study protocol</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-05 15:51:27 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chen-1995">
<DESCRIPTION>
<P>The study was not entered into a trials registry and we cannot tell if there were any deviations from the study protocol</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-05 15:53:20 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Corona-1998">
<DESCRIPTION>
<P>The study was not entered into a trials registry and we cannot tell if there were any deviations from the study protocol </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-05 15:53:07 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Donato-1996">
<DESCRIPTION>
<P>The study was not entered into a trials registry and we cannot tell if there were any deviations from the study protocol </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-05 15:54:02 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Emmerson-1993">
<DESCRIPTION>
<P>The study was not entered into a trials registry and we cannot tell if there were any deviations from the study protocol </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-05 15:55:00 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Giannakopoulou-1998a">
<DESCRIPTION>
<P>The study was not entered into a trials registry and we cannot tell if there were any deviations from the study protocol </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-05 15:55:44 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Giannakopoulou-1998b">
<DESCRIPTION>
<P>The study was not entered into a trials registry and we cannot tell if there were any deviations from the study protocol</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-05 15:57:17 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Griffiths-1997">
<DESCRIPTION>
<P>The study was not entered into a trials registry and we cannot tell if there were any deviations from the study protocol</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-05 15:57:56 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Javier-Manchon-1997">
<DESCRIPTION>
<P> The study was not entered into a trials registry and we cannot tell if there were any deviations from the study protocol</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-05 15:58:46 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Juul-2003">
<DESCRIPTION>
<P>The study was not entered into a trials registry and we cannot tell if there were any deviations from the study protocol</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-05 15:59:35 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kivivuori-1999">
<DESCRIPTION>
<P>The study was not entered into a trials registry and we cannot tell if there were any deviations from the study protocol</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-05 16:00:06 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kumar-1998">
<DESCRIPTION>
<P>The study was not entered into a trials registry and we cannot tell if there were any deviations from the study protocol</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-05 16:00:44 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Maier-2002">
<DESCRIPTION>
<P>The study was not entered into a trials registry and we cannot tell if there were any deviations from the study protocol</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-05 16:01:17 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Meyer-1994">
<DESCRIPTION>
<P>The study was not entered into a trials registry and we cannot tell if there were any deviations from the study protocol</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-05 16:02:05 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pollak-2001">
<DESCRIPTION>
<P>The study was not entered into a trials registry and we cannot tell if there were any deviations from the study protocol</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-05 16:02:34 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Reiter-2005">
<DESCRIPTION>
<P>The study was not entered into a trials registry and we cannot tell if there were any deviations from the study protocol</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-05 16:03:06 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rocha-2001">
<DESCRIPTION>
<P>The study was not entered into a trials registry and we cannot tell if there were any deviations from the study protocol</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-07 11:58:05 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Romagnoli-2000">
<DESCRIPTION>
<P>The protocol for the study was not available to us and therefore we can not ascertain if there were deviations from the protocol. This study was reported as a 'Research letter' format allowing for a limited number of details</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-05 16:03:31 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ronnestad-1995">
<DESCRIPTION>
<P>The study was not entered into a trials registry and we cannot tell if there were any deviations from the study protocol</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-05 16:04:01 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Samanci-1996">
<DESCRIPTION>
<P>The study was not entered into a trials registry and we cannot tell if there were any deviations from the study protocol</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-05 16:04:18 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Shannon-1991">
<DESCRIPTION>
<P>The study was not entered into a trials registry and we cannot tell if there were any deviations from the study protocol</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-05 16:04:36 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Shannon-1992">
<DESCRIPTION>
<P>The study was not entered into a trials registry and we cannot tell if there were any deviations from the study protocol</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-05 16:04:54 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Shannon-1995">
<DESCRIPTION>
<P>The study was not entered into a trials registry and we cannot tell if there were any deviations from the study protocol</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-05 16:05:13 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Whitehall-1999">
<DESCRIPTION>
<P>The study was not entered into a trials registry and we cannot tell if there were any deviations from the study protocol</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-05 16:05:31 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yamada-1999a">
<DESCRIPTION>
<P>The study was not entered into a trials registry and we cannot tell if there were any deviations from the study protocol</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-05 16:05:49 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yamada-1999b">
<DESCRIPTION>
<P>The study was not entered into a trials registry and we cannot tell if there were any deviations from the study protocol</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2013-11-22 15:04:52 -0500" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-12 16:07:54 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Akisu-2001">
<DESCRIPTION>
<P>Appears free of other biases</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-12 16:12:03 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Al_x002d_Kharfy-1996">
<DESCRIPTION>
<P>Appears free of other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-12 16:15:33 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Atasay-2002">
<DESCRIPTION>
<P>Appears free of other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-13 08:06:00 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bader-1996">
<DESCRIPTION>
<P>Appears free of other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-12 16:19:20 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bechensteen-1993">
<DESCRIPTION>
<P>Appears free of other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-28 15:42:56 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bierer-2009">
<DESCRIPTION>
<P>Appears free of other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-15 11:28:21 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chen-1995">
<DESCRIPTION>
<P>Appears free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-12 16:25:38 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Corona-1998">
<DESCRIPTION>
<P>Appears free of other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-12 16:28:35 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Donato-1996">
<DESCRIPTION>
<P>Appears free of other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-13 14:22:19 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Emmerson-1993">
<DESCRIPTION>
<P>Appears free of other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-12 16:33:57 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Giannakopoulou-1998a">
<DESCRIPTION>
<P>Appears free of other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-12 16:35:45 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Giannakopoulou-1998b">
<DESCRIPTION>
<P>Appears free of other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-13 08:12:24 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Griffiths-1997">
<DESCRIPTION>
<P>Appears free of other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-13 08:18:18 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Javier-Manchon-1997">
<DESCRIPTION>
<P>Appears free of other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-13 08:24:10 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Juul-2003">
<DESCRIPTION>
<P>Appears free of other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-15 11:31:03 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kivivuori-1999">
<DESCRIPTION>
<P>Appears free of other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-13 08:32:19 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kumar-1998">
<DESCRIPTION>
<P>Appears free of other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-13 12:05:53 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Maier-2002">
<DESCRIPTION>
<P>Appears free of other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-13 12:16:32 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Meyer-1994">
<DESCRIPTION>
<P>Appears free of other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-13 12:25:04 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pollak-2001">
<DESCRIPTION>
<P>Appears free of other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-13 14:15:05 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Reiter-2005">
<DESCRIPTION>
<P>Appears free of other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-22 15:04:52 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Rocha-2001">
<DESCRIPTION>
<P>We have serious concerns about possible 'other bias' as noted under 'Notes' above.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-07 11:58:32 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Romagnoli-2000">
<DESCRIPTION>
<P>This study was reported in a 'Research letter' format allowing only for few details. We obtained information from the Editorial office of the European Journal of Pediatrics, that 'Research letters' are peer-reviewed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-13 13:28:38 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ronnestad-1995">
<DESCRIPTION>
<P>Appears free of other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-13 13:32:27 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Samanci-1996">
<DESCRIPTION>
<P>Appears free of other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-13 13:35:20 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shannon-1991">
<DESCRIPTION>
<P>Appears free of other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-13 13:39:05 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shannon-1992">
<DESCRIPTION>
<P>Appears free of other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-13 13:44:10 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shannon-1995">
<DESCRIPTION>
<P>Appears free of other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-13 13:47:55 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Whitehall-1999">
<DESCRIPTION>
<P>Appears free of other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-13 13:50:51 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yamada-1999a">
<DESCRIPTION>
<P>Appears free of other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-13 13:53:39 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yamada-1999b">
<DESCRIPTION>
<P>Appears free of other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2013-11-21 14:59:00 -0500" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2013-11-21 14:59:00 -0500" MODIFIED_BY="[Empty name]" NO="1">
<TITLE>Transfusion guidelines</TITLE>
<TABLE COLS="2" ROWS="31">
<TR>
<TH>
<P>Reference</P>
</TH>
<TH>
<P>Indications</P>
</TH>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Akisu-2001" TYPE="STUDY">Akisu 2001</LINK>
</P>
</TD>
<TD>
<P>Guidelines for transfusions were not presented</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Al_x002d_Kharfy-1996" TYPE="STUDY">Al-Kharfy 1996</LINK>
</P>
</TD>
<TD>
<P>The indications for transfusion were 1) shock, 2) cumulative loss of &#8805; 10% of the blood volume in 72 hours or less when further blood sampling is expected, 3) Hb &lt; 130 g/dL in acutely ill neonates with cardiorespiratory disease, and 4) Hb &lt; 80 to 100 g/L with clinical signs of anaemia. A volume of 15 mL/kg was recommended for each transfusion</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Atasay-2002" TYPE="STUDY">Atasay 2002</LINK>
</P>
</TD>
<TD>
<P>Criteria for blood transfusion (10 mL/kg packed red cells) were as follows: a Hct &lt; 30% when signs and symptoms attributed to anaemia including persistent tachycardia (180 beats/min for 24 hours), frequent apnoea with bradycardia and daily weight gain &lt; 10 g/kg despite optimal protein and caloric intake (3.5 g/kg, 100 kcal/kg/day). Infants were transfused with a Hct of 35% to 40% if they received more than 40% oxygen or ventilation therapy</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Bader-1996" TYPE="STUDY">Bader 1996</LINK>
</P>
</TD>
<TD>
<P>Criteria for blood transfusion (10 mL/kg of red cells) were as follows: a) a Hct &lt; 25%, b) an increased frequency of apnoeic events which required either stimulation or aminophylline therapy, c) changes in heart rate patterns, e.g. an increase in frequency of bradycardia (&lt; 80 beats/min) or tachycardia (&gt; 180 beats/min, d) failure of weight gain of &gt; 10 g/kg/day despite an optimal caloric intake of &gt; 120 kcal/day and e) lethargy without evidence of sepsis</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Bechensteen-1993" TYPE="STUDY">Bechensteen 1993</LINK>
</P>
</TD>
<TD>
<P>Indications of blood transfusions were: 1) Hb &lt; 80 g/L or 2) otherwise at the discretion of the clinician caring for the infant according to symptoms and signs</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Bierer-2009" TYPE="STUDY">Bierer 2009</LINK>
</P>
</TD>
<TD>
<P>Very specific transfusion criteria were in place for infants on mechanical ventilation, for infants who required supplemental oxygen and for infants on room air</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Chen-1995" TYPE="STUDY">Chen 1995</LINK>
</P>
</TD>
<TD>
<P>Transfusions were given because of frequent and prolonged apnoeas</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Corona-1998" TYPE="STUDY">Corona 1998</LINK>
</P>
</TD>
<TD>
<P>Transfusions were considered based on the clinical condition (pallor, tachycardia, tachypnoea, apnoea with or without bradycardia, poor weight gain, difficulties with sucking) and haematological parameters (Hb &lt; 70 g/L, Hct &lt; 26%, with low reticulocyte counts)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Donato-1996" TYPE="STUDY">Donato 1996</LINK>
</P>
</TD>
<TD>
<P>During the first week of life, infants were given transfusions of packed red blood cells for replacement when blood drawn for analysis was in excess of 8 mL/kg of body weight; fresh whole blood was given if signs attributable to hypovolaemia or anaemia developed. Subsequently, infants with heart rate &gt; 180 beats/min, severe, apnoea/bradycardia or poor weight gain (&lt; 10 g/day in spite of a 100 calories/day intake during 5 consecutive days) were transfused if the Hct was &lt; 25% (or &lt; 30% if oxygen or mechanical ventilation was required); asymptomatic infants were transfused only when a central Hct &lt; 23% was reached</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Emmerson-1993" TYPE="STUDY">Emmerson 1993</LINK>
</P>
</TD>
<TD>
<P>The decision to give a blood transfusion to a study infant was made by the medical staff of the neonatal unit who were blinded to the randomisation. The unit policy at the time of the study was to transfuse a preterm infant who had a Hb &lt; 100 g/L and who had symptoms consistent with those caused by anaemia. The symptoms and signs of anaemia included poor feeding, tachycardia, tachypnoea, apnoea, and pallor. Infants with a Hb &lt; 80 g/L were transfused even if asymptomatic</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Giannakopoulou-1998a" TYPE="STUDY">Giannakopoulou 1998a</LINK>; <LINK REF="STD-Giannakopoulou-1998b" TYPE="STUDY">Giannakopoulou 1998b</LINK>
</P>
</TD>
<TD>
<P>Indications for blood transfusion were a Hb &lt; 80 g/L or otherwise at the discretion of the physician treating the infants according to symptoms and signs</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Griffiths-1997" TYPE="STUDY">Griffiths 1997</LINK>
</P>
</TD>
<TD>
<P>Infants were transfused if they were ventilated and/or oxygen-dependent with a Hb of &lt; 120 g/L, had clinically symptomatic anaemia, or were asymptomatic with a Hb of &lt; 70 g/L. Infants were transfused if they were ventilated and/or oxygen-dependent with a Hb of &lt; 120 g/L, had clinically symptomatic anaemia, or were asymptomatic with a haemoglobin of &lt; 70 g/L</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Javier-Manchon-1997" TYPE="STUDY">Javier Manchon 1997</LINK>
</P>
</TD>
<TD>
<P>Transfusion guidelines were similar in all three centres (details not provided)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Juul-2003" TYPE="STUDY">Juul 2003</LINK>
</P>
</TD>
<TD>
<P>By NICU policy, on admission, infants weighing &lt; 1000 g at birth were assigned 1 unit of packed red blood cells divided into 8 aliquots. These aliquots were used for transfusions during the first month of life. The following transfusion guideline was used for infants of all birth weights: Transfusion is recommended for a Hct &lt; 35% if the infant requires positive pressure with a mean airway pressure &gt; 6 cm water and requires &gt; 35% oxygen. Transfusion is recommended for Hct &lt; 30% if the infant requires oxygen (&lt; 35% FIO2), is receiving continuous positive airway pressure or intubated with mean airway pressure &lt; 6 cm water, if an infant has significant apnoea and bradycardia while receiving methylxanthines (&gt; 9 episodes in 12 hours or 2 episodes in 24 hours requiring mask-and-bag ventilation), if the heart rate is &gt; 180 beats/min or respiratory rate &gt; 80/min and persists for 24 hours, if weight gain &lt; 10 g per day over 4 days despite adequate calories, or in the presence of sepsis. If the Hct is &lt; 20%, no symptoms are necessary for transfusion<BR/>Transfusion volumes were standardised as follows: Infants received an initial transfusion of 15 mL/kg over a period of 3 to 4 hours. A follow-up Hct was checked after 4 hours. If the Hct was &lt; 30%, a second aliquot of 10 mL/kg was given</P>
<P>If the Hct was between 30% and 35%, an additional 5 mL/kg was given<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Kivivuori-1999" TYPE="STUDY">Kivivuori 1999</LINK>
</P>
</TD>
<TD>
<P>The Hct values were maintained at &gt; 30% by red blood cell transfusions (10 mL/kg per time) in asymptomatic infants. In infants who had symptoms or signs of anaemia, red blood cells were transfused if the Hct value was &lt; 40%. The transfusion policies were the same in all study hospitals<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Kumar-1998" TYPE="STUDY">Kumar 1998</LINK>
</P>
</TD>
<TD>
<P>The need for erythrocyte transfusion was assessed by the clinicians caring for each infant and the decision to transfuse was made without consulting the study investigators. According to the practice in the NICU, infants received transfusion if a Hct level of &lt; 27% was associated with one of the following signs and symptoms of anaemia: 1) frequent apnoea and bradycardia, defined as &gt; 6 episodes in 12 hours or any episode requiring bag-and-mask ventilation, in an infant with therapeutic serum levels of theophylline; 2) persistent tachycardia, defined as &gt; 180 beats/min for more than 12 hours; 3) poor weight gain (&lt; 10 g/day averaged over a 7-day period) despite adequate caloric intake; and 4) increasing oxygen requirement in infants with chronic lung disease despite optimum diuretic and bronchodilator therapy</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Maier-2002" TYPE="STUDY">Maier 2002</LINK>
</P>
</TD>
<TD>
<P>Infants with artificial ventilation or in &gt; 40% of inspired oxygen were not transfused unless Hct dropped to &lt; 40%. Spontaneously breathing infants were not transfused unless Hct dropped to &lt; 35% during the first 2 weeks of life, 30% during the 3rd to 4th weeks, and 0.25 thereafter. Transfusion was allowed when life-threatening anaemia or hypovolaemia was assumed by the treating neonatologist, or surgery was planned. Twelve of the 14 centres used satellite packs of the original red cell pack to reduce donor exposure<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Meyer-1994" TYPE="STUDY">Meyer 1994</LINK>
</P>
</TD>
<TD>
<P>The need for blood transfusion was assessed by the attending neonatal physician and decisions were made independently of the investigators. The following guidelines were developed, based on existing literature and nursery practices: a. Hct &lt; 30% and 1) weight gain of &lt; 10 g/day averaged over 1-week period (infant tolerating full oral feeds and receiving adequate calories). 2) Three or more episodes of apnoea (respirations absent for 20 seconds) or bradycardia (heart rate of &lt; 100 beats per minute) in a 24-hour period not due to other causes and not responsive to methylxanthine treatment. 3) Tachycardia (&gt; 170 beats/min) or tachypnoea (&gt; 70 breaths/min) sustained over a 24-hour period or associated with acute cardiac decompression. 4) Requirement for surgery. a. Development of a clinically significant patent ductus arteriosus (i.e. at least three of the following features: heart rate &gt; 160 beats/min, brisk brachial and/or dorsalis pedis pulses, palpable precordial pulsation, systolic murmur, cardiomegaly on chest radiograph). b. Pulmonary disease and fractional inspired oxygen concentrations increasing by &gt; 10% per week. d. Systemic infection (either clinically suspected or proven on blood culture) associated with a sudden decrease in Hct &#8804; 22% and/or an absolute reticulocyte count of &lt; 100 000/microlitre</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Pollak-2001" TYPE="STUDY">Pollak 2001</LINK>
</P>
</TD>
<TD>
<P>Standard NICU transfusion criteria were used (authors refer to <LINK REF="STD-Shannon-1995" TYPE="STUDY">Shannon 1995</LINK>; see below)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Reiter-2005" TYPE="STUDY">Reiter 2005</LINK>
</P>
</TD>
<TD>
<P>Conservative transfusion guidelines were in place and followed. Criteria for red blood cell transfusion in the acutely ill infant requiring mechanical ventilation or nasal continuous positive airway pressure included: phlebotomy loss of &gt; 15% of blood volume associated with hypotension, or Hct &lt; 30%. Criteria for red blood cell transfusion in the convalescent infant requiring no more than supplemental oxygen included: Hct &lt; 28% with symptomatic anaemia (tachycardia, poor somatic growth or metabolic acidosis) or Hct &lt; 20%</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Rocha-2001" TYPE="STUDY">Rocha 2001</LINK>
</P>
</TD>
<TD>
<P>The decision for blood transfusion within the whole study population was made by the assistant doctor of each newborn, and was based on the following criteria: Hct &#8804; 20%, inadequate weight gain, 3 or more apnoea or bradycardia episodes within 24 hours, presurgical procedure requirement, disease associated with sudden Hct decline, restoration of the blood collected for lab exams, maintenance of Hct up to 30% associated with minimal ventilatory support requirement, and Hct up to 35% when ventilation requirements are greater. The assistant doctor who recommended blood transfusion did not know to which group the infant belonged</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Romagnoli-2000" TYPE="STUDY">Romagnoli 2000</LINK>
</P>
</TD>
<TD>
<P>Infants on mechanical ventilation and/or on more than 30% of inspired oxygen received packed erythrocytes when their Hct levels dropped below 40%. Otherwise the transfusion was performed when the Hct fell below 35% from the 2nd to the 4th week of life and below 23% thereafter</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Ronnestad-1995" TYPE="STUDY">Ronnestad 1995</LINK>
</P>
</TD>
<TD>
<P>Transfusions were given on the orders of the attending physician if Hb was &lt; 90 g/L or otherwise as necessary according to signs and symptoms</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Samanci-1996" TYPE="STUDY">Samanci 1996</LINK>
</P>
</TD>
<TD>
<P>The need for packed erythrocyte transfusions was judged by the attending neonatologist. Guidelines for erythrocyte transfusions were developed as follows: 1) Hct of &#8804; 22% and an absolute reticulocyte count of 100 000/microlitre, 2) Hct of &#8804; 30% and a) tachycardia (&gt; 180 beats/min) and tachypnoea (&gt; 70 breaths/min) persisting for 24 hours; or b) 3 or more episodes of apnoea or bradycardia in 24 hours, not due to other causes and not responsive to methylxanthine treatment; or c) average weight gain of &lt; 10 g/day over a 1-week period (infant tolerating full oral feed and receiving adequate calories); or d) undergoing surgery. 3) Systemic infection associated with a sudden decrease in Hct</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Shannon-1991" TYPE="STUDY">Shannon 1991</LINK>
</P>
</TD>
<TD>
<P>Transfusions were ordered by the clinicians caring for each infant without consulting the investigators. Written guidelines for erythrocyte transfusions were developed for the nursery 1 year before the start of the study. A copy of these guidelines was taped to the bed of each study infant. In general, babies who were otherwise well received transfusions only if they had a Hct &lt; 25% and signs referable to their anaemia, such as slowing in rate of growth, persistent severe tachycardia and tachypnoea, or worsening of episodes of apnoea and bradycardia</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Shannon-1992" TYPE="STUDY">Shannon 1992</LINK>
</P>
</TD>
<TD>
<P>See <LINK REF="STD-Shannon-1991" TYPE="STUDY">Shannon 1991</LINK> above</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Shannon-1995" TYPE="STUDY">Shannon 1995</LINK>
</P>
</TD>
<TD>
<P>Transfuse infants at Hct &#8804; 20%: a) if asymptomatic with reticulocytes &lt; 100 000/microlitre. Transfuse infants at Hct &#8804; 30%: a) if receiving &lt; 35% supplemental hood oxygen, b) if on CPAP or mechanical ventilation with mean airway pressure &lt; 6 cm water, c) if significant apnoea and bradycardia are noted (9 episodes in 12 hours or 2 episodes in 24 hours requiring bag-and-mask ventilation) while receiving therapeutic doses of methylxanthines, d) if heart rate &gt; 180 beats/min or respiratory rate &gt; 80 breaths /min persists for 24 hours, e) if weight gain &lt; 10 g/day is observed over 4 days while receiving &#8805; 100 kcal/kg/day, f) if undergoing surgery. Transfuse for Hct &#8804; 35%: a) if receiving &gt; 35% supplemental hood oxygen, b) if intubated on CPAP or mechanical ventilation with mean airway pressure &#8805; 6 - 8 cm water. Do not transfuse: a) to replace blood removed for laboratory tests alone, b) for low Hct alone</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Whitehall-1999" TYPE="STUDY">Whitehall 1999</LINK>
</P>
</TD>
<TD>
<P>Guidelines for red cell transfusions for anaemia of prematurity were based on the existing policy in the nursery, generally adopted by the neonatologists. They were as follows:<BR/>I. Transfuse infants at Hb 80 g/L, (a) If reticulocyte count is &lt; 4% and (b) If receiving supplemental oxygen &gt; 30% or (c) If unexplained recurrent apnoeas/bradycardias are noted (&gt; 1 - 2/hour) or (d) If persistent tachycardia (heart rate &gt; 170/min) or tachypnoea (respiratory rate &gt; 60/min) is noted, or (e) If there is failure to gain weight or successive weight loss on weekly recordings for 3 consecutive weeks. In absence of a clear evidence in the literature justifying red cell transfusions at a Hb of 80 g/L in otherwise asymptomatic neonates who are failing to thrive, it was decided that failure to gain weight or successive weight loss on weekly recordings for 3 consecutive weeks was a fair and substantial clinical indicator of the need to transfuse<BR/>II. Transfuse infants at Hb 100 g/L, (a) If receiving supplemental oxygen 30% and (b) needing intermittent mandatory ventilation or continuous positive airway pressure by nasal prongs for recurrent (&gt; 1 - 2 per hour), apnoeas/bradycardias with saturations &lt; 90% on the pulse oximeter<BR/>III. Transfuse Infants at Hb 120 g/L, (a) If receiving mechanical ventilatory support with mean airway pressure 10 cm of water and supplemental oxygen 30% during the acute phase of illness after birth<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Yamada-1999a" TYPE="STUDY">Yamada 1999a</LINK>
</P>
</TD>
<TD>
<P>Conservative red blood cell transfusion guidelines were followed (details not presented, as we were unable to translate the information)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Yamada-1999b" TYPE="STUDY">Yamada 1999b</LINK>
</P>
</TD>
<TD>
<P>Conservative red blood cell transfusion guidelines were followed (details not presented, as we were unable to translate the information)</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>CPAP: continuous positive airways pressure<BR/>Hb: haemoglobin<BR/>Hct: hematocrit<BR/>NICU: neonatal intensive care unit</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2013-11-21 17:31:26 -0500" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2013-11-21 17:31:26 -0500" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Late initiation of EPO (8-28 days) vs. placebo or no intervention</NAME>
<DICH_OUTCOME CHI2="60.087849294545876" CI_END="0.7904212256119221" CI_START="0.6408056465501186" CI_STUDY="95" CI_TOTAL="95" DF="19" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7116926194117689" ESTIMABLE="YES" EVENTS_1="254" EVENTS_2="322" I2="68.3796304526336" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-0.10214140591744063" LOG_CI_START="-0.19327367005934618" LOG_EFFECT_SIZE="-0.1477075379883934" METHOD="MH" MODIFIED="2013-11-21 17:31:26 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="3.747941475062966E-6" P_Q="1.0" P_Z="2.105592922451154E-10" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="20" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="605" TOTAL_2="537" WEIGHT="99.99999999999997" Z="6.353434920733217">
<NAME>Use of one or more red blood cell transfusions (low and high dose of EPO)</NAME>
<GROUP_LABEL_1>Late EPO</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Late EPO</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Placebo/no treatment</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2617285296697793" CI_START="0.022015653228549727" EFFECT_SIZE="0.16666666666666666" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.10096592325294027" LOG_CI_START="-1.6572684240202276" LOG_EFFECT_SIZE="-0.7781512503836436" ORDER="85531" O_E="0.0" SE="1.0327955589886444" STUDY_ID="STD-Akisu-2001" TOTAL_1="20" TOTAL_2="20" VAR="1.0666666666666667" WEIGHT="1.7836867261315703"/>
<DICH_DATA CI_END="1.2458080285893722" CI_START="0.8122761850311588" EFFECT_SIZE="1.005952380952381" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="12" LOG_CI_END="0.09545112535079402" LOG_CI_START="-0.09029627957517267" LOG_EFFECT_SIZE="0.0025774228878106755" ORDER="85521" O_E="0.0" SE="0.10910894511799613" STUDY_ID="STD-Atasay-2002" TOTAL_1="14" TOTAL_2="13" VAR="0.01190476190476189" WEIGHT="3.6994983949395532"/>
<DICH_DATA CI_END="0.916079102200123" CI_START="0.059432034104573137" EFFECT_SIZE="0.23333333333333334" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" LOG_CI_END="-0.038067023967759434" LOG_CI_START="-1.2259794054430517" LOG_EFFECT_SIZE="-0.6320232147054056" ORDER="85522" O_E="0.0" SE="0.6977856131397107" STUDY_ID="STD-Bader-1996" TOTAL_1="15" TOTAL_2="14" VAR="0.48690476190476195" WEIGHT="2.460257553284925"/>
<DICH_DATA CI_END="2.0195435340227306" CI_START="0.006955353521815352" EFFECT_SIZE="0.11851851851851852" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.3052532194183947" LOG_CI_START="-2.157680791096557" LOG_EFFECT_SIZE="-0.9262137858390813" ORDER="85523" O_E="0.0" SE="1.4467396294964603" STUDY_ID="STD-Bechensteen-1993" TOTAL_1="14" TOTAL_2="15" VAR="2.0930555555555554" WEIGHT="1.2946113334825913"/>
<DICH_DATA CI_END="0.9675352817538995" CI_START="0.2733644973017557" EFFECT_SIZE="0.5142857142857142" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="10" LOG_CI_END="-0.014333189211736446" LOG_CI_START="-0.5632578892822028" LOG_EFFECT_SIZE="-0.2887955392469696" ORDER="85534" O_E="0.0" SE="0.32244108604248" STUDY_ID="STD-Corona-1998" TOTAL_1="42" TOTAL_2="18" VAR="0.10396825396825399" WEIGHT="4.161935694306997"/>
<DICH_DATA CI_END="0.9332445458261052" CI_START="0.2712206954584329" EFFECT_SIZE="0.5031055900621118" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="7" LOG_CI_END="-0.030004539547436173" LOG_CI_START="-0.5666771747589638" LOG_EFFECT_SIZE="-0.2983408571532" ORDER="85524" O_E="0.0" SE="0.31524416249564025" STUDY_ID="STD-Donato-1996" TOTAL_1="23" TOTAL_2="9" VAR="0.09937888198757763" WEIGHT="2.991391280283154"/>
<DICH_DATA CI_END="0.9728329540890739" CI_START="0.29238775603648015" EFFECT_SIZE="0.5333333333333333" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="-0.011961726376606465" LOG_CI_START="-0.5340408177508689" LOG_EFFECT_SIZE="-0.27300127206373764" ORDER="85537" O_E="0.0" SE="0.3066718426064236" STUDY_ID="STD-Emmerson-1993" TOTAL_1="15" TOTAL_2="8" VAR="0.09404761904761905" WEIGHT="2.71430588759152"/>
<DICH_DATA CI_END="2.9423243908144285" CI_START="0.11345695312726019" EFFECT_SIZE="0.5777777777777777" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.46869055193139536" LOG_CI_START="-0.945168883540447" LOG_EFFECT_SIZE="-0.23823916580452575" ORDER="85538" O_E="0.0" SE="0.8305080311132396" STUDY_ID="STD-Javier-Manchon-1997" TOTAL_1="15" TOTAL_2="13" VAR="0.6897435897435897" WEIGHT="0.955546460427627"/>
<DICH_DATA CI_END="2.0521983886549444" CI_START="0.23633814244437093" EFFECT_SIZE="0.6964285714285714" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.3122193422747811" LOG_CI_START="-0.6264661822341836" LOG_EFFECT_SIZE="-0.15712341997970122" ORDER="85532" O_E="0.0" SE="0.551388523664851" STUDY_ID="STD-Kivivuori-1999" TOTAL_1="28" TOTAL_2="13" VAR="0.304029304029304" WEIGHT="1.6241700270466333"/>
<DICH_DATA CI_END="0.7716992950035634" CI_START="0.015998043658039977" EFFECT_SIZE="0.1111111111111111" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="9" LOG_CI_END="-0.11255189650552389" LOG_CI_START="-1.7959331223731259" LOG_EFFECT_SIZE="-0.9542425094393249" ORDER="85525" O_E="0.0" SE="0.9888264649460884" STUDY_ID="STD-Kumar-1998" TOTAL_1="15" TOTAL_2="15" VAR="0.9777777777777779" WEIGHT="2.6755300891973555"/>
<DICH_DATA CI_END="1.12749355545595" CI_START="0.8439104389374585" EFFECT_SIZE="0.9754504504504504" ESTIMABLE="YES" EVENTS_1="61" EVENTS_2="60" LOG_CI_END="0.05211406821038122" LOG_CI_START="-0.07370364097993631" LOG_EFFECT_SIZE="-0.010794786384777516" ORDER="85533" O_E="0.0" SE="0.07390594518609753" STUDY_ID="STD-Maier-2002" TOTAL_1="74" TOTAL_2="71" VAR="0.005462088733850451" WEIGHT="18.20590589430844"/>
<DICH_DATA CI_END="0.802202200629343" CI_START="0.15528189021510708" EFFECT_SIZE="0.35294117647058826" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="17" LOG_CI_END="-0.09571615098081242" LOG_CI_START="-0.8088791910084481" LOG_EFFECT_SIZE="-0.45229767099463025" ORDER="85526" O_E="0.0" SE="0.41891549992621585" STUDY_ID="STD-Meyer-1994" TOTAL_1="40" TOTAL_2="40" VAR="0.17549019607843136" WEIGHT="5.0537790573727825"/>
<DICH_DATA CI_END="2.9127186917646344" CI_START="0.03556141346709918" EFFECT_SIZE="0.3218390804597701" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.4642985428103939" LOG_CI_START="-1.4490209853631926" LOG_EFFECT_SIZE="-0.4923612212763993" ORDER="85539" O_E="0.0" SE="1.1238933619335767" STUDY_ID="STD-Reiter-2005" TOTAL_1="29" TOTAL_2="28" VAR="1.2631362889983577" WEIGHT="0.907489737856413"/>
<DICH_DATA CI_END="1.190898996890678" CI_START="0.738019137050866" EFFECT_SIZE="0.9375" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="64" LOG_CI_END="0.07587492944823938" LOG_CI_START="-0.1319323766487264" LOG_EFFECT_SIZE="-0.028028723600243537" MODIFIED="2013-05-09 14:20:49 -0400" MODIFIED_BY="[Empty name]" ORDER="157" O_E="0.0" SE="0.12206704026411297" STUDY_ID="STD-Romagnoli-2000" TOTAL_1="115" TOTAL_2="115" VAR="0.014900362318840578" WEIGHT="19.025991745403417"/>
<DICH_DATA CI_END="1.080768408129708" CI_START="0.13011575740204556" EFFECT_SIZE="0.375" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="8" LOG_CI_END="0.03373264136606" LOG_CI_START="-0.8856701059106221" LOG_EFFECT_SIZE="-0.42596873227228116" ORDER="85527" O_E="0.0" SE="0.5400617248673217" STUDY_ID="STD-Samanci-1996" TOTAL_1="12" TOTAL_2="12" VAR="0.2916666666666667" WEIGHT="2.378248968175427"/>
<DICH_DATA CI_END="1.3576109393017348" CI_START="0.41433078042912114" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" LOG_CI_END="0.13277532876397893" LOG_CI_START="-0.3826528019805788" LOG_EFFECT_SIZE="-0.12493873660829995" ORDER="85528" O_E="0.0" SE="0.3027650354097491" STUDY_ID="STD-Shannon-1991" TOTAL_1="10" TOTAL_2="10" VAR="0.09166666666666662" WEIGHT="2.378248968175427"/>
<DICH_DATA CI_END="1.994875924249409" CI_START="0.055698256598548955" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.29991588895031257" LOG_CI_START="-1.2541583983896376" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="85529" O_E="0.0" SE="0.9128709291752768" STUDY_ID="STD-Shannon-1992" TOTAL_1="4" TOTAL_2="4" VAR="0.8333333333333333" WEIGHT="0.8918433630657852"/>
<DICH_DATA CI_END="1.0602206859071692" CI_START="0.6516017231973248" EFFECT_SIZE="0.8311688311688312" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="55" LOG_CI_END="0.025396273468690313" LOG_CI_START="-0.18601777584587964" LOG_EFFECT_SIZE="-0.08031075118859467" ORDER="85530" O_E="0.0" SE="0.1241856590838005" STUDY_ID="STD-Shannon-1995" TOTAL_1="77" TOTAL_2="80" VAR="0.01542207792207792" WEIGHT="16.03803245258429"/>
<DICH_DATA CI_END="0.5973653107848271" CI_START="0.157587651968836" EFFECT_SIZE="0.3068181818181818" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="22" LOG_CI_END="-0.2237600006340454" LOG_CI_START="-0.8024778153483172" LOG_EFFECT_SIZE="-0.5131189079911813" ORDER="85536" O_E="0.0" SE="0.33994170906254734" STUDY_ID="STD-Yamada-1999a" TOTAL_1="28" TOTAL_2="27" VAR="0.11556036556036559" WEIGHT="6.659097110891196"/>
<DICH_DATA CI_END="1.076280136512388" CI_START="0.6133684229639238" EFFECT_SIZE="0.8125" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="12" LOG_CI_END="0.03192532514723446" LOG_CI_START="-0.21227858584541046" LOG_EFFECT_SIZE="-0.09017663034908802" ORDER="85535" O_E="0.0" SE="0.14344658614593475" STUDY_ID="STD-Yamada-1999b" TOTAL_1="15" TOTAL_2="12" VAR="0.020576923076923076" WEIGHT="4.100429255474874"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="38.706769382025215" CI_END="0.8576239435225974" CI_START="0.6776786235134823" CI_STUDY="95" CI_TOTAL="95" DF="13" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7623604223322445" ESTIMABLE="YES" EVENTS_1="202" EVENTS_2="259" I2="66.41414355278901" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="-0.06670310265761989" LOG_CI_START="-0.16897621339576696" LOG_EFFECT_SIZE="-0.11783965802669343" METHOD="MH" MODIFIED="2013-11-21 17:31:26 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="2.2266572682250185E-4" P_Q="0.653795876589705" P_Z="6.28513558860277E-6" Q="0.2011479237754304" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="14" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="465" TOTAL_2="447" WEIGHT="100.0" Z="4.516563229883036">
<NAME>Use of one or more red blood cell transfusions (high dose of EPO)</NAME>
<GROUP_LABEL_1>Late EPO</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Late EPO</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Placebo/no treatment</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="23.58875084191411" CI_END="0.8797583728523471" CI_START="0.616034479143007" DF="5" EFFECT_SIZE="0.736180338634356" ESTIMABLE="YES" EVENTS_1="72" EVENTS_2="91" I2="78.80345579336208" ID="CMP-001.02.01" LOG_CI_END="-0.05563659119777958" LOG_CI_START="-0.2103949799094473" LOG_EFFECT_SIZE="-0.13301578555361346" NO="1" P_CHI2="2.603946513690669E-4" P_Z="7.538611427674214E-4" STUDIES="6" TAU2="0.0" TOTAL_1="168" TOTAL_2="150" WEIGHT="35.72485113955047" Z="3.369202163846646">
<NAME>High dose iron</NAME>
<DICH_DATA CI_END="0.916079102200123" CI_START="0.059432034104573137" EFFECT_SIZE="0.23333333333333334" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" LOG_CI_END="-0.038067023967759434" LOG_CI_START="-1.2259794054430517" LOG_EFFECT_SIZE="-0.6320232147054056" ORDER="85540" O_E="0.0" SE="0.6977856131397107" STUDY_ID="STD-Bader-1996" TOTAL_1="15" TOTAL_2="14" VAR="0.48690476190476195" WEIGHT="3.1736729829000465"/>
<DICH_DATA CI_END="1.16564670550934" CI_START="0.028941825338230066" EFFECT_SIZE="0.1836734693877551" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" LOG_CI_END="0.06656694056238294" LOG_CI_START="-1.5384740817407605" LOG_EFFECT_SIZE="-0.7359535705891888" ORDER="85541" O_E="0.0" SE="0.9428090415820634" STUDY_ID="STD-Donato-1996" TOTAL_1="7" TOTAL_2="9" VAR="0.8888888888888888" WEIGHT="2.348848598281753"/>
<DICH_DATA CI_END="2.0521983886549444" CI_START="0.23633814244437093" EFFECT_SIZE="0.6964285714285714" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.3122193422747811" LOG_CI_START="-0.6264661822341836" LOG_EFFECT_SIZE="-0.15712341997970122" ORDER="85543" O_E="0.0" SE="0.551388523664851" STUDY_ID="STD-Kivivuori-1999" TOTAL_1="28" TOTAL_2="13" VAR="0.304029304029304" WEIGHT="2.095140213101494"/>
<DICH_DATA CI_END="0.7716992950035634" CI_START="0.015998043658039977" EFFECT_SIZE="0.1111111111111111" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="9" LOG_CI_END="-0.11255189650552389" LOG_CI_START="-1.7959331223731259" LOG_EFFECT_SIZE="-0.9542425094393249" ORDER="85542" O_E="0.0" SE="0.9888264649460884" STUDY_ID="STD-Kumar-1998" TOTAL_1="15" TOTAL_2="15" VAR="0.9777777777777779" WEIGHT="3.4513693689038005"/>
<DICH_DATA CI_END="1.12749355545595" CI_START="0.8439104389374585" EFFECT_SIZE="0.9754504504504504" ESTIMABLE="YES" EVENTS_1="61" EVENTS_2="60" LOG_CI_END="0.05211406821038122" LOG_CI_START="-0.07370364097993631" LOG_EFFECT_SIZE="-0.010794786384777516" ORDER="85544" O_E="0.0" SE="0.07390594518609753" STUDY_ID="STD-Maier-2002" TOTAL_1="74" TOTAL_2="71" VAR="0.005462088733850451" WEIGHT="23.48518007346034"/>
<DICH_DATA CI_END="2.9127186917646344" CI_START="0.03556141346709918" EFFECT_SIZE="0.3218390804597701" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.4642985428103939" LOG_CI_START="-1.4490209853631926" LOG_EFFECT_SIZE="-0.4923612212763993" ORDER="85545" O_E="0.0" SE="1.1238933619335767" STUDY_ID="STD-Reiter-2005" TOTAL_1="29" TOTAL_2="28" VAR="1.2631362889983577" WEIGHT="1.1706399029030434"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="16.84634518610726" CI_END="0.9060294031411376" CI_START="0.6661943241354493" DF="7" EFFECT_SIZE="0.7769116075027163" ESTIMABLE="YES" EVENTS_1="130" EVENTS_2="168" I2="58.44796053583945" ID="CMP-001.02.02" LOG_CI_END="-0.04285770804643221" LOG_CI_START="-0.17639907174564512" LOG_EFFECT_SIZE="-0.10962838989603868" MODIFIED="2013-05-09 14:22:57 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.018414345936336396" P_Z="0.0012909023302915673" STUDIES="8" TAU2="0.0" TOTAL_1="297" TOTAL_2="297" WEIGHT="64.27514886044952" Z="3.2179946336824323">
<NAME>Low dose iron</NAME>
<DICH_DATA CI_END="1.2617285296697793" CI_START="0.022015653228549727" EFFECT_SIZE="0.16666666666666666" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.10096592325294027" LOG_CI_START="-1.6572684240202276" LOG_EFFECT_SIZE="-0.7781512503836436" ORDER="85551" O_E="0.0" SE="1.0327955589886444" STUDY_ID="STD-Akisu-2001" TOTAL_1="20" TOTAL_2="20" VAR="1.0666666666666667" WEIGHT="2.3009129126025334"/>
<DICH_DATA CI_END="1.2458080285893722" CI_START="0.8122761850311588" EFFECT_SIZE="1.005952380952381" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="12" LOG_CI_END="0.09545112535079402" LOG_CI_START="-0.09029627957517267" LOG_EFFECT_SIZE="0.0025774228878106755" ORDER="85550" O_E="0.0" SE="0.10910894511799613" STUDY_ID="STD-Atasay-2002" TOTAL_1="14" TOTAL_2="13" VAR="0.01190476190476189" WEIGHT="4.772263818731181"/>
<DICH_DATA CI_END="2.9423243908144285" CI_START="0.11345695312726019" EFFECT_SIZE="0.5777777777777777" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.46869055193139536" LOG_CI_START="-0.945168883540447" LOG_EFFECT_SIZE="-0.23823916580452575" ORDER="85552" O_E="0.0" SE="0.8305080311132396" STUDY_ID="STD-Javier-Manchon-1997" TOTAL_1="15" TOTAL_2="13" VAR="0.6897435897435897" WEIGHT="1.232631917465643"/>
<DICH_DATA CI_END="0.802202200629343" CI_START="0.15528189021510708" EFFECT_SIZE="0.35294117647058826" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="17" LOG_CI_END="-0.09571615098081242" LOG_CI_START="-0.8088791910084481" LOG_EFFECT_SIZE="-0.45229767099463025" ORDER="85547" O_E="0.0" SE="0.41891549992621585" STUDY_ID="STD-Meyer-1994" TOTAL_1="40" TOTAL_2="40" VAR="0.17549019607843136" WEIGHT="6.519253252373845"/>
<DICH_DATA CI_END="1.190898996890678" CI_START="0.738019137050866" EFFECT_SIZE="0.9375" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="64" LOG_CI_END="0.07587492944823938" LOG_CI_START="-0.1319323766487264" LOG_EFFECT_SIZE="-0.028028723600243537" MODIFIED="2013-05-09 14:22:57 -0400" MODIFIED_BY="[Empty name]" ORDER="158" O_E="0.0" SE="0.12206704026411297" STUDY_ID="STD-Romagnoli-2000" TOTAL_1="115" TOTAL_2="115" VAR="0.014900362318840578" WEIGHT="24.54307106776036"/>
<DICH_DATA CI_END="1.080768408129708" CI_START="0.13011575740204556" EFFECT_SIZE="0.375" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="8" LOG_CI_END="0.03373264136606" LOG_CI_START="-0.8856701059106221" LOG_EFFECT_SIZE="-0.42596873227228116" ORDER="85549" O_E="0.0" SE="0.5400617248673217" STUDY_ID="STD-Samanci-1996" TOTAL_1="12" TOTAL_2="12" VAR="0.2916666666666667" WEIGHT="3.067883883470045"/>
<DICH_DATA CI_END="1.994875924249409" CI_START="0.055698256598548955" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.29991588895031257" LOG_CI_START="-1.2541583983896376" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="85546" O_E="0.0" SE="0.9128709291752768" STUDY_ID="STD-Shannon-1992" TOTAL_1="4" TOTAL_2="4" VAR="0.8333333333333333" WEIGHT="1.1504564563012667"/>
<DICH_DATA CI_END="1.0602206859071692" CI_START="0.6516017231973248" EFFECT_SIZE="0.8311688311688312" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="55" LOG_CI_END="0.025396273468690313" LOG_CI_START="-0.18601777584587964" LOG_EFFECT_SIZE="-0.08031075118859467" ORDER="85548" O_E="0.0" SE="0.1241856590838005" STUDY_ID="STD-Shannon-1995" TOTAL_1="77" TOTAL_2="80" VAR="0.01542207792207792" WEIGHT="20.688675551744648"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="14.560916649634837" CI_END="0.666156737942077" CI_START="0.4155183744850188" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5261182043057762" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="70" I2="58.793802997626045" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="-0.1764235750118582" LOG_CI_START="-0.38140976667888354" LOG_EFFECT_SIZE="-0.2789166708453709" METHOD="MH" MODIFIED="2013-11-21 17:31:26 -0500" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.023960969783959007" P_Q="0.7718495526606244" P_Z="9.623557862580337E-8" Q="0.08407475350123163" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="140" TOTAL_2="99" WEIGHT="99.99999999999999" Z="5.3336922365261765">
<NAME>Use of one or more red blood cell transfusions (low dose of EPO)</NAME>
<GROUP_LABEL_1>Late EPO</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Late EPO</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Placebo/no treatment</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.7422053432841051" CI_END="0.7862111669022998" CI_START="0.31363551827524433" DF="2" EFFECT_SIZE="0.496571995590959" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="18" I2="0.0" ID="CMP-001.03.01" LOG_CI_END="-0.10446079199696855" LOG_CI_START="-0.5035747606640248" LOG_EFFECT_SIZE="-0.30401777633049676" NO="1" P_CHI2="0.4184902024286532" P_Z="0.002827140800210672" STUDIES="3" TAU2="0.0" TOTAL_1="45" TOTAL_2="32" WEIGHT="27.834480732208164" Z="2.985933538020571">
<NAME>High dose of iron</NAME>
<DICH_DATA CI_END="2.0195435340227306" CI_START="0.006955353521815352" EFFECT_SIZE="0.11851851851851852" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.3052532194183947" LOG_CI_START="-2.157680791096557" LOG_EFFECT_SIZE="-0.9262137858390813" ORDER="85553" O_E="0.0" SE="1.4467396294964603" STUDY_ID="STD-Bechensteen-1993" TOTAL_1="14" TOTAL_2="15" VAR="2.0930555555555554" WEIGHT="5.40045431827992"/>
<DICH_DATA CI_END="1.1733544710348631" CI_START="0.35220840447129464" EFFECT_SIZE="0.6428571428571429" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.06942923254066719" LOG_CI_START="-0.4532002850184934" LOG_EFFECT_SIZE="-0.1918855262389131" ORDER="85554" O_E="0.0" SE="0.30699516567208635" STUDY_ID="STD-Donato-1996" TOTAL_1="16" TOTAL_2="9" VAR="0.09424603174603174" WEIGHT="11.111334751447636"/>
<DICH_DATA CI_END="0.9728329540890739" CI_START="0.29238775603648015" EFFECT_SIZE="0.5333333333333333" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="-0.011961726376606465" LOG_CI_START="-0.5340408177508689" LOG_EFFECT_SIZE="-0.27300127206373764" ORDER="85555" O_E="0.0" SE="0.3066718426064236" STUDY_ID="STD-Emmerson-1993" TOTAL_1="15" TOTAL_2="8" VAR="0.09404761904761905" WEIGHT="11.322691662480606"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="12.24562960535055" CI_END="0.707699038161975" CI_START="0.4082548944055738" DF="3" EFFECT_SIZE="0.5375142752483354" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="52" I2="75.50146381457435" ID="CMP-001.03.02" LOG_CI_END="-0.15015139464658697" LOG_CI_START="-0.3890685999762513" LOG_EFFECT_SIZE="-0.2696099973114191" NO="2" P_CHI2="0.0065874170716200275" P_Z="9.711178694886493E-6" STUDIES="4" TAU2="0.0" TOTAL_1="95" TOTAL_2="67" WEIGHT="72.16551926779182" Z="4.423506326161704">
<NAME>Low dose of iron</NAME>
<DICH_DATA CI_END="0.9675352817538995" CI_START="0.2733644973017557" EFFECT_SIZE="0.5142857142857142" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="10" LOG_CI_END="-0.014333189211736446" LOG_CI_START="-0.5632578892822028" LOG_EFFECT_SIZE="-0.2887955392469696" ORDER="85557" O_E="0.0" SE="0.32244108604248" STUDY_ID="STD-Corona-1998" TOTAL_1="42" TOTAL_2="18" VAR="0.10396825396825399" WEIGHT="17.36146054913693"/>
<DICH_DATA CI_END="1.3576109393017348" CI_START="0.41433078042912114" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" LOG_CI_END="0.13277532876397893" LOG_CI_START="-0.3826528019805788" LOG_EFFECT_SIZE="-0.12493873660829995" ORDER="85556" O_E="0.0" SE="0.3027650354097491" STUDY_ID="STD-Shannon-1991" TOTAL_1="10" TOTAL_2="10" VAR="0.09166666666666662" WEIGHT="9.920834599506817"/>
<DICH_DATA CI_END="0.5973653107848271" CI_START="0.157587651968836" EFFECT_SIZE="0.3068181818181818" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="22" LOG_CI_END="-0.2237600006340454" LOG_CI_START="-0.8024778153483172" LOG_EFFECT_SIZE="-0.5131189079911813" ORDER="85558" O_E="0.0" SE="0.33994170906254734" STUDY_ID="STD-Yamada-1999a" TOTAL_1="28" TOTAL_2="27" VAR="0.11556036556036559" WEIGHT="27.778336878619086"/>
<DICH_DATA CI_END="1.076280136512388" CI_START="0.6133684229639238" EFFECT_SIZE="0.8125" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="12" LOG_CI_END="0.03192532514723446" LOG_CI_START="-0.21227858584541046" LOG_EFFECT_SIZE="-0.09017663034908802" ORDER="85559" O_E="0.0" SE="0.14344658614593475" STUDY_ID="STD-Yamada-1999b" TOTAL_1="15" TOTAL_2="12" VAR="0.020576923076923076" WEIGHT="17.104887240528992"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="53.0681895824176" CI_END="2.567731368119782" CI_START="-5.78402632300128" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.6081474774407487" ESTIMABLE="YES" I2="92.4625278693787" I2_Q="0.0" ID="CMP-001.04" MODIFIED="2013-11-21 17:31:26 -0500" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="8.246459071159506E-11" P_Q="1.0" P_Z="0.45037506663257976" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="104" TOTAL_2="93" UNITS="" WEIGHT="100.00000000000001" Z="0.7547898907468719">
<NAME>Total volume (mL/kg) of red blood cells transfused per infant</NAME>
<GROUP_LABEL_1>Late EPO</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Late EPO</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Placebo/no treatment</GRAPH_LABEL_2>
<CONT_DATA CI_END="37.25943330243045" CI_START="16.740566697569545" EFFECT_SIZE="27.0" ESTIMABLE="YES" MEAN_1="43.0" MEAN_2="16.0" MODIFIED="2012-03-25 12:32:00 -0400" MODIFIED_BY="[Empty name]" ORDER="148" SD_1="15.0" SD_2="7.0" SE="5.2345009313209605" STUDY_ID="STD-Bierer-2009" TOTAL_1="10" TOTAL_2="10" WEIGHT="16.567196951686622"/>
<CONT_DATA CI_END="2.9423786362384448" CI_START="-20.942378636238445" EFFECT_SIZE="-9.0" ESTIMABLE="YES" MEAN_1="10.2" MEAN_2="19.2" ORDER="85561" SD_1="11.62" SD_2="15.0" SE="6.093162287898351" STUDY_ID="STD-Emmerson-1993" TOTAL_1="15" TOTAL_2="8" WEIGHT="12.226836565353096"/>
<CONT_DATA CI_END="3.3956177247413915" CI_START="-7.595617724741391" EFFECT_SIZE="-2.1" ESTIMABLE="YES" MEAN_1="1.0" MEAN_2="3.1" ORDER="85562" SD_1="5.0" SD_2="14.0" SE="2.8039381172767066" STUDY_ID="STD-Reiter-2005" TOTAL_1="29" TOTAL_2="28" WEIGHT="57.73813463951837"/>
<CONT_DATA CI_END="22.969448773520405" CI_START="-45.16944877352041" EFFECT_SIZE="-11.100000000000001" ESTIMABLE="YES" MEAN_1="45.6" MEAN_2="56.7" ORDER="85560" SD_1="56.0" SD_2="56.5" SE="17.382691234255258" STUDY_ID="STD-Whitehall-1999" TOTAL_1="22" TOTAL_2="20" WEIGHT="1.5023307831133916"/>
<CONT_DATA CI_END="-18.027910536693184" CI_START="-42.17208946330682" EFFECT_SIZE="-30.1" ESTIMABLE="YES" MEAN_1="7.9" MEAN_2="38.0" ORDER="85563" SD_1="17.5" SD_2="27.0" SE="6.15934249737746" STUDY_ID="STD-Yamada-1999a" TOTAL_1="28" TOTAL_2="27" WEIGHT="11.965501060328524"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="160.63798656072694" CI_END="-0.05846074729472911" CI_START="-0.37897989014814304" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.21872031872143607" ESTIMABLE="YES" I2="93.77482237290143" I2_Q="0.0" ID="CMP-001.05" MODIFIED="2013-11-21 17:31:26 -0500" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Q="1.0" P_Z="0.007474372526878867" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="418" TOTAL_2="399" UNITS="" WEIGHT="99.99999999999999" Z="2.6749350666845544">
<NAME>Number of red blood cell transfusions per infant</NAME>
<GROUP_LABEL_1>Late EPO</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Late EPO</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Placebo/no treatment</GRAPH_LABEL_2>
<CONT_DATA CI_END="-1.1603174694976581" CI_START="-3.2396825305023413" EFFECT_SIZE="-2.1999999999999997" ESTIMABLE="YES" MEAN_1="3.48" MEAN_2="5.68" ORDER="85564" SD_1="1.58" SD_2="2.3" SE="0.5304600179917717" STUDY_ID="STD-Al_x002d_Kharfy-1996" TOTAL_1="27" TOTAL_2="28" WEIGHT="2.3760001328219573"/>
<CONT_DATA CI_END="1.933769839560332" CI_START="1.2662301604396682" EFFECT_SIZE="1.6" ESTIMABLE="YES" MEAN_1="2.1" MEAN_2="0.5" MODIFIED="2013-11-04 08:41:10 -0500" MODIFIED_BY="[Empty name]" ORDER="160" SD_1="0.5" SD_2="0.2" SE="0.17029386365926402" STUDY_ID="STD-Bierer-2009" TOTAL_1="10" TOTAL_2="10" WEIGHT="23.054397347888553"/>
<CONT_DATA CI_END="0.22078860056066363" CI_START="-2.4807886005606634" EFFECT_SIZE="-1.13" ESTIMABLE="YES" MEAN_1="0.87" MEAN_2="2.0" ORDER="85568" SD_1="1.41" SD_2="1.87" SE="0.6891905214664716" STUDY_ID="STD-Donato-1996" TOTAL_1="23" TOTAL_2="9" WEIGHT="1.4075803005583207"/>
<CONT_DATA CI_END="-0.29762169811558825" CI_START="-1.1623783018844116" EFFECT_SIZE="-0.73" ESTIMABLE="YES" MEAN_1="0.07" MEAN_2="0.8" ORDER="85565" SD_1="0.3" SD_2="0.8" SE="0.2206052281036573" STUDY_ID="STD-Kumar-1998" TOTAL_1="15" TOTAL_2="15" WEIGHT="13.737894310043181"/>
<CONT_DATA CI_END="0.6957269492342237" CI_START="-1.095726949234224" EFFECT_SIZE="-0.20000000000000018" ESTIMABLE="YES" MEAN_1="2.9" MEAN_2="3.1" ORDER="85572" SD_1="2.9" SD_2="2.6" SE="0.45701194322936733" STUDY_ID="STD-Maier-2002" TOTAL_1="74" TOTAL_2="71" WEIGHT="3.201081064663405"/>
<CONT_DATA CI_END="0.1947572610758762" CI_START="-1.194757261075876" EFFECT_SIZE="-0.5" ESTIMABLE="YES" MEAN_1="3.2" MEAN_2="3.7" MODIFIED="2013-05-09 14:16:19 -0400" MODIFIED_BY="[Empty name]" ORDER="156" SD_1="2.2" SD_2="3.1" SE="0.3544745038970271" STUDY_ID="STD-Romagnoli-2000" TOTAL_1="115" TOTAL_2="115" WEIGHT="5.320859180291234"/>
<CONT_DATA CI_END="-0.1783647508723164" CI_START="-1.2216352491276838" EFFECT_SIZE="-0.7000000000000001" ESTIMABLE="YES" MEAN_1="0.4" MEAN_2="1.1" ORDER="85566" SD_1="0.7" SD_2="0.6" SE="0.26614532371118854" STUDY_ID="STD-Samanci-1996" TOTAL_1="12" TOTAL_2="12" WEIGHT="9.438741502429668"/>
<CONT_DATA CI_END="0.0010220753447828246" CI_START="-1.0010220753447827" EFFECT_SIZE="-0.5" ESTIMABLE="YES" MEAN_1="1.1" MEAN_2="1.6" ORDER="85567" SD_1="1.5" SD_2="1.7" SE="0.25562820505722605" STUDY_ID="STD-Shannon-1995" TOTAL_1="77" TOTAL_2="80" WEIGHT="10.231380374697071"/>
<CONT_DATA CI_END="0.7431768692632104" CI_START="-1.7431768692632108" EFFECT_SIZE="-0.5000000000000002" ESTIMABLE="YES" MEAN_1="1.7" MEAN_2="2.2" ORDER="85569" SD_1="2.0" SD_2="2.1" SE="0.6342855680355511" STUDY_ID="STD-Whitehall-1999" TOTAL_1="22" TOTAL_2="20" WEIGHT="1.6618128469046325"/>
<CONT_DATA CI_END="-0.4548832826122975" CI_START="-1.1451167173877026" EFFECT_SIZE="-0.8" ESTIMABLE="YES" MEAN_1="0.3" MEAN_2="1.1" ORDER="85570" SD_1="0.6" SD_2="0.7" SE="0.17608319342086853" STUDY_ID="STD-Yamada-1999a" TOTAL_1="28" TOTAL_2="27" WEIGHT="21.563336495525117"/>
<CONT_DATA CI_END="-0.5336416227087664" CI_START="-1.6663583772912338" EFFECT_SIZE="-1.1" ESTIMABLE="YES" MEAN_1="1.1" MEAN_2="2.2" ORDER="85571" SD_1="0.8" SD_2="0.7" SE="0.2889636655359978" STUDY_ID="STD-Yamada-1999b" TOTAL_1="15" TOTAL_2="12" WEIGHT="8.006916444176866"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="14.023337892089826" CI_END="0.6879723678746821" CI_START="0.20208807241296084" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="0.4450302201438215" ESTIMABLE="YES" I2="92.86903012895331" I2_Q="0.0" ID="CMP-001.06" MODIFIED="2013-11-21 17:31:26 -0500" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.8055661639670983E-4" P_Q="1.0" P_Z="3.302558043639048E-4" Q="0.0" RANDOM="NO" SCALE="4.465559853060928" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="84" TOTAL_2="81" UNITS="" WEIGHT="100.0" Z="3.590332972935276">
<NAME>Number of donors the infant was exposed to</NAME>
<GROUP_LABEL_1>Late EPO</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Late EPO</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Placebo/no treatment</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.9771807648699358" CI_START="0.4228192351300644" EFFECT_SIZE="0.7000000000000001" ESTIMABLE="YES" MEAN_1="1.1" MEAN_2="0.4" MODIFIED="2012-03-25 12:33:59 -0400" MODIFIED_BY="[Empty name]" ORDER="149" SD_1="0.4" SD_2="0.2" SE="0.14142135623730953" STUDY_ID="STD-Bierer-2009" TOTAL_1="10" TOTAL_2="10" WEIGHT="76.82092910398377"/>
<CONT_DATA CI_END="0.10460884022386852" CI_START="-0.9046088402238688" EFFECT_SIZE="-0.40000000000000013" ESTIMABLE="YES" MEAN_1="1.7" MEAN_2="2.1" ORDER="85573" SD_1="1.6" SD_2="1.5" SE="0.25745822076536035" STUDY_ID="STD-Maier-2002" TOTAL_1="74" TOTAL_2="71" WEIGHT="23.179070896016235"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="7.624127609189502" CI_END="1.391577155234567" CI_START="0.48824103597021923" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="RR" EFFECT_SIZE="0.824272450045624" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="23" I2="0.0" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="0.1435072905577271" LOG_CI_START="-0.3113657215463177" LOG_EFFECT_SIZE="-0.08392921549429527" METHOD="MH" MODIFIED="2013-11-21 17:31:26 -0500" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.4710199999761252" P_Q="1.0" P_Z="0.46951338309072077" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="14" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="403" TOTAL_2="364" WEIGHT="99.99999999999999" Z="0.7232710459502641">
<NAME>Mortality during initial hospital stay (all causes)</NAME>
<GROUP_LABEL_1>Late EPO</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Late EPO</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Placebo/no treatment</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.846177810893223" CI_START="0.1570870412502831" EFFECT_SIZE="1.037037037037037" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.835448174569156" LOG_CI_START="-0.8038596402026924" LOG_EFFECT_SIZE="0.015794267183231885" ORDER="85574" O_E="0.0" SE="0.9629375251015392" STUDY_ID="STD-Al_x002d_Kharfy-1996" TOTAL_1="27" TOTAL_2="28" VAR="0.9272486772486773" WEIGHT="7.328693989566109"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="85575" O_E="0.0" SE="0.0" STUDY_ID="STD-Bechensteen-1993" TOTAL_1="14" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="85576" O_E="0.0" SE="0.0" STUDY_ID="STD-Chen-1995" TOTAL_1="26" TOTAL_2="19" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.584832367137514" CI_START="0.004381816391715505" EFFECT_SIZE="0.08333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.19998333224633755" LOG_CI_START="-2.3583458243415873" LOG_EFFECT_SIZE="-1.0791812460476249" ORDER="85580" O_E="0.0" SE="1.5027752105133134" STUDY_ID="STD-Donato-1996" TOTAL_1="23" TOTAL_2="9" VAR="2.2583333333333333" WEIGHT="13.172489196932549"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="85582" O_E="0.0" SE="0.0" STUDY_ID="STD-Emmerson-1993" TOTAL_1="15" TOTAL_2="8" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="7.618637080220918" CI_START="0.014584119172649873" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8818772861059678" LOG_CI_START="-1.8361197955452926" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="85583" O_E="0.0" SE="1.5965649400644928" STUDY_ID="STD-Giannakopoulou-1998a" TOTAL_1="16" TOTAL_2="16" VAR="2.5490196078431375" WEIGHT="5.598307908696333"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="85584" O_E="0.0" SE="0.0" STUDY_ID="STD-Giannakopoulou-1998b" TOTAL_1="18" TOTAL_2="18" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="6.959404618367658" CI_START="0.5747618107219936" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.8425720870218129" LOG_CI_START="-0.24051209569385046" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="85586" O_E="0.0" SE="0.6362090102803518" STUDY_ID="STD-Griffiths-1997" TOTAL_1="21" TOTAL_2="21" VAR="0.40476190476190477" WEIGHT="11.196615817392667"/>
<DICH_DATA CI_END="2.4684565036874453" CI_START="0.46040789275397365" EFFECT_SIZE="1.0660660660660661" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="9" LOG_CI_END="0.3924254789831556" LOG_CI_START="-0.3368572398856071" LOG_EFFECT_SIZE="0.027784119548774248" ORDER="85587" O_E="0.0" SE="0.42838427907119103" STUDY_ID="STD-Maier-2002" TOTAL_1="74" TOTAL_2="71" VAR="0.18351309055534407" WEIGHT="34.284809813257546"/>
<DICH_DATA CI_END="4.038645960707643" CI_START="0.009904309609993965" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6062357833382839" LOG_CI_START="-2.0041757920103214" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="85577" O_E="0.0" SE="1.5333686811054679" STUDY_ID="STD-Meyer-1994" TOTAL_1="40" TOTAL_2="40" VAR="2.351219512195122" WEIGHT="9.330513181160555"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="85585" O_E="0.0" SE="0.0" STUDY_ID="STD-Pollak-2001" TOTAL_1="20" TOTAL_2="9" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="65.90289327402995" CI_START="0.13656456572516806" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8189044814432243" LOG_CI_START="-0.8646619720038995" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="85578" O_E="0.0" SE="1.5763402186230246" STUDY_ID="STD-Shannon-1991" TOTAL_1="10" TOTAL_2="10" VAR="2.484848484848485" WEIGHT="1.8661026362321111"/>
<DICH_DATA CI_END="8.369527567885342" CI_START="0.014316517179162006" EFFECT_SIZE="0.34615384615384615" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.922700944199822" LOG_CI_START="-1.8441626212628086" LOG_EFFECT_SIZE="-0.4607308385314931" ORDER="85579" O_E="0.0" SE="1.6252693545482877" STUDY_ID="STD-Shannon-1995" TOTAL_1="77" TOTAL_2="80" VAR="2.641500474833808" WEIGHT="5.492679457588855"/>
<DICH_DATA CI_END="2.682457857611826" CI_START="0.034232546950948406" EFFECT_SIZE="0.30303030303030304" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.4285329077673812" LOG_CI_START="-1.465560787523156" LOG_EFFECT_SIZE="-0.5185139398778875" ORDER="85581" O_E="0.0" SE="1.1126000125286661" STUDY_ID="STD-Whitehall-1999" TOTAL_1="22" TOTAL_2="20" VAR="1.2378787878787878" WEIGHT="11.72978799917327"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="12.012221422383018" CI_END="1.6351397243206147" CI_START="0.9870995317329033" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2704509656790173" ESTIMABLE="YES" EVENTS_1="84" EVENTS_2="64" I2="83.35029026127263" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="0.21355486947869595" LOG_CI_START="-0.005639054115567391" LOG_EFFECT_SIZE="0.1039579076815643" METHOD="MH" MODIFIED="2013-11-21 17:31:26 -0500" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.0024636574274246037" P_Q="1.0" P_Z="0.06301032320123576" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="209" TOTAL_2="195" WEIGHT="100.0" Z="1.8591186436459994">
<NAME>Retinopathy of prematurity (all stages or stage not reported)</NAME>
<GROUP_LABEL_1>Late EPO</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Late EPO</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Placebo/no treatment</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1925711332577675" CI_START="0.6179589207091898" EFFECT_SIZE="0.8584637268847796" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="38" LOG_CI_END="0.07648429283582406" LOG_CI_START="-0.2090403940087359" LOG_EFFECT_SIZE="-0.06627805058645592" MODIFIED="2013-07-17 07:11:29 -0400" MODIFIED_BY="[Empty name]" ORDER="85590" O_E="0.0" SE="0.16771861442248898" STUDY_ID="STD-Maier-2002" TOTAL_1="74" TOTAL_2="71" VAR="0.028129533623799524" WEIGHT="58.92906636381458"/>
<DICH_DATA CI_END="3.5615959542140976" CI_START="0.007074149795315843" EFFECT_SIZE="0.15873015873015872" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.5516446493191779" LOG_CI_START="-2.1503257482263414" LOG_EFFECT_SIZE="-0.7993405494535817" ORDER="85588" O_E="0.0" SE="1.5871507864874146" STUDY_ID="STD-Pollak-2001" TOTAL_1="20" TOTAL_2="9" VAR="2.519047619047619" WEIGHT="3.0876716218134614"/>
<DICH_DATA CI_END="2.9973257485907645" CI_START="1.3345229499598623" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="25" LOG_CI_END="0.476733944523113" LOG_CI_START="0.12532604680484935" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2013-05-09 14:06:58 -0400" MODIFIED_BY="[Empty name]" ORDER="151" O_E="0.0" SE="0.206418738616856" STUDY_ID="STD-Romagnoli-2000" TOTAL_1="115" TOTAL_2="115" VAR="0.042608695652173914" WEIGHT="37.98326201437195"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.4288890807627825" CI_END="3.2434178650742913" CI_START="0.9239685872564417" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.7311314862467835" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="14" I2="17.657829011611007" I2_Q="0.0" ID="CMP-001.09" LOG_CI_END="0.511002904517931" LOG_CI_START="-0.03434279351267523" LOG_EFFECT_SIZE="0.23833005550262787" METHOD="MH" MODIFIED="2013-11-21 17:31:26 -0500" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.2968749405716923" P_Q="1.0" P_Z="0.08669247948215315" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="219" TOTAL_2="223" WEIGHT="100.0" Z="1.7131090495642523">
<NAME>Retinopathy of prematurity (stage &#8805; 3)</NAME>
<GROUP_LABEL_1>Late EPO</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Late EPO</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Placebo/no treatment</GRAPH_LABEL_2>
<DICH_DATA CI_END="8.59468391795795" CI_START="0.2815406720616985" EFFECT_SIZE="1.5555555555555556" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9342299095034828" LOG_CI_START="-0.5504588570256566" LOG_EFFECT_SIZE="0.19188552623891317" ORDER="85591" O_E="0.0" SE="0.8721135307871393" STUDY_ID="STD-Al_x002d_Kharfy-1996" TOTAL_1="27" TOTAL_2="28" VAR="0.7605820105820106" WEIGHT="14.120468683638544"/>
<DICH_DATA CI_END="4.671768946771456" CI_START="1.0570453421826416" EFFECT_SIZE="2.2222222222222223" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="9" LOG_CI_END="0.6694813555890299" LOG_CI_START="0.02409361686028285" LOG_EFFECT_SIZE="0.3467874862246563" MODIFIED="2013-04-20 16:36:30 -0400" MODIFIED_BY="[Empty name]" ORDER="150" O_E="0.0" SE="0.3791039524500965" STUDY_ID="STD-Romagnoli-2000" TOTAL_1="115" TOTAL_2="115" VAR="0.143719806763285" WEIGHT="64.71881480001"/>
<DICH_DATA CI_END="3.257778328525036" CI_START="0.036815820531824396" EFFECT_SIZE="0.3463203463203463" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.5129215299498976" LOG_CI_START="-1.433965515750299" LOG_EFFECT_SIZE="-0.46052199290020074" ORDER="85592" O_E="0.0" SE="1.1436110878905994" STUDY_ID="STD-Shannon-1995" TOTAL_1="77" TOTAL_2="80" VAR="1.3078463203463204" WEIGHT="21.16071651635146"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.477534114533838" CI_END="1.0887089648947748" CI_START="0.5217558717715138" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.753684479795183" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="51" I2="0.0" I2_Q="0.0" ID="CMP-001.10" LOG_CI_END="0.036911799101261925" LOG_CI_START="-0.28253265474239664" LOG_EFFECT_SIZE="-0.12281042782056735" METHOD="MH" MODIFIED="2013-11-21 17:31:26 -0500" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.8306135197129948" P_Q="1.0" P_Z="0.1318064534869351" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="279" TOTAL_2="272" WEIGHT="99.99999999999999" Z="1.5070164002413542">
<NAME>Proven sepsis</NAME>
<GROUP_LABEL_1>Late EPO</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Late EPO</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Placebo/no treatment</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6792902447734972" CI_START="0.28462972365423694" EFFECT_SIZE="0.691358024691358" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="9" LOG_CI_END="0.22512576511342464" LOG_CI_START="-0.5457197488583233" LOG_EFFECT_SIZE="-0.16029699187244936" ORDER="85593" O_E="0.0" SE="0.4527984706538385" STUDY_ID="STD-Al_x002d_Kharfy-1996" TOTAL_1="27" TOTAL_2="28" VAR="0.20502645502645506" WEIGHT="17.038997544591343"/>
<DICH_DATA CI_END="3.070127994092063" CI_START="0.036191035463317964" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.4871564816560677" LOG_CI_START="-1.4413989910953926" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="85594" O_E="0.0" SE="1.132843031197762" STUDY_ID="STD-Meyer-1994" TOTAL_1="40" TOTAL_2="40" VAR="1.2833333333333334" WEIGHT="5.784844845385949"/>
<DICH_DATA CI_END="1.8131657024381236" CI_START="0.1116831184969486" EFFECT_SIZE="0.45" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.25843749541712513" LOG_CI_START="-0.9520124678664378" LOG_EFFECT_SIZE="-0.3467874862246563" ORDER="85596" O_E="0.0" SE="0.711024300256718" STUDY_ID="STD-Pollak-2001" TOTAL_1="20" TOTAL_2="9" VAR="0.5055555555555555" WEIGHT="7.979096338463379"/>
<DICH_DATA CI_END="1.2805418519977643" CI_START="0.49978842862616374" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="30" LOG_CI_END="0.1073937770993782" LOG_CI_START="-0.30121380311549095" LOG_EFFECT_SIZE="-0.09691001300805639" MODIFIED="2013-05-09 14:10:49 -0400" MODIFIED_BY="[Empty name]" ORDER="153" O_E="0.0" SE="0.24001811525835692" STUDY_ID="STD-Romagnoli-2000" TOTAL_1="115" TOTAL_2="115" VAR="0.05760869565217391" WEIGHT="57.8484484538595"/>
<DICH_DATA CI_END="3.082329609652608" CI_START="0.3502026639521719" EFFECT_SIZE="1.0389610389610389" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.48887907824978294" LOG_CI_START="-0.4556805546108595" LOG_EFFECT_SIZE="0.016599261819461673" ORDER="85595" O_E="0.0" SE="0.554839003987932" STUDY_ID="STD-Shannon-1995" TOTAL_1="77" TOTAL_2="80" VAR="0.3078463203463203" WEIGHT="11.348612817699824"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.0349133476484973" CI_END="1.6855895906693092" CI_START="0.4590835021917647" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8796740149296497" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="17" I2="0.0" I2_Q="0.0" ID="CMP-001.11" LOG_CI_END="0.22675184062992151" LOG_CI_START="-0.3381083139336504" LOG_EFFECT_SIZE="-0.055678236651864436" METHOD="MH" MODIFIED="2013-11-21 17:31:26 -0500" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.9044566591639047" P_Q="1.0" P_Z="0.6992100032167076" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="328" TOTAL_2="328" WEIGHT="99.99999999999999" Z="0.3863871001652343">
<NAME>Necrotising Enterocolitis &#8805; Bell's stage 2</NAME>
<GROUP_LABEL_1>Late EPO</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Late EPO</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Placebo/no treatment</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.19412630745404" CI_START="0.3212238177512495" EFFECT_SIZE="0.839527027027027" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.34126162462948395" LOG_CI_START="-0.4931922606086594" LOG_EFFECT_SIZE="-0.0759653179895877" ORDER="85601" O_E="0.0" SE="0.49016234280223503" STUDY_ID="STD-Maier-2002" TOTAL_1="74" TOTAL_2="71" VAR="0.24025912230137578" WEIGHT="45.140578633213366"/>
<DICH_DATA CI_END="7.9453474498525" CI_START="0.01398442444617999" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9001128936458906" LOG_CI_START="-1.8543554030852154" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="85597" O_E="0.0" SE="1.6179883123378205" STUDY_ID="STD-Meyer-1994" TOTAL_1="40" TOTAL_2="40" VAR="2.6178861788617884" WEIGHT="8.292293794530327"/>
<DICH_DATA CI_END="3.9023847258272193" CI_START="0.2562535655138467" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.5913300831177857" LOG_CI_START="-0.5913300831177857" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-05-09 14:09:52 -0400" MODIFIED_BY="[Empty name]" ORDER="152" O_E="0.0" SE="0.6947004359090139" STUDY_ID="STD-Romagnoli-2000" TOTAL_1="115" TOTAL_2="115" VAR="0.4826086956521739" WEIGHT="22.112783452080873"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="85598" O_E="0.0" SE="0.0" STUDY_ID="STD-Samanci-1996" TOTAL_1="12" TOTAL_2="12" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="65.90289327402995" CI_START="0.13656456572516806" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8189044814432243" LOG_CI_START="-0.8646619720038995" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="85599" O_E="0.0" SE="1.5763402186230246" STUDY_ID="STD-Shannon-1991" TOTAL_1="10" TOTAL_2="10" VAR="2.484848484848485" WEIGHT="2.764097931510109"/>
<DICH_DATA CI_END="3.3683358300411115" CI_START="0.1802626143611184" EFFECT_SIZE="0.7792207792207793" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.5274153850433899" LOG_CI_START="-0.7440943346210663" LOG_EFFECT_SIZE="-0.10833947478883822" ORDER="85600" O_E="0.0" SE="0.7468911034055234" STUDY_ID="STD-Shannon-1995" TOTAL_1="77" TOTAL_2="80" VAR="0.5578463203463203" WEIGHT="21.690246188665313"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.14625450338120768" CI_END="1.424268914132527" CI_START="0.5344021256440052" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8724289857639427" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="28" I2="0.0" I2_Q="0.0" ID="CMP-001.12" LOG_CI_END="0.15359199554935565" LOG_CI_START="-0.2721318230743783" LOG_EFFECT_SIZE="-0.05926991376251131" METHOD="MH" MODIFIED="2013-11-21 17:31:26 -0500" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.9294825606720821" P_Q="1.0" P_Z="0.5852458437519316" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="228" TOTAL_2="226" WEIGHT="100.0" Z="0.5457382991482957">
<NAME>Intraventricular haemorrhage all grades (or grade not specified)</NAME>
<GROUP_LABEL_1>Late EPO</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Late EPO</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Placebo/no treatment</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.819859519092422" CI_START="0.1251291875829771" EFFECT_SIZE="0.691358024691358" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5820473913921204" LOG_CI_START="-0.902641375137019" LOG_EFFECT_SIZE="-0.16029699187244936" ORDER="85602" O_E="0.0" SE="0.8721135307871393" STUDY_ID="STD-Al_x002d_Kharfy-1996" TOTAL_1="27" TOTAL_2="28" VAR="0.7605820105820106" WEIGHT="10.401399251666039"/>
<DICH_DATA CI_END="1.5377397380166085" CI_START="0.47300461231326657" EFFECT_SIZE="0.8528528528528528" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="18" LOG_CI_END="0.18688283747589846" LOG_CI_START="-0.3251346243944628" LOG_EFFECT_SIZE="-0.0691258934592822" ORDER="85604" O_E="0.0" SE="0.3007615916299628" STUDY_ID="STD-Maier-2002" TOTAL_1="74" TOTAL_2="71" VAR="0.09045753499978852" WEIGHT="64.87922598357207"/>
<DICH_DATA CI_END="2.76007931567844" CI_START="0.3623084287178159" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.4409215624516424" LOG_CI_START="-0.4409215624516423" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-05-09 14:11:52 -0400" MODIFIED_BY="[Empty name]" ORDER="154" O_E="0.0" SE="0.5179990167620587" STUDY_ID="STD-Romagnoli-2000" TOTAL_1="115" TOTAL_2="115" VAR="0.2683229813664596" WEIGHT="24.719374764761884"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="85603" O_E="0.0" SE="0.0" STUDY_ID="STD-Samanci-1996" TOTAL_1="12" TOTAL_2="12" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-001.13" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-11-21 17:31:26 -0500" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="74" TOTAL_2="71" WEIGHT="0.0" Z="0.0">
<NAME>Periventricular leukomalacia</NAME>
<GROUP_LABEL_1>Late EPO</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Late EPO</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Placebo/no treatment</GRAPH_LABEL_2>
<DICH_DATA CI_END="40.05497766189744" CI_START="0.5745618323124977" EFFECT_SIZE="4.797297297297297" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.6026564938726116" LOG_CI_START="-0.2406632272243757" LOG_EFFECT_SIZE="0.6809966333241179" ORDER="85605" O_E="0.0" SE="1.082775128752149" STUDY_ID="STD-Maier-2002" TOTAL_1="74" TOTAL_2="71" VAR="1.1724019794442329" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="39.20950612081476" CI_END="1.5531968203958986" CI_START="0.9989425062124647" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2456140350877194" ESTIMABLE="YES" EVENTS_1="70" EVENTS_2="57" I2="97.44959807216459" I2_Q="0.0" ID="CMP-001.14" LOG_CI_END="0.19122649281533802" LOG_CI_START="-4.595067221701452E-4" LOG_EFFECT_SIZE="0.09538349304658392" METHOD="MH" MODIFIED="2013-11-21 17:31:26 -0500" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="3.806928106087071E-10" P_Q="1.0" P_Z="0.051108552941774535" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="142" TOTAL_2="143" WEIGHT="100.0" Z="1.950567193660381">
<NAME>Bronchopulmonary dysplasia (supplementary oxygen at 28 days)</NAME>
<GROUP_LABEL_1>Late EPO</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Late EPO</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Placebo/no treatment</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0718805080254385" CI_START="0.9329398123323905" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="28" LOG_CI_END="0.030146373418638774" LOG_CI_START="-0.030146373418638742" LOG_EFFECT_SIZE="0.0" ORDER="85606" O_E="0.0" SE="0.035416257946127044" STUDY_ID="STD-Al_x002d_Kharfy-1996" TOTAL_1="27" TOTAL_2="28" VAR="0.001254311326906607" WEIGHT="49.122807017543856"/>
<DICH_DATA CI_END="2.198103599587318" CI_START="1.0002136057837578" EFFECT_SIZE="1.4827586206896552" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="29" LOG_CI_END="0.3420481574545323" LOG_CI_START="9.27579067286212E-5" LOG_EFFECT_SIZE="0.17107045768063045" MODIFIED="2013-05-09 14:12:55 -0400" MODIFIED_BY="[Empty name]" ORDER="155" O_E="0.0" SE="0.20086629440090725" STUDY_ID="STD-Romagnoli-2000" TOTAL_1="115" TOTAL_2="115" VAR="0.04034726822635194" WEIGHT="50.87719298245614"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.578056007954572" CI_END="1.3451266225453127" CI_START="0.5851845803535651" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.887213254035684" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="31" I2="56.313334818863886" I2_Q="100.00000000000001" ID="CMP-001.15" LOG_CI_END="0.12876316826730477" LOG_CI_START="-0.23270712607985658" LOG_EFFECT_SIZE="-0.051971978906275945" METHOD="MH" MODIFIED="2013-11-21 17:31:26 -0500" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="0.10136508878385142" P_Q="0.0" P_Z="0.573023082930276" Q="4.271889949913254E-33" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="115" TOTAL_2="101" WEIGHT="100.00000000000001" Z="0.5636048574644164">
<NAME>Bronchopulmonary dysplasia (supplementary oxygen at 36 weeks postmenstrual age)</NAME>
<GROUP_LABEL_1>Late EPO</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Late EPO</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Placebo/no treatment</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1856159082932725" CI_START="0.28700507086449045" EFFECT_SIZE="0.5833333333333334" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="12" LOG_CI_END="0.07394401792745411" LOG_CI_START="-0.54211042999419" LOG_EFFECT_SIZE="-0.23408320603336796" ORDER="85608" O_E="0.0" SE="0.36187343222787294" STUDY_ID="STD-Griffiths-1997" TOTAL_1="21" TOTAL_2="21" VAR="0.13095238095238093" WEIGHT="36.95836873406967"/>
<DICH_DATA CI_END="2.2112921564422536" CI_START="0.7171429884897254" EFFECT_SIZE="1.2592905405405406" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="16" LOG_CI_END="0.3446461254590933" LOG_CI_START="-0.14439424332690604" LOG_EFFECT_SIZE="0.10012594106609359" ORDER="85609" O_E="0.0" SE="0.28726473341376346" STUDY_ID="STD-Maier-2002" TOTAL_1="74" TOTAL_2="71" VAR="0.08252102706328059" WEIGHT="50.29736618521666"/>
<DICH_DATA CI_END="1.496284726631453" CI_START="0.06014897993553316" EFFECT_SIZE="0.3" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.17501424288608128" LOG_CI_START="-1.2207717334467565" LOG_EFFECT_SIZE="-0.5228787452803376" ORDER="85607" O_E="0.0" SE="0.8198915917499228" STUDY_ID="STD-Pollak-2001" TOTAL_1="20" TOTAL_2="9" VAR="0.672222222222222" WEIGHT="12.74426508071368"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.9597625723127683" CI_END="4.52220594802015" CI_START="0.24859774183725694" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0602877848965444" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" I2="0.0" I2_Q="100.0" ID="CMP-001.16" LOG_CI_END="0.6553503368797557" LOG_CI_START="-0.6045028206343287" LOG_EFFECT_SIZE="0.025423758122713514" METHOD="MH" MODIFIED="2013-11-21 17:31:26 -0500" MODIFIED_BY="[Empty name]" NO="16" P_CHI2="0.3753557487166277" P_Q="0.0" P_Z="0.9369499799983098" Q="8.791549642438909E-35" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="191" TOTAL_2="172" WEIGHT="100.0" Z="0.07910390187138787">
<NAME>SIDS</NAME>
<GROUP_LABEL_1>Late EPO</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Late EPO</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Placebo/no treatment</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="85613" O_E="0.0" SE="0.0" STUDY_ID="STD-Bader-1996" TOTAL_1="15" TOTAL_2="14" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="85610" O_E="0.0" SE="0.0" STUDY_ID="STD-Donato-1996" TOTAL_1="23" TOTAL_2="9" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="52.38149707039079" CI_START="0.15101050356331455" EFFECT_SIZE="2.8125" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.7191779064626134" LOG_CI_START="-0.8209928442237755" LOG_EFFECT_SIZE="0.4490925311194189" ORDER="85614" O_E="0.0" SE="1.4921088730011924" STUDY_ID="STD-Emmerson-1993" TOTAL_1="15" TOTAL_2="8" VAR="2.2263888888888888" WEIGHT="17.81325491019851"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="85615" O_E="0.0" SE="0.0" STUDY_ID="STD-Griffiths-1997" TOTAL_1="21" TOTAL_2="21" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="71.50812704867249" CI_START="0.12585982001561988" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8543554030852154" LOG_CI_START="-0.9001128936458906" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="85611" O_E="0.0" SE="1.6179883123378205" STUDY_ID="STD-Meyer-1994" TOTAL_1="40" TOTAL_2="40" VAR="2.6178861788617884" WEIGHT="13.916605398592585"/>
<DICH_DATA CI_END="4.257593484143146" CI_START="0.010131567242201725" EFFECT_SIZE="0.2076923076923077" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6291641925598968" LOG_CI_START="-1.9943233688555957" LOG_EFFECT_SIZE="-0.6825795881478495" ORDER="85612" O_E="0.0" SE="1.5410495800483324" STUDY_ID="STD-Shannon-1995" TOTAL_1="77" TOTAL_2="80" VAR="2.3748338081671414" WEIGHT="68.27013969120891"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.09135769462073452" CI_END="1.5360074737611484" CI_START="0.049745555206284445" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.2764227642276423" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-001.17" LOG_CI_END="0.1863933288500044" LOG_CI_START="-1.30324571764429" LOG_EFFECT_SIZE="-0.5584261943971428" METHOD="MH" MODIFIED="2013-11-21 17:31:26 -0500" MODIFIED_BY="[Empty name]" NO="17" P_CHI2="0.762458189117032" P_Q="1.0" P_Z="0.14170343008307865" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="85" TOTAL_2="79" WEIGHT="100.0" Z="1.469477094626299">
<NAME>Neutropenia</NAME>
<GROUP_LABEL_1>Late EPO</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Late EPO</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Placebo/no treatment</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="85616" O_E="0.0" SE="0.0" STUDY_ID="STD-Bechensteen-1993" TOTAL_1="14" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="4.139982673332583" CI_START="0.008491883366192953" EFFECT_SIZE="0.1875" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.616998523514185" LOG_CI_START="-2.07099597938671" LOG_EFFECT_SIZE="-0.7269987279362623" ORDER="85621" O_E="0.0" SE="1.578941276791368" STUDY_ID="STD-Emmerson-1993" TOTAL_1="15" TOTAL_2="8" VAR="2.4930555555555554" WEIGHT="39.02439024390244"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="85617" O_E="0.0" SE="0.0" STUDY_ID="STD-Giannakopoulou-1998a" TOTAL_1="16" TOTAL_2="16" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="85618" O_E="0.0" SE="0.0" STUDY_ID="STD-Giannakopoulou-1998b" TOTAL_1="18" TOTAL_2="18" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="85620" O_E="0.0" SE="0.0" STUDY_ID="STD-Ronnestad-1995" TOTAL_1="12" TOTAL_2="12" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.685665908545172" CI_START="0.04137190361525649" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.42905198632986163" LOG_CI_START="-1.3832944957691864" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="85619" O_E="0.0" SE="1.064581294844754" STUDY_ID="STD-Shannon-1991" TOTAL_1="10" TOTAL_2="10" VAR="1.133333333333333" WEIGHT="60.975609756097555"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.2676627874050157" CI_END="3.137311714930669" CI_START="0.4566342130930936" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1969143102892161" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" I2="21.114667880480898" I2_Q="0.0" ID="CMP-001.18" LOG_CI_END="0.49655767118381156" LOG_CI_START="-0.3404315523269696" LOG_EFFECT_SIZE="0.07806305942842097" METHOD="MH" MODIFIED="2013-11-21 17:31:26 -0500" MODIFIED_BY="[Empty name]" NO="18" P_CHI2="0.26020569648666036" P_Q="1.0" P_Z="0.7146650828403986" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="186" TOTAL_2="177" WEIGHT="99.99999999999999" Z="0.36559798072655647">
<NAME>Hypertension</NAME>
<GROUP_LABEL_1>Late EPO</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Late EPO</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Placebo/no treatment</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="85629" O_E="0.0" SE="0.0" STUDY_ID="STD-Akisu-2001" TOTAL_1="1" TOTAL_2="1" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.5008237420044144" CI_START="0.298636549152874" EFFECT_SIZE="0.8641975308641975" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.39808308374475404" LOG_CI_START="-0.5248570414735398" LOG_EFFECT_SIZE="-0.06338697886439294" ORDER="85622" O_E="0.0" SE="0.5421395981805276" STUDY_ID="STD-Al_x002d_Kharfy-1996" TOTAL_1="27" TOTAL_2="28" VAR="0.29391534391534396" WEIGHT="92.31265455327383"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="85623" O_E="0.0" SE="0.0" STUDY_ID="STD-Bechensteen-1993" TOTAL_1="14" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="85624" O_E="0.0" SE="0.0" STUDY_ID="STD-Donato-1996" TOTAL_1="23" TOTAL_2="9" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="85625" O_E="0.0" SE="0.0" STUDY_ID="STD-Giannakopoulou-1998a" TOTAL_1="16" TOTAL_2="16" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="85626" O_E="0.0" SE="0.0" STUDY_ID="STD-Giannakopoulou-1998b" TOTAL_1="18" TOTAL_2="18" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="85628" O_E="0.0" SE="0.0" STUDY_ID="STD-Shannon-1991" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="106.43983710357865" CI_START="0.25328918105504317" EFFECT_SIZE="5.1923076923076925" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0271042012319342" LOG_CI_START="-0.5963833601835581" LOG_EFFECT_SIZE="0.7153604205241881" ORDER="85627" O_E="0.0" SE="1.5410495800483324" STUDY_ID="STD-Shannon-1995" TOTAL_1="77" TOTAL_2="80" VAR="2.3748338081671414" WEIGHT="7.687345446726159"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.8114223139860463" CI_END="12.128247685467455" CI_START="-12.83117144340787" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.35146187897020686" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.19" MODIFIED="2013-11-21 17:31:26 -0500" MODIFIED_BY="[Empty name]" NO="19" P_CHI2="0.36770013446372984" P_Q="1.0" P_Z="0.955980874451575" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="38" TOTAL_2="17" UNITS="" WEIGHT="100.0" Z="0.055197808984541116">
<NAME>Length of hospital stay (days)</NAME>
<GROUP_LABEL_1>Late EPO</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Late EPO</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Placebo/no treatment</GRAPH_LABEL_2>
<CONT_DATA CI_END="50.53583204626163" CI_START="-20.615832046261644" EFFECT_SIZE="14.959999999999994" ESTIMABLE="YES" MEAN_1="97.86" MEAN_2="82.9" ORDER="85630" SD_1="47.58" SD_2="45.6" SE="18.151268251294034" STUDY_ID="STD-Donato-1996" TOTAL_1="23" TOTAL_2="9" WEIGHT="12.305487520216461"/>
<CONT_DATA CI_END="10.826566453414499" CI_START="-15.826566453414499" EFFECT_SIZE="-2.5" ESTIMABLE="YES" MEAN_1="44.9" MEAN_2="47.4" ORDER="85631" SD_1="12.39" SD_2="16.97" SE="6.799393539132736" STUDY_ID="STD-Emmerson-1993" TOTAL_1="15" TOTAL_2="8" WEIGHT="87.69451247978354"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="60.08784929454589" CI_END="0.790421225611922" CI_START="0.6408056465501186" CI_STUDY="95" CI_TOTAL="95" DF="19" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7116926194117688" ESTIMABLE="YES" EVENTS_1="254" EVENTS_2="322" I2="68.3796304526336" I2_Q="87.12485900663448" ID="CMP-001.20" LOG_CI_END="-0.1021414059174407" LOG_CI_START="-0.19327367005934618" LOG_EFFECT_SIZE="-0.14770753798839348" METHOD="MH" MODIFIED="2013-11-21 17:31:26 -0500" MODIFIED_BY="[Empty name]" NO="20" P_CHI2="3.7479414748409212E-6" P_Q="0.005321228410603562" P_Z="2.1055929224511466E-10" Q="7.766905236341053" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="20" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="605" TOTAL_2="537" WEIGHT="100.0" Z="6.353434920733218">
<NAME>Use of one or more red blood cell transfusions (secondary analysis based on study quality)</NAME>
<GROUP_LABEL_1>Late EPO</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Late EPO</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Placebo/no treatment</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="9.619196131246483" CI_END="0.9578743966132394" CI_START="0.7337660742700759" DF="4" EFFECT_SIZE="0.8383649179484518" ESTIMABLE="YES" EVENTS_1="116" EVENTS_2="133" I2="58.41648360816126" ID="CMP-001.20.01" LOG_CI_END="-0.01869143500709406" LOG_CI_START="-0.13444237175410131" LOG_EFFECT_SIZE="-0.0765669033805977" MODIFIED="2013-06-16 10:24:04 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.04735486258684751" P_Z="0.009515575592201501" STUDIES="5" TAU2="0.0" TOTAL_1="182" TOTAL_2="175" WEIGHT="40.22833656572547" Z="2.592953063727316">
<NAME>HIgh quality studies</NAME>
<DICH_DATA CI_END="0.9728329540890739" CI_START="0.29238775603648015" EFFECT_SIZE="0.5333333333333333" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="-0.011961726376606465" LOG_CI_START="-0.5340408177508689" LOG_EFFECT_SIZE="-0.27300127206373764" ORDER="85632" O_E="0.0" SE="0.3066718426064236" STUDY_ID="STD-Emmerson-1993" TOTAL_1="15" TOTAL_2="8" VAR="0.09404761904761905" WEIGHT="2.7143058875915202"/>
<DICH_DATA CI_END="1.12749355545595" CI_START="0.8439104389374585" EFFECT_SIZE="0.9754504504504504" ESTIMABLE="YES" EVENTS_1="61" EVENTS_2="60" LOG_CI_END="0.05211406821038122" LOG_CI_START="-0.07370364097993631" LOG_EFFECT_SIZE="-0.010794786384777516" ORDER="85633" O_E="0.0" SE="0.07390594518609753" STUDY_ID="STD-Maier-2002" TOTAL_1="74" TOTAL_2="71" VAR="0.005462088733850451" WEIGHT="18.205905894308444"/>
<DICH_DATA CI_END="1.080768408129708" CI_START="0.13011575740204556" EFFECT_SIZE="0.375" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="8" LOG_CI_END="0.03373264136606" LOG_CI_START="-0.8856701059106221" LOG_EFFECT_SIZE="-0.42596873227228116" ORDER="85634" O_E="0.0" SE="0.5400617248673217" STUDY_ID="STD-Samanci-1996" TOTAL_1="12" TOTAL_2="12" VAR="0.2916666666666667" WEIGHT="2.3782489681754275"/>
<DICH_DATA CI_END="1.994875924249409" CI_START="0.055698256598548955" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.29991588895031257" LOG_CI_START="-1.2541583983896376" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="85635" O_E="0.0" SE="0.9128709291752768" STUDY_ID="STD-Shannon-1992" TOTAL_1="4" TOTAL_2="4" VAR="0.8333333333333333" WEIGHT="0.8918433630657854"/>
<DICH_DATA CI_END="1.0602206859071692" CI_START="0.6516017231973248" EFFECT_SIZE="0.8311688311688312" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="55" LOG_CI_END="0.025396273468690313" LOG_CI_START="-0.18601777584587964" LOG_EFFECT_SIZE="-0.08031075118859467" ORDER="85636" O_E="0.0" SE="0.1241856590838005" STUDY_ID="STD-Shannon-1995" TOTAL_1="77" TOTAL_2="80" VAR="0.01542207792207792" WEIGHT="16.038032452584293"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="48.963967094333356" CI_END="0.7319713045392124" CI_START="0.5361199972639176" DF="14" EFFECT_SIZE="0.6264379089637127" ESTIMABLE="YES" EVENTS_1="138" EVENTS_2="189" I2="71.40754552622793" ID="CMP-001.20.02" LOG_CI_END="-0.13550594424837292" LOG_CI_START="-0.27073799329810133" LOG_EFFECT_SIZE="-0.20312196877323713" MODIFIED="2013-06-16 10:20:46 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="9.094259483255485E-6" P_Z="3.912963098298563E-9" STUDIES="15" TAU2="0.0" TOTAL_1="423" TOTAL_2="362" WEIGHT="59.77166343427453" Z="5.887831265767747">
<NAME>Studies of uncertain quality</NAME>
<DICH_DATA CI_END="1.2617285296697793" CI_START="0.022015653228549727" EFFECT_SIZE="0.16666666666666666" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.10096592325294027" LOG_CI_START="-1.6572684240202276" LOG_EFFECT_SIZE="-0.7781512503836436" ORDER="85637" O_E="0.0" SE="1.0327955589886444" STUDY_ID="STD-Akisu-2001" TOTAL_1="20" TOTAL_2="20" VAR="1.0666666666666667" WEIGHT="1.7836867261315708"/>
<DICH_DATA CI_END="1.2458080285893722" CI_START="0.8122761850311588" EFFECT_SIZE="1.005952380952381" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="12" LOG_CI_END="0.09545112535079402" LOG_CI_START="-0.09029627957517267" LOG_EFFECT_SIZE="0.0025774228878106755" ORDER="85638" O_E="0.0" SE="0.10910894511799613" STUDY_ID="STD-Atasay-2002" TOTAL_1="14" TOTAL_2="13" VAR="0.01190476190476189" WEIGHT="3.699498394939554"/>
<DICH_DATA CI_END="0.916079102200123" CI_START="0.059432034104573137" EFFECT_SIZE="0.23333333333333334" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" LOG_CI_END="-0.038067023967759434" LOG_CI_START="-1.2259794054430517" LOG_EFFECT_SIZE="-0.6320232147054056" ORDER="85639" O_E="0.0" SE="0.6977856131397107" STUDY_ID="STD-Bader-1996" TOTAL_1="15" TOTAL_2="14" VAR="0.48690476190476195" WEIGHT="2.4602575532849253"/>
<DICH_DATA CI_END="2.0195435340227306" CI_START="0.006955353521815352" EFFECT_SIZE="0.11851851851851852" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.3052532194183947" LOG_CI_START="-2.157680791096557" LOG_EFFECT_SIZE="-0.9262137858390813" ORDER="85650" O_E="0.0" SE="1.4467396294964603" STUDY_ID="STD-Bechensteen-1993" TOTAL_1="14" TOTAL_2="15" VAR="2.0930555555555554" WEIGHT="1.2946113334825915"/>
<DICH_DATA CI_END="0.9675352817538995" CI_START="0.2733644973017557" EFFECT_SIZE="0.5142857142857142" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="10" LOG_CI_END="-0.014333189211736446" LOG_CI_START="-0.5632578892822028" LOG_EFFECT_SIZE="-0.2887955392469696" ORDER="85640" O_E="0.0" SE="0.32244108604248" STUDY_ID="STD-Corona-1998" TOTAL_1="42" TOTAL_2="18" VAR="0.10396825396825399" WEIGHT="4.161935694306998"/>
<DICH_DATA CI_END="0.9332445458261052" CI_START="0.2712206954584329" EFFECT_SIZE="0.5031055900621118" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="7" LOG_CI_END="-0.030004539547436173" LOG_CI_START="-0.5666771747589638" LOG_EFFECT_SIZE="-0.2983408571532" ORDER="85641" O_E="0.0" SE="0.31524416249564025" STUDY_ID="STD-Donato-1996" TOTAL_1="23" TOTAL_2="9" VAR="0.09937888198757763" WEIGHT="2.991391280283155"/>
<DICH_DATA CI_END="2.9423243908144285" CI_START="0.11345695312726019" EFFECT_SIZE="0.5777777777777777" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.46869055193139536" LOG_CI_START="-0.945168883540447" LOG_EFFECT_SIZE="-0.23823916580452575" ORDER="85642" O_E="0.0" SE="0.8305080311132396" STUDY_ID="STD-Javier-Manchon-1997" TOTAL_1="15" TOTAL_2="13" VAR="0.6897435897435897" WEIGHT="0.9555464604276271"/>
<DICH_DATA CI_END="2.0521983886549444" CI_START="0.23633814244437093" EFFECT_SIZE="0.6964285714285714" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.3122193422747811" LOG_CI_START="-0.6264661822341836" LOG_EFFECT_SIZE="-0.15712341997970122" ORDER="85643" O_E="0.0" SE="0.551388523664851" STUDY_ID="STD-Kivivuori-1999" TOTAL_1="28" TOTAL_2="13" VAR="0.304029304029304" WEIGHT="1.6241700270466335"/>
<DICH_DATA CI_END="0.7716992950035634" CI_START="0.015998043658039977" EFFECT_SIZE="0.1111111111111111" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="9" LOG_CI_END="-0.11255189650552389" LOG_CI_START="-1.7959331223731259" LOG_EFFECT_SIZE="-0.9542425094393249" ORDER="85644" O_E="0.0" SE="0.9888264649460884" STUDY_ID="STD-Kumar-1998" TOTAL_1="15" TOTAL_2="15" VAR="0.9777777777777779" WEIGHT="2.675530089197356"/>
<DICH_DATA CI_END="0.802202200629343" CI_START="0.15528189021510708" EFFECT_SIZE="0.35294117647058826" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="17" LOG_CI_END="-0.09571615098081242" LOG_CI_START="-0.8088791910084481" LOG_EFFECT_SIZE="-0.45229767099463025" ORDER="85645" O_E="0.0" SE="0.41891549992621585" STUDY_ID="STD-Meyer-1994" TOTAL_1="40" TOTAL_2="40" VAR="0.17549019607843136" WEIGHT="5.053779057372783"/>
<DICH_DATA CI_END="2.9127186917646344" CI_START="0.03556141346709918" EFFECT_SIZE="0.3218390804597701" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.4642985428103939" LOG_CI_START="-1.4490209853631926" LOG_EFFECT_SIZE="-0.4923612212763993" ORDER="85646" O_E="0.0" SE="1.1238933619335767" STUDY_ID="STD-Reiter-2005" TOTAL_1="29" TOTAL_2="28" VAR="1.2631362889983577" WEIGHT="0.9074897378564132"/>
<DICH_DATA CI_END="1.190898996890678" CI_START="0.738019137050866" EFFECT_SIZE="0.9375" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="64" LOG_CI_END="0.07587492944823938" LOG_CI_START="-0.1319323766487264" LOG_EFFECT_SIZE="-0.028028723600243537" MODIFIED="2013-06-16 10:20:46 -0400" MODIFIED_BY="[Empty name]" ORDER="160" O_E="0.0" SE="0.12206704026411297" STUDY_ID="STD-Romagnoli-2000" TOTAL_1="115" TOTAL_2="115" VAR="0.014900362318840578" WEIGHT="19.02599174540342"/>
<DICH_DATA CI_END="1.3576109393017348" CI_START="0.41433078042912114" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" LOG_CI_END="0.13277532876397893" LOG_CI_START="-0.3826528019805788" LOG_EFFECT_SIZE="-0.12493873660829995" ORDER="85647" O_E="0.0" SE="0.3027650354097491" STUDY_ID="STD-Shannon-1991" TOTAL_1="10" TOTAL_2="10" VAR="0.09166666666666662" WEIGHT="2.3782489681754275"/>
<DICH_DATA CI_END="0.5973653107848271" CI_START="0.157587651968836" EFFECT_SIZE="0.3068181818181818" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="22" LOG_CI_END="-0.2237600006340454" LOG_CI_START="-0.8024778153483172" LOG_EFFECT_SIZE="-0.5131189079911813" ORDER="85648" O_E="0.0" SE="0.33994170906254734" STUDY_ID="STD-Yamada-1999a" TOTAL_1="28" TOTAL_2="27" VAR="0.11556036556036559" WEIGHT="6.659097110891197"/>
<DICH_DATA CI_END="1.076280136512388" CI_START="0.6133684229639238" EFFECT_SIZE="0.8125" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="12" LOG_CI_END="0.03192532514723446" LOG_CI_START="-0.21227858584541046" LOG_EFFECT_SIZE="-0.09017663034908802" ORDER="85649" O_E="0.0" SE="0.14344658614593475" STUDY_ID="STD-Yamada-1999b" TOTAL_1="15" TOTAL_2="12" VAR="0.020576923076923076" WEIGHT="4.100429255474875"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="47.20584633666823" CI_END="0.8231150988763823" CI_START="0.660382096895025" CI_STUDY="95" CI_TOTAL="95" DF="17" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7372723207756692" ESTIMABLE="YES" EVENTS_1="235" EVENTS_2="288" I2="63.98751146466606" I2_Q="73.14537961921918" ID="CMP-001.21" LOG_CI_END="-0.0845394317235578" LOG_CI_START="-0.18020470906928726" LOG_EFFECT_SIZE="-0.13237207039642251" METHOD="MH" MODIFIED="2013-11-21 17:31:26 -0500" MODIFIED_BY="[Empty name]" NO="21" P_CHI2="1.1345477357349587E-4" P_Q="0.053643886554488596" P_Z="5.827811946171588E-8" Q="3.7237539977130925" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="18" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="562" TOTAL_2="498" WEIGHT="100.00000000000001" Z="5.424005401633233">
<NAME>Use of one or more red blood cell transfusions (secondary analysis based on RBC transfusion guidelines)</NAME>
<GROUP_LABEL_1>Late EPO</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Late EPO</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Placebo/no treatment</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="39.06300441465555" CI_END="0.8483050770991114" CI_START="0.6816166608161096" DF="14" EFFECT_SIZE="0.7604070449474076" ESTIMABLE="YES" EVENTS_1="232" EVENTS_2="275" I2="64.16046279648803" ID="CMP-001.21.01" LOG_CI_END="-0.07144793374155221" LOG_CI_START="-0.16645980261332188" LOG_EFFECT_SIZE="-0.11895386817743701" MODIFIED="2013-06-16 10:56:49 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="3.5664573388782816E-4" P_Z="9.214648345653419E-7" STUDIES="15" TAU2="0.0" TOTAL_1="513" TOTAL_2="450" WEIGHT="95.47980377535619" Z="4.907708904540344">
<NAME>Strict RBC transfusion guidelines</NAME>
<DICH_DATA CI_END="1.2458080285893722" CI_START="0.8122761850311588" EFFECT_SIZE="1.005952380952381" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="12" LOG_CI_END="0.09545112535079402" LOG_CI_START="-0.09029627957517267" LOG_EFFECT_SIZE="0.0025774228878106755" ORDER="85662" O_E="0.0" SE="0.10910894511799613" STUDY_ID="STD-Atasay-2002" TOTAL_1="14" TOTAL_2="13" VAR="0.01190476190476189" WEIGHT="4.145538727335089"/>
<DICH_DATA CI_END="0.916079102200123" CI_START="0.059432034104573137" EFFECT_SIZE="0.23333333333333334" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" LOG_CI_END="-0.038067023967759434" LOG_CI_START="-1.2259794054430517" LOG_EFFECT_SIZE="-0.6320232147054056" ORDER="85656" O_E="0.0" SE="0.6977856131397107" STUDY_ID="STD-Bader-1996" TOTAL_1="15" TOTAL_2="14" VAR="0.48690476190476195" WEIGHT="2.75688536054304"/>
<DICH_DATA CI_END="0.9675352817538995" CI_START="0.2733644973017557" EFFECT_SIZE="0.5142857142857142" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="10" LOG_CI_END="-0.014333189211736446" LOG_CI_START="-0.5632578892822028" LOG_EFFECT_SIZE="-0.2887955392469696" ORDER="85659" O_E="0.0" SE="0.32244108604248" STUDY_ID="STD-Corona-1998" TOTAL_1="42" TOTAL_2="18" VAR="0.10396825396825399" WEIGHT="4.663731068251976"/>
<DICH_DATA CI_END="0.9332445458261052" CI_START="0.2712206954584329" EFFECT_SIZE="0.5031055900621118" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="7" LOG_CI_END="-0.030004539547436173" LOG_CI_START="-0.5666771747589638" LOG_EFFECT_SIZE="-0.2983408571532" ORDER="85657" O_E="0.0" SE="0.31524416249564025" STUDY_ID="STD-Donato-1996" TOTAL_1="23" TOTAL_2="9" VAR="0.09937888198757763" WEIGHT="3.3520567053061074"/>
<DICH_DATA CI_END="0.9728329540890739" CI_START="0.29238775603648015" EFFECT_SIZE="0.5333333333333333" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="-0.011961726376606465" LOG_CI_START="-0.5340408177508689" LOG_EFFECT_SIZE="-0.27300127206373764" ORDER="85653" O_E="0.0" SE="0.3066718426064236" STUDY_ID="STD-Emmerson-1993" TOTAL_1="15" TOTAL_2="8" VAR="0.09404761904761905" WEIGHT="3.041563740164332"/>
<DICH_DATA CI_END="2.0521983886549444" CI_START="0.23633814244437093" EFFECT_SIZE="0.6964285714285714" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.3122193422747811" LOG_CI_START="-0.6264661822341836" LOG_EFFECT_SIZE="-0.15712341997970122" ORDER="85661" O_E="0.0" SE="0.551388523664851" STUDY_ID="STD-Kivivuori-1999" TOTAL_1="28" TOTAL_2="13" VAR="0.304029304029304" WEIGHT="1.8199926120007712"/>
<DICH_DATA CI_END="0.7716992950035634" CI_START="0.015998043658039977" EFFECT_SIZE="0.1111111111111111" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="9" LOG_CI_END="-0.11255189650552389" LOG_CI_START="-1.7959331223731259" LOG_EFFECT_SIZE="-0.9542425094393249" ORDER="85660" O_E="0.0" SE="0.9888264649460884" STUDY_ID="STD-Kumar-1998" TOTAL_1="15" TOTAL_2="15" VAR="0.9777777777777779" WEIGHT="2.9981128295905557"/>
<DICH_DATA CI_END="1.12749355545595" CI_START="0.8439104389374585" EFFECT_SIZE="0.9754504504504504" ESTIMABLE="YES" EVENTS_1="61" EVENTS_2="60" LOG_CI_END="0.05211406821038122" LOG_CI_START="-0.07370364097993631" LOG_EFFECT_SIZE="-0.010794786384777516" ORDER="85663" O_E="0.0" SE="0.07390594518609753" STUDY_ID="STD-Maier-2002" TOTAL_1="74" TOTAL_2="71" VAR="0.005462088733850451" WEIGHT="20.400951668018493"/>
<DICH_DATA CI_END="0.802202200629343" CI_START="0.15528189021510708" EFFECT_SIZE="0.35294117647058826" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="17" LOG_CI_END="-0.09571615098081242" LOG_CI_START="-0.8088791910084481" LOG_EFFECT_SIZE="-0.45229767099463025" ORDER="85654" O_E="0.0" SE="0.41891549992621585" STUDY_ID="STD-Meyer-1994" TOTAL_1="40" TOTAL_2="40" VAR="0.17549019607843136" WEIGHT="5.663102011448828"/>
<DICH_DATA CI_END="2.9127186917646344" CI_START="0.03556141346709918" EFFECT_SIZE="0.3218390804597701" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.4642985428103939" LOG_CI_START="-1.4490209853631926" LOG_EFFECT_SIZE="-0.4923612212763993" ORDER="85664" O_E="0.0" SE="1.1238933619335767" STUDY_ID="STD-Reiter-2005" TOTAL_1="29" TOTAL_2="28" VAR="1.2631362889983577" WEIGHT="1.0169037667617091"/>
<DICH_DATA CI_END="1.190898996890678" CI_START="0.738019137050866" EFFECT_SIZE="0.9375" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="64" LOG_CI_END="0.07587492944823938" LOG_CI_START="-0.1319323766487264" LOG_EFFECT_SIZE="-0.028028723600243537" MODIFIED="2013-06-16 10:56:49 -0400" MODIFIED_BY="[Empty name]" ORDER="160" O_E="0.0" SE="0.12206704026411297" STUDY_ID="STD-Romagnoli-2000" TOTAL_1="115" TOTAL_2="115" VAR="0.014900362318840578" WEIGHT="21.319913454866175"/>
<DICH_DATA CI_END="1.080768408129708" CI_START="0.13011575740204556" EFFECT_SIZE="0.375" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="8" LOG_CI_END="0.03373264136606" LOG_CI_START="-0.8856701059106221" LOG_EFFECT_SIZE="-0.42596873227228116" ORDER="85658" O_E="0.0" SE="0.5400617248673217" STUDY_ID="STD-Samanci-1996" TOTAL_1="12" TOTAL_2="12" VAR="0.2916666666666667" WEIGHT="2.664989181858272"/>
<DICH_DATA CI_END="1.3576109393017348" CI_START="0.41433078042912114" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" LOG_CI_END="0.13277532876397893" LOG_CI_START="-0.3826528019805788" LOG_EFFECT_SIZE="-0.12493873660829995" ORDER="85651" O_E="0.0" SE="0.3027650354097491" STUDY_ID="STD-Shannon-1991" TOTAL_1="10" TOTAL_2="10" VAR="0.09166666666666662" WEIGHT="2.664989181858272"/>
<DICH_DATA CI_END="1.994875924249409" CI_START="0.055698256598548955" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.29991588895031257" LOG_CI_START="-1.2541583983896376" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="85652" O_E="0.0" SE="0.9128709291752768" STUDY_ID="STD-Shannon-1992" TOTAL_1="4" TOTAL_2="4" VAR="0.8333333333333333" WEIGHT="0.9993709431968519"/>
<DICH_DATA CI_END="1.0602206859071692" CI_START="0.6516017231973248" EFFECT_SIZE="0.8311688311688312" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="55" LOG_CI_END="0.025396273468690313" LOG_CI_START="-0.18601777584587964" LOG_EFFECT_SIZE="-0.08031075118859467" ORDER="85655" O_E="0.0" SE="0.1241856590838005" STUDY_ID="STD-Shannon-1995" TOTAL_1="77" TOTAL_2="80" VAR="0.01542207792207792" WEIGHT="17.971702524155702"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.4432170940579518" CI_END="0.7697804053449975" CI_START="0.08028458980938352" DF="2" EFFECT_SIZE="0.2485990830361691" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="13" I2="0.0" ID="CMP-001.21.02" LOG_CI_END="-0.11363314800740607" LOG_CI_START="-1.0953678071871853" LOG_EFFECT_SIZE="-0.6045004775972956" NO="2" P_CHI2="0.4859699979787133" P_Z="0.015792103798614336" STUDIES="3" TAU2="0.0" TOTAL_1="49" TOTAL_2="48" WEIGHT="4.520196224643826" Z="2.4136851106343515">
<NAME>No or less strict RBC guidelines</NAME>
<DICH_DATA CI_END="1.2617285296697793" CI_START="0.022015653228549727" EFFECT_SIZE="0.16666666666666666" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.10096592325294027" LOG_CI_START="-1.6572684240202276" LOG_EFFECT_SIZE="-0.7781512503836436" ORDER="85667" O_E="0.0" SE="1.0327955589886444" STUDY_ID="STD-Akisu-2001" TOTAL_1="20" TOTAL_2="20" VAR="1.0666666666666667" WEIGHT="1.9987418863937039"/>
<DICH_DATA CI_END="2.0195435340227306" CI_START="0.006955353521815352" EFFECT_SIZE="0.11851851851851852" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.3052532194183947" LOG_CI_START="-2.157680791096557" LOG_EFFECT_SIZE="-0.9262137858390813" ORDER="85665" O_E="0.0" SE="1.4467396294964603" STUDY_ID="STD-Bechensteen-1993" TOTAL_1="14" TOTAL_2="15" VAR="2.0930555555555554" WEIGHT="1.4506997562534947"/>
<DICH_DATA CI_END="2.9423243908144285" CI_START="0.11345695312726019" EFFECT_SIZE="0.5777777777777777" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.46869055193139536" LOG_CI_START="-0.945168883540447" LOG_EFFECT_SIZE="-0.23823916580452575" ORDER="85666" O_E="0.0" SE="0.8305080311132396" STUDY_ID="STD-Javier-Manchon-1997" TOTAL_1="15" TOTAL_2="13" VAR="0.6897435897435897" WEIGHT="1.070754581996627"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2013-11-21 17:31:40 -0500" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2013-11-21 17:31:40 -0500" MODIFIED_BY="[Empty name]" NO="1" REF_ID="CMP-001.01" SETTINGS="SHOW_MORE_DECIMALS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Late initiation of EPO (8 - 28 days) vs placebo or no intervention, outcome: 1.1 Use of one or more red blood cell transfusions (low and high dose of EPO).</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAukAAAHACAMAAAAoUQZaAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2013-11-21 17:31:40 -0500" MODIFIED_BY="[Empty name]" NO="2" REF_ID="CMP-001.06" SETTINGS="SHOW_MORE_DECIMALS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Late initiation of EPO (8 - 28 days) vs placebo or no intervention, outcome: 1.6 Number of donors the infant was exposed to.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAvQAAACQCAMAAABQ+A9BAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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==
</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2013-11-21 17:31:40 -0500" MODIFIED_BY="[Empty name]" NO="3" REF_ID="CMP-001.08" SETTINGS="SHOW_MORE_DECIMALS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Late initiation of EPO (8 - 28 days) vs placebo or no intervention, outcome: 1.8 Retinopathy of prematurity (all stages or stage not reported).</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAt4AAACwCAMAAAAPK5luAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA
AMAAwMD/gADAwMD/gICA/4CAgP/g4OBAAAAAQAAAAECAgID///8AAAALCwsWFhYhISEsLCw3NzdC
QkJNTU1YWFhjY2Nubm55eXmEhISPj4+ampqlpaWwsLC7u7vGxsbR0dHc3Nzn5+cAAAAAADMAAGYA
AJkAAMwAAP8AMwAAMzMAM2YAM5kAM8wAM/8AZgAAZjMAZmYAZpkAZswAZv8AmQAAmTMAmWYAmZkA
mcwAmf8AzAAAzDMAzGYAzJkAzMwAzP8A/wAA/zMA/2YA/5kA/8wA//8zAAAzADMzAGYzAJkzAMwz
AP8zMwAzMzMzM2YzM5kzM8wzM/8zZgAzZjMzZmYzZpkzZswzZv8zmQAzmTMzmWYzmZkzmcwzmf8z
zAAzzDMzzGYzzJkzzMwzzP8z/wAz/zMz/2Yz/5kz/8wz//9mAABmADNmAGZmAJlmAMxmAP9mMwBm
MzNmM2ZmM5lmM8xmM/9mZgBmZjNmZmZmZplmZsxmZv9mmQBmmTNmmWZmmZlmmcxmmf9mzABmzDNm
zGZmzJlmzMxmzP9m/wBm/zNm/2Zm/5lm/8xm//+ZAACZADOZAGaZAJmZAMyZAP+ZMwCZMzOZM2aZ
M5mZM8yZM/+ZZgCZZjOZZmaZZpmZZsyZZv+ZmQCZmTOZmWaZmZmZmcyZmf+ZzACZzDOZzGaZzJmZ
zMyZzP+Z/wCZ/zOZ/2aZ/5mZ/8yZ///MAADMADPMAGbMAJnMAMzMAP/MMwDMMzPMM2bMM5nMM8zM
M//MZgDMZjPMZmbMZpnMZszMZv/MmQDMmTPMmWbMmZnMmczMmf/MzADMzDPMzGbMzJnMzMzMzP/M
/wDM/zPM/2bM/5nM/8zM////AAD/ADP/AGb/AJn/AMz/AP//MwD/MzP/M2b/M5n/M8z/M///ZgD/
ZjP/Zmb/Zpn/Zsz/Zv//mQD/mTP/mWb/mZn/mcz/mf//zAD/zDP/zGb/zJn/zMz/zP///wD//zP/
/2b//5n//8z///9BjlLGAAAfEElEQVR42u1dfXAjZ3l/bFm7WsmWvWu73F1y9Hx2QydT0sl9+PtI
0V0CIdBj2oR/KEfgD9KZpEk7c5PyMTQBhqYFAglDkhI6TdNMoYVLhqQcJDQnuNjy5cThMFCgpPbp
kiPncLZ3fbZlWVrb6vvu96e0sqSVLL+/5Lyrfb+efd/f++yz7/60amKBgKBR0Uy6gIDQm4CA0JuA
gNDbFbGY8VNX2JyGgTc0dbeIU2kq0lWkOjmvuVq35iBJ23KMRRwLdjEFWnUpU5n+iVEUYzwh4x5O
G9esCIPreVd7EJEhN3e5G3lzt7Efq2lkgKkrevdAyvBp8OqUKS2eSqXwZr0twOfEfNMS/2CWWylY
nZzXXK1bc/D0UpM1x2tXO5Yc3J1yb9WlTGX6J76+HLu8lkrZT0FO+/yawYpUqjaDGF9nu1Kim5E4
zdCP1TSyPoOT7ghFhcYoNLOBz9NUlLekn4ccdIzyQS4ycrlYXTgvgsjQFMMBH6XosIg2NHUc19oR
YpIAuA30YY2NxTJMiAM4TtP4ANDYhFgsHFbtECMUzciWxWIcQ7d3fAzl549TdJ5HR55gQqxUpopg
YAN7vDHUR9h2dGohOmlIS4apYDijmKidm8+YA+kS081QVETiskiHREOaqR/1/t4e9F6ey702fATR
Mg57DoevHOix5WiCNcgAvAp3FK9NcslRPpseWoGeA5HoYBT2HDjZOolrzX9vKAbth09GDrQjercA
vKV1eAXaJ8Mn8QHIYhMA5q+odrT/ILc89FROPry2OLJ/4xGUv2ey9b8P70FH/rp1OKOUqRrGIIA3
Nw68+drQDZg4bceW+w1pN8znVgZZxUSIKufmM7ogiDdLQzPtA7h18U5YChrSTP2o9/f2oHdmd/Sj
kJd2D8J0BrNMjb7xlu+BFpSMvCwHTxapSsorV9mGXNsqTM/GM8ihR6fQPkAqCgNwAPZNo0/8+qsA
L87KuaJqo1LhoGrHSnM0qrX5YlD6t47yT/2RdJFI4dJVDmzve/k03tmAXc+fQDMc2oZPBI1pmXPH
o8gmBQflc/M7+r4ueQXvjMBfrJ3A4WPrVDhoTDP1o62/G5ze7HUbP4FRxR/deqtKmTgC7qAdq0cv
Ip+Mggu+aEdLeXEUct16G6pyBE8KQKP/8VuldK4fXkJtcPjoNQH0F/nBUTx1+nWG4Fmk2sH+3cZ5
VImMfvnfIZQfJa7LGUer2zXxn49BH975+vjwU7vwQ7mNCZW98c/gtBfve6wV2aT5c3RueZ/HL/6z
8fUlvPOJRPb6j0s9nshpaQmUZupHW383enACr7+qGXgiHs+ZOy+XvYdDPhndFf+ymGOS8yKswMXf
4F6WZ0QA14rdBc+jFprxRo5NZNyODxyxdJRkRxpep53CH5Qo+hTVtg7iMAg+8ubPTg1jxxilBzNK
2iGcdot8pprd6FSa/B5APjwkPQ4/MnPy7NQy2lkIDajLJTyD0sz96NDfjUzvALxtEm3GERcp2CvG
wg55wn3cPH9j4k2PVd4Ob+uV7hV7Z2IhVOtkdwyv3+35HzRB0KdeCMFaQM38n9A7CROgTwdQ7WiW
LeszXzdCuFbNyETxi0o5EM5k8EwK3/oDmbdzc2Od5rRsr26Fcm5+Y+FaGhvJ3LpwUbpVYM6Pp7W0
Cbrb3I96fzf6wmAPQio6vdo5A6l/fvQhcebeAzNvLgT0NHWRaeV18Utfaol8zss6I9re9djBX+6F
1MzU+EOXTn9j5o5vr84sBHrg8r/8NhOYuff81OwVaIp/AxdA/2buzXzz8qJ0Z3b+IVGqRbEjen71
6V2QSk09LCp5lfwPz1wJKJ9wmWounEYG56+G1Mr77/zypdYVdCQQHlha0dOY0Y80IxPbp76yJpkm
nZvvq7v/N4CNnPj8l790KYKN/EJo8N+eUNLaBi4wpn7U+7vCaCKSKoLGBXkoT0DoTUBA6E1AQOhN
QEDoTUBA6E1A4IHefCtNHY4krVrmAnLcZP4wRUdEDzmLQhFzO8FRW23OPxaGUowo0NjmtNoWayLO
1sSSwFMxiodkLGRLV/bM7aNK0XioVUsbrYSqfnc0R9kRWyUlY1LO2053AOQzaq9S1HGxTLF1vdtn
fKyza3lh6Vfv/OyaRcvsppVG+Oahf//C8jvf/dPiOYtCEXM7wVFbnUrhEuong8LaixEFGtucVtub
NT1fXL3/CLz1w8ETO+96Xi1oyfmaReIOX1x9bgzkNCmLVqN0Es5iaS0Pe/CJE8N3ND294+hjKGNT
dGVNjMgP6LsXg298um1eLGfM6t8+o/e+F9aAia8GVQ0u+idGQiwAE+sGUXY4si43FmuVZoUI16IS
j6u5AdpvZkRIhkMdMUUlDVGaagc1Qyz2BBZbu6Ir1or+tsa6ZG11LMZG6Ixkj64btkCqX5INSxrx
Lu9nnpEeykdirE2r3RUOFjTTHZK2WqpD1jNbknnYCePoHw+fwbpz6RRRTrpD6rwuJsTZtOITPLx/
oqD/7KIZ4MOUqGjOeeZm/UndKhyahvfAOtyPP23MrkOnct3IjIY4Jp4u++pf5/Y1G3f34QERDXLl
loEwj2ULIjyFR03X5c6+Ibl+uN48hPmXhx6Fg4Pfk78xMn8R2g+cjOzv0DPcExlscTdm7ky/CGL/
mZyq8d4Ij9wj2aPphi2Q65dkw8t07rXhJe9nzkwMzIA4cO3GZGvYrNVeHvxddLBtE50p68alOmQ9
s7VJyMEX0b+/gkDPgUjkwB65jyOfkVJnFx204pk7QMwUbHQuNPTi3kEm2COfx1NDL+vSO0lVeQo+
C7fRaCCbZ5r53HklLIBXKxLc1rl9BnovTsDQfZGkMZWGqZ8AvIlG5C7sInVdbkZS4Z22lrgwDc9B
CKKCfOqdKG90Ggynf2EK6ALxawg60X+0pvFOzSqaYE03bIGh/kyzphH3Fiwz8CBqbP8qTE2btdob
cNXaic1IpA/o2mqznllGYlhcGx8aXxN/NT6LenJKFoSiPh6SkoWggyaUneoe4Yxmm09CCnAm3rsy
kQLlPJ6D6QtajiD0PYs2n0o8Eh7cDaE9zF7qO1SH3KFcRehd5/YZ6B28NDkBAzcYU0exDheYxNrM
2sQsGHS5ctv9l35qLsFxMIbY0S8r1zmsq+43mYkyuIkzsZh7ui8rZvvOaxpvDhRNsK4bNsNQv0Ej
XhxSYxNfTa4mjtq12q2Joet3bkaLo+jGJWtMemZ1MFtGqX5qtAW5CqnVU0qn9KvdZTd/Fi7DZaPZ
5pOQyoWGRylO1ZzndRsAXj+avjMBsJwNTqPIcyF7PnPh7vQHpKlWIVVjndtnXBjkFi69ojiQhBSk
YEUqbiU4+gej2HnbdLnclUuTiIfj6vcKJGlxAHgtcA3Ih8bUDMnCRnPfHukY+TZn13hrumHrnbGu
Zk7rGnFv4OjRG1CEZ9dq8zOvnBpZ2VRn8ur5OenCW5CnbkEmh9C/Ju0Um/RCDggm6ImgzS+a168y
E+NZUdWcJ4zVcfdkV/LKt2TwhW2S5kaCT8pT7ZqK0LvO7TPQOxTjuOdQ/2MNbhPMdEnX/j4cH34f
+kFSyFt0uaFYhvsvVOJ26Noj3xL3IrsyMKnF14raOADdcoYjfa7BiYTpxEBi2qLxxvZoumELlPrx
XG+GtskS1zvGhsZTDlrt8K0BHj68ic40WfM2mzVB5J1nYQ459aCsO2fk4KTPEKPbvFbLaMDqFy1M
OjLyw8hIi3oeQejt0fKgO7qXRmlg6C4Gf/kD3ocak2cy07fKyzfXZaK+7TPQe+lsmro/+WM4Mb4b
hMRH8aRae3n5YUzjcZjYKRHiXPqWc7p4+KXke4NHkgswlFimZGe6MhEH4cyDLCiv27hw7pb0uQUQ
Jpa+Lze3fHa+QDgMnasQ7ESl9keSWjPYntNn9+x42eFklfoj41dBOBF5vqSFauQ7AF000TntOftj
NSGcuBquJBd3nnlkE5154dwD6Z9ekeoIT1z5M9uFPAF0EIITkHgVLuxL/778ncn5l9MhGDe2b8KX
IWhrJ2H80H1g4h3CmcPjynnEz6w0aXleCIQfeIWH04HF9n0pgK7mWdgfkSbV7DPrO9pRz5WN+rbP
i96bh13DP5/z7sPC56c+ftZpTSdW3a+Qb03QoVTbu85kSijRvbRakTzVQh3Z54XedL45XEKgP3bT
OgTDs44X7xyhs+0WYHUNAqf7SygRYeYqkqdaqCP7yLd1CAgICCqCP/e3uRbivQn8hL98I4JYggYG
ib0JfIDxJQ9+vtCTeG+CBgahN0EDwyhPFVj9r3lPOyLfGjhuqgWteoEtmEnJJrAVaKzMU9KscTRG
kBP1NrRG2WLmO5RROwdt3VPBaWClVAHY7UJv6bSFAje5gtz/jpuqsVutXih2Py5AsVxeGyv3lFRr
hAKLB3obeqMCW4TdDmVUQ9mCqSZjBENlrNDI7HYJTgRBHR11T3Dku+vByoEthZq+NeZ9VlbFTg82
s5aUQhflqsOksfLzB39M3pvF7kNw8BK16BIbKwQP7BbqxBtJ1rDFIowKUN8luLAfZv3yR06Iu37w
k97uHVB46leX/L6Gh1JjbFVvJ2RvYWpDCscF/L/Hk1VLKyGIw4AIHu5EGjswcaW3LU6rKVi3QazG
PGOrfjvBWqMXmdcF6eoa+7CbD7LUZrcfvQ23mKwH/vgSuQhFlk5YL7l8jU1Kj54rHloVtGM7PNBr
tsxo1u61hZqyW51mLOthPLzlqu3VWvCv0YIjI2wDdrvE3tp1yxyFCvJtkXJQ2QjVXfhmBR/9jPnM
/GjDGIXL+2zRogLraKgtVRkZE8kFtiYdqz2Ij/n7hRaiOWkMFHDUxdfSfYTP9CYP5RuF3/UbjtXd
ygnBVgO7yVvIBr94E+9NQOhNQEDoTbDV0UroTdCwePhi495aWlSBpgfEJmGlg9i76utLRVZpK6w9
r8zpFLTGkKjqr0vQexs122phm97bVJspVROcm9fZI38DjUtvdwW+ZeDtYu+qry8VkYFUWHsuVN9m
Q6KgexOvem+TZlsZOwedp4sxhkwmGcDDx6CR6e3odQSTCshFf1lrcQ5b4bkk+GjxZlozlGG9nQbr
dGWylD226ZkdAId3kzvhad8G0ZXeJq9j9gn+GdY4k6WE1jxfeQyhYumjooUu1hxsfmGT577otdN8
fmrZYr0mu8rga/p1D9/C5crfMRRIM1lckt7b8f6oqC16bGII5oxo6tjkO1mjUJ9oKTrdhUqGo9sK
RRTVVnaxJdK11OuMWjVboGxTxzaIvW2RimkwiPOuVpBTB1+la2osentZ9xbqPwioS6uE6i/ObMaY
7XQdbnG+qJpUxJr2W15ZdtB8+3Khh4LvOTFaVT/Bibs1ujrbOEW96r1dRsrpe5z6V94KaMUbFUTv
3Rggeu9NBycEW4HfvhZrmFtLgi0Bovcm3ptgu4HQm4DQm4CAxN4EBJ6h/mJD1Cd6C5u72dAfJFfl
9d+212Hbm9c3ApT9Zm62rGo8WGPrl0q93xuML2Gydb1z2e30fu9NfzFBH9MqvP7b8jpsB/brmzIH
S2uFLWMuFrHG1i+Ver+3vsjn1PUuZRv8NYMtBbyEwAra/NY9jDwMFt/Blk+twu7QPVkwbcprrFxV
jRdr2LLNK9y4no+tULNVGFT8J1Be0LB5ehve6i2Y3pkqHQDd2fjx0EvwsqjLespcoTarZ01ZvbmF
ogzWGHtX026b3tvYmn6ZNnzBo2BcWgW2lzSHyp9wamxSoR97cHz7tqPkw5ve26NZgsMXFgTYfgKM
Fo/kEGo60X12YFWuxuXStxm9NxRqwiIpZ+tU7FlNWNe9XW41BPxq4SpfXOsjKmTrunGBKODKorfn
RQG/Ol+oWmb3MxCqabpQ/cnnNFT1t0ISVeDrygkrOMmmFdW3+etV1myOUvByZcUlVcOW/YOUlZSN
O1dTxvu99Rd2F+gVWyrRe2+ZyzdB6aOynfXepT2UL/ehIEG93TQQvXfllxQIKg6i9y7z1pKAgNCb
gIDQm4CA0JuAgNCbgIDQm4DQm4CA0JuAgNCbgIDQm4CA0JuAgNCbgIDQm4DQm4CA0JuAgNCbgADY
KKE3QaMiufhaB6E3QYPi0BwsjvlP75gE9VNX2JAgbbgQiK0UnechKedsp9EszGeU/AxFHRdx3pCP
X3DqCtPU3SKIeYpuRXa1SjbUEmHUV8iaw/kk8Kb+lBFBn/lWmsprNiOIxymqNQkdwa+jDIUGvlWu
bSxCUZGkYbzwJtl6WDl3PkJTUVEaqyhvbloKDULUzbgRkY7JJX1G/k2A+T/p9qexAKPtplI9EE+p
nwav1nZ7AO/yl/43yx584sTwHU1P7zj6WCoFTdGVNTEi/9Bn92LwjU+3zYsobzh7+R/96quNjSgf
5XN/y8wHDxzPfav/F135hWztyC22DaK+aj688PAb/5B9fOfZV1MpY3J38wBK3rU8Rw8vZNlRyWZM
uCb+u+c/0XRs4tT6zEOPu1Y+808D0kDAf6ylZ85+XkylUktvSeakAYrD44c++V2Qzn3X8i+69l2R
xmr/HU0my7CTun5u4bffQvOAw7Wl5LH1Dz2/opE/7JwPZAM1Ck6O03QUKDSzQWRoiuGUw3unArAK
h6bhPbAO90vcml2HzpCcmhkNcUw8jXdPDvf61lur2dklyMHXYHoaDqEdZgpqyG54l/SXhrl9yJYN
3IkmvH0N/30ezk+h5JxsM0IOpvYBA08G8/CHtHvlH9xQdjK5IA3YUfNLCc07MbBvGjDX4V65FzLy
WJksQ8iOCcEcGiexNv00Fp3vRN6783IbXxt6t0+GTx5oRx0VhyifTQ+tqPMfpqAJkFGn4LNwGx3m
oXmmmc+dV1NfVSu41l+G9aJzyAPHwW64HXioKZK/xX+lXjoGa5CmIyaDzl7Cf3djY/OyzaekyzXe
O4b68HY+e9698qNv6Pt70bkiVzgSmlWPHJNrlarj8Z9meaxUyy6qk6Q5jMcOHg3XpIc2LsM82szD
zO7a0DsL01GFoJnd0btgQ6M3B0HoexbtfirxSHhwN4T2MHup71DSbfAIqF4eje66j/3VlUaOawTv
/SuEoK9PHuIaYVnqhBboQ74YIDEeHjANYlpKnpI5OKIdlvaeBCayfy/dQ7uuKtzD6T5wBYaQ8z6Q
0CMLpVYECp5l0KgpY6Va1qnmG5mPDL4Vup6vjSfweXSaHQzg+hWCdlz3uWdgVGMtwOtH03cmUF9l
g9PIOS1kz2cu3J3+AE5N6I6T8/McupZGPymg1iU8mFzKJppqvjRw8ewyhyxKZ/txL9kwLvdmQjuQ
kLt9IXfb6lw2uurhCn9k9JWPoHgkT3PWWhGE5B1d483w+llprOzITCFXtfrJ2vRNSzeeZ+jfjou1
WhjkeTgi7azAh35joD0P3D3ZlXxQn4eTNDcSfBJ/CsI1WnHwj2HJJTh5RAoHeDgMwWUxnQ/UnN5c
OpfJu78f6TDwIrJYsVkaA7SHB6KvJTg8W/zSJ96Y/zl+u1Q3GM41gCuREFzOpZsCyIrsygZlK6zM
pf778LqJ/30z+iMp9obuGa429A5B7yRMIG/Ao/juGv0uEfdUmBJfGqWBobsYwDc176OhT16IY/pW
+UwsgnfbfPy5tYNNFxjpZq5vEr6P7OrmRkM1p3f4YyI7SiFrZvrA4VYxAZO/h3pTsTkWQ/u9vfAV
7FcZmJgp8iQC5e881j6Hd9dhWj8ehN4+dOuPklG73Mi8NFaHKDCt/KEPNOz9JYo94/E4vrvyH4c6
cOzdlfGF3Q70Tp1L33LuCnx9/GoYSvwxb+i/PnghEH7gFR5OBxbb96Gwr6t5FvZHpJv32WfWd7Sf
W8C7a/A13zorNPxBvHQ7d2r5lqQAkeYr6Q/xNaf3CxcjmUkBWgN7ls9dsCdfSN6SPjWv2owwty+d
Tu5HMUdgFt/PFK0/O/V2ab16DQwceTGZXt4nhUKRpj0rrzDqWMlRi47Fc/sP71urYe803YqCkx8H
fWrM8zMYfmfoiqeM0dwlDgh8RKyAH+5KZzZbtCqmxmHm6rm9fr25s4QXII/dlPF2bQ7xhHG+goIm
17XYyFyhywGdl9fK/aQ3dGwsQv3Rm4CgIvT2EURSRdDAIPQmIPQmICD0JiAg9CYgIPQmICgThufn
ylK7ulKo/9RWsR/dqu5vx2k/v+jHT9T52hiBn/Rm63JQtd9eFxqtMYLaBCeCICi/gCvtWQ6DnoDy
OObc0iBuuzG9t9mF4R/fFowO3fhB3Zfy2HJWybH6Mn/kH732qTGCGtC7oCNDXDbQmK2+2/P3p8+V
mUqwHehtDkEFt4SqklC7SPgYmRCGbwt6S9Ry9M6sAy+qvoDiH+sEQvHGvbV09d/SupkWf0MBb155
t8qy/sUovjZG4K/3VgMNfNMI+j2WMf6wxCJSzkaIvf0N9AmqDqL3JvATRO9NQEDoTUBA6E1A6E1A
QOhN0NgQql4Anq6+UcYShN4EDQzjurf8wMa7zts+bewPz7U1dCUDnlmsvRgYpNbanqUu+Rkq61S9
Xrd92dpWr3FjaMLRNmsRljzO3LL0LhusE+HBJMFi7VcbwZJTkyM6zh+36vGGLZjFoF7RNkZ9mINt
tiImQRnBFqW37Nmk8VTkJNoudmEK+eQEg3vDnwQtv8o1VjB6PsHmIN28LmvWcEltWsjFVmQq6ppf
lwq3DaN9CL79KFGE3nbFt9mFgUXxrbtIViWlVX+lxi2C0TOzhbjDWsMefaI4FDPzXvDMSlylzm6r
bcWvH42FTUSj9VjChd6Ct/M2ulXWiTAOFrHmLVv6iWitsq6FhGJTpnB7dts0DYrk12UJjkBUKVs0
OFFv8Qw8F7xdMoQt6Xw8TQD5qmSM7Un4vcVjb7Y4Y0oIgh3oIBTxw8WvPWyhQp6CE7f2ChUm31Jr
kJWTAuuDgnO8yxrCWeOuE43Y0mMswamssPl7QcFT0L8NAu4yrn4s1HmJFrcwV1N8ayGpvKtowM3K
aMMnwfR9Lu8CakFbiDaXkSsyKc9thcxzyvFc9HrVA/rCtzt7zUXUWhqY7EUfPtgzljb5S/MU1ici
RfNYs25K713Exoo6O88hC7vp6kksbe8N/eEDW6TbSprupfkGQXuS4T5Epjy2rCU/lBcQfGS39yuS
UM3Js535XsEe3IzvLitPyU8t2QrkqEroxW66dkJxv0abrfjQF8lDJFUEDQxCbwJCbwICQm8CgrqC
+/u9zbemJa7osDaNk3W92CDTc7pFMCZbFjRLE3aTtZFSbuasDwmKZ/TNKC952MLr3oLbE7sSz8NK
b6fvORR8+CiA+V20ZmG3UKqwm4AEJzpR5Hd166/5Nr7CW1C/fuD0tm/7e77VSoyJar2CO7udKLkZ
mhJqk+AEHN2g8essFuk3FHjbt0WialSOG/XhRp21PUpxkqQ4vr21sHZKkbESjhN6e3Z+pi8qWN/2
7ZFJjlJBtlDgZY4yvAm7SWRCghPX4IT1/nsihpyOwYlbYoFIRE9kHb7iy+J3uJLIpH7A10WDvCfv
rX9rxaPzM+v7BFeKFdGqbIKTAuFxjWB+F+ZVpiTpbxxvx5vbZgHGbtxobp2zZBkP/PCQ2xs1zYfF
d5+y5djlVOyDXoMTr9d1VrB9rUAo6J3tCzECS24dtzyGTHyM61tuCaD7SNvc2BExaMny4k0eK3/L
y/Zjw07zIuslOGFlTaCy0ejKmqSCxk+GfdYiJzQV0itm9SUYQdIgCm6+2WJMAWWgksVWhoTf1cQY
EwyxyBnHQGylIqI9XtgAyETm4FC4w5p0ZF2uIUyFUJoYojmAZIQKJ9HBJIPr4sN0GAUca0GItYeC
Y6C3gRtEx9T8ch3SQZYKcWM0nZHranZwhkpgK29Y7RZO+ayHv/pCh54i/66BfpOpJbHGirWMchjt
EElbWgVTFpev6GhWOJUhqApu4sXwCvLFcWgRcj/otLGbDSBSTqG96TVr0oty5HDTCzkGkfFR5sIK
wMGF3PwRdPDgG8+j1LfS2dBTAOu/RkcuLR5GsUYw92yL7PyR9w5cUvPLdUgH//5NYTU7s9Ah17X1
HsqXKOwmzruqyDDAj0h7oSC8Q4kOYhjSdsfqaYAR5JaBy5uj69iOP43INRwCAdXw3PTOVakSBlci
cIdCAAPTMPUc8CINkOKYUZQ8DVFaq2OKU/MrdWDs55jBfRwzItfVsvV6lK1iboJSVzB6Fhh5D9Nr
3BZ7Qz9Agkf85neCJfbOrUh7yRvXsWPPc2olY3gySEnoGEdBNsipB9BE6dfpzWn5UR3rysF+rfQI
EEkVQXm4qqnzJXlvPB6P5xzzBHvRn143R/qOJgrdfqI5gD8kUCU4uBalRT50jG+CawNa3nF0wHQV
UPKjOhZtFeM0Qm+CcrDx66kjMu9CIrwUdo4Pb+uCrtvCLjXkg1OY+S29MzcDrIrA4atBOzDIS3+B
gb4g5H6nL430waQcACXku1glv1LHmGnhG6cRehNsDnKAHfnoTkyhv9wB8x3BByLm2Fv13s+kqeVn
Zl3qiRzY8Tja/Ciz5yyaCe10phV9uhLqngcY6qRW47Cu+/21LHVUvkVtaZVnjpxfqYPeYZpV7fQK
+WU0ggYG8d4EhN4EBITeBASE3gQEhN4EBITeBASE3gSE3gQEhN4EBITeBAS1xf8DobadLhRzDyUA
AAAASUVORK5CYII=
</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2013-11-21 17:31:39 -0500" MODIFIED_BY="[Empty name]" NO="4" REF_ID="CMP-001.09" SETTINGS="SHOW_MORE_DECIMALS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Late initiation of EPO (8 - 28 days) vs placebo or no intervention, outcome: 1.9 Retinopathy of prematurity (stage &#8805; 3).</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAt4AAACwCAMAAAAPK5luAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2013-11-21 17:31:40 -0500" MODIFIED_BY="[Empty name]" NO="5" REF_ID="CMP-001.01" SETTINGS="SHOW_CI_LINES:YES;SHOW_EFFECT_ESTIMATE:YES;SHOW_AUTOGENERATED_NUM_FOR_STUDY_NAMES:NO;SHOW_STUDY_NAMES:NO;DISTINGUISH_SUBGROUPS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT">
<CAPTION>
<P>Funnel plot of comparison: 1 Late initiation of EPO (8 - 28 days) vs placebo or no intervention, outcome: 1.1 Use of one or more red blood cell transfusions (low and high dose of EPO).</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAGQCAMAAABF6+6qAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK MODIFIED="2013-11-25 13:04:45 -0500" MODIFIED_BY="[Empty name]">
<FEEDBACK_ITEM ID="FBK-01" MODIFIED="2013-11-25 13:04:45 -0500" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2013-11-19 09:31:21 -0500" MODIFIED_BY="[Empty name]">Feedback from Dr. R. Ohls</TITLE>
<DATE_SUBMITTED>
<DATE DAY="27" MONTH="3" YEAR="2013"/>
</DATE_SUBMITTED>
<FEEDBACK_SUMMARY MODIFIED="2013-11-19 09:32:53 -0500" MODIFIED_BY="[Empty name]">
<P>Our inclusion of the study by Dr. Romagnoli and co-workers (<LINK REF="STD-Romagnoli-2000" TYPE="STUDY">Romagnoli 2000</LINK>) in the Early EPO review was questioned by Dr. Robin Ohls, who suggested the study should be included in the Late EPO review. We contacted Dr. Romagnoli and he informed us that the mean (± SD) age of the infants when EPO treatment was started was 10 ± 1 days. We therefore moved the study to this Late EPO review.</P>
</FEEDBACK_SUMMARY>
<FEEDBACK_REPLY MODIFIED="2013-11-19 09:35:02 -0500" MODIFIED_BY="[Empty name]">
<P>As expected, when the study by <LINK REF="STD-Romagnoli-2000" TYPE="STUDY">Romagnoli 2000</LINK> (n = 230) was added the results of the meta-analyses changed. The outcome of BPD (defined as need for supplemental oxygen at 28 days of life) is now of borderline statistical significance with an increased risk in the EPO group. Becasue of the very high heterogeneity (I² = 97%) the results should be interpreted with caution.</P>
<P>Our decision to divide the EPO studies into early and late based on initiating EPO treatment at the cut-off of &#8804; 7 days of age for early and &gt; 7 days for late treatment with EPO, although somewhat arbitrary, was chosen based on previously published meta-analyses (<LINK REF="REF-Garcia-2002" TYPE="REFERENCE">Garcia 2002</LINK>; <LINK REF="REF-Kotto_x002d_Kome-2004" TYPE="REFERENCE">Kotto-Kome 2004</LINK>) to allow us to compare the results between our reviews and previously published reviews.</P>
<P>In this update there is a trend towards a non-significant increased risk of retinopathy (ROP) of prematurity.</P>
<P>The concern for an increased risk of ROP is real and because of the arbitrary cut-off age for early vs late EPO treatment we decided post hoc to perform a secondary analysis including all studies that reported on ROP stage &#8805; 3 regardless of the age at initiation of EPO treatment. This analysis is included in the updated Early EPO review and shows an increased risk of ROP &#8805; 3 when all studies of EPO regardless of age at initiation of the treatment were included in the analysis.</P>
</FEEDBACK_REPLY>
<FEEDBACK_CONTRIBUTORS MODIFIED="2013-11-25 13:04:45 -0500" MODIFIED_BY="[Empty name]">
<P>Dr. R. Ohls</P>
</FEEDBACK_CONTRIBUTORS>
</FEEDBACK_ITEM>
</FEEDBACK>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>